



# International Urogynecology Consultation: Patient Reported Outcome Measures (PROs) use in the evaluation of patients with pelvic organ prolapse

Sara Cichowski<sup>1</sup> · Magdalena Emilia Grzybowska<sup>2</sup> · Gabriela E. Halder<sup>3</sup> · Sierra Jansen<sup>4</sup> · Daniela Gold<sup>5</sup> · Montserrat España<sup>6</sup> · Swati Jha<sup>7</sup> · Ahmed Al-Badr<sup>8</sup> · Abdelmageed Abdelrahman<sup>9</sup> · Rebecca G. Rogers<sup>10</sup>

Accepted: 22 July 2022 / Published online: 18 August 2022  
© The International Urogynecological Association 2022

## Abstract

**Introduction and hypothesis** Patient-reported outcome measure instruments include patient-reported outcomes (PROs) and patient-reported goals (PRGs), which allow practitioners to measure symptoms and determine outcomes of treatment that matter to patients.

**Methods** This is a structured review completed by the International Urogynecology Consultation (IUC), sponsored by the International Urogynecological Association (IUGA). The aim of this working group was to evaluate and synthesize the existing evidence for PROs and PRGs in the initial clinical work-up/evaluation and research arena for patients with pelvic organ prolapse (POP).

**Results** The initial search generated 3589 non-duplicated studies. After abstract review by 4 authors, 211 full texts were assessed for eligibility by 2 writing group members, and 199 studies were reviewed in detail. Any disagreements on abstract or full-text articles were resolved by a third reviewer or during video meetings as a group. The list of POP PROs and information on PRGs was developed from these articles. Tables were generated to describe the validation of each PRO and to provide currently available, validated translations.

**Conclusions** All patients presenting for POP should be evaluated for vaginal, bladder, bowel and sexual symptoms including their goals for symptom treatment. This screening can be facilitated by a validated PRO; however, most PROs provide more information than needed to provide clinical care and were designed for research purposes.

**Keywords** Patient-reported outcomes · Patient-reported goals · Quality of life measures

## Introduction

This report is part of a series of articles that are the product of the International Urogynecology Consultation (IUC), sponsored by the International Urogynecological

Association (IUGA). This is a 4-year, 4-chapter project with 16 reports dedicated to reviewing and summarizing the world's literature on pelvic organ prolapse. This report is from the second year and chapter of the project, which is focused on evaluation of the patient with pelvic organ

✉ Sara Cichowski  
cichowss@ohsu.edu

<sup>1</sup> Oregon Health & Sciences, Portland, OR, USA

<sup>2</sup> Department of Gynecology, Gynecological Oncology and Gynecological Endocrinology Medical University of Gdansk, Gdansk, Poland

<sup>3</sup> University of Texas Medical Branch, Galveston, USA

<sup>4</sup> University of New Mexico, Albuquerque, NM, USA

<sup>5</sup> Department of Gynecology, Medical University Graz, Graz, Austria

<sup>6</sup> Departamento Gynaecology, Hospital Clinic, Barcelona, Spain

<sup>7</sup> Sheffield Teaching Hospitals NHS trust, Sheffield, UK

<sup>8</sup> King Fahad Medical City, Riyadh, Saudi Arabia

<sup>9</sup> Liverpool Women's Hospital NHS Foundation Trust, Liverpool, UK

<sup>10</sup> Albany Med, Albany, NY, USA

prolapse. Prior and subsequent years will be devoted to defining the condition, non-surgical management and, finally, surgical treatment of pelvic organ prolapse. This report will focus on reviewing the literature on patient-reported outcome measures (PROs) for the evaluation of subjects with pelvic organ prolapse.

Pelvic organ prolapse (POP) is the herniation of pelvic organs into the vagina. When defined by symptomatology there is an incidence of 3–6%; however, upon vaginal examination up to 50% of women have signs of POP [1]. POP significantly impacts a woman's quality of life causing physical, social, psychological, occupational, domestic and/or sexual limitations and affects mental well-being. The Pelvic Organ Prolapse Quantification System (POP-Q) objectively assesses the anatomical support of the vagina; however, prolapse stage may not always correspond to patient symptoms or concerns [2]. Additionally, postoperative POP-Q improvement or worsening does not necessarily correlate with subjective patient outcome. Prior research found that patients reporting the absence of symptoms (urinary, defecatory, pressure) are frequently satisfied with surgery, even with anatomical failure [3]. Patient-reported outcome measure instruments include patient-reported outcomes (PROs) and patient-reported goals (PRGs), which allow practitioners to measure symptoms and determine outcomes of treatment that matter to patients.

According to the International Consultation of Incontinence (ICI), the most useful assessments of the presence, severity and impact of pelvic floor disorders (PFDs) on patients are psychometrically validated PROs [4]. PROs are considered an essential part of patient evaluation and are becoming progressively more important as we strive to make healthcare more patient centered [5]. Not only do PROs help provide personalized clinical care, but they are also a major outcome utilized in clinical trials [6, 7]. The joint terminology report from IUGA and the International Continence Society for reporting outcomes of surgical procedures recommends that PROs are used in clinical trials [8].

However, while PROs assess condition impact, they may not reflect patient treatment expectation and goals, which are at the heart of clinical care for the individual patient. Therefore, evaluation of Patient-Reported Goals (PRGs) and goal attainment will help tailor patient treatment plans, engage in shared-decision making and improve patient satisfaction. In addition, the majority of PROs were not designed for use in the clinical setting but were developed for research purposes.

This chapter will describe the differences and roles of PROs and PRGs in clinical care, research and future directions in POP initial evaluation and treatment.

## Background

### What are patient-reported outcomes (PROs)?

A PRO is a validated questionnaire (also referred to as instruments) that assesses health-related quality of life, symptom-specific details, sexual function and global impression of improvement [9]. PROs are completed by patients to measure their perception of functional well-being and health status. PROs describe or reflect how a patient feels, functions, or survives and are used in both clinical practice and research [10]. PROs also ask specific questions about a patient's condition and can be used to evaluate benefits and treatment effect [6]. Careful consideration is required to choose appropriate PROs for both clinical use and research purposes. Most PROs require considerable time for patients to complete and may impose additional workload on clinicians with evaluation and upload into the electronic medical record.

### What are patient-reported goals (PRGs)?

PRGs are usually written by the patient as free text in the order of goal importance as decided by the patient. Patient goal setting may be the most sensitive and specific way to understand an individual patient's perspective and can be used over time to understand changes in patient priorities. Goals were first described as a prolapse measure in 2003 [11]. The same year, they were used to measure patient satisfaction after surgery for POP and/or incontinence [11]. Others have expanded on this work by having patients not only set goals but rank their level of goal attainment in both surgical and non-surgical management of PFDs over the course of a year [12]. Goal attainment was highly associated with patient satisfaction in these studies. Further qualitative work found that there are five basic types of goals patients list in relationship to pelvic floor disorders: symptom, information seeking, lifestyle, emotional and other [13].

### Why do we use patient-reported outcomes and patient-reported goals?

Within the constraints of an outpatient clinic visit women may not always divulge clear information about their pelvic floor symptomatology or which symptoms are the most bothersome. For example, a cohort of women undergoing pessary fitting predominantly listed resolution of bladder symptoms as a treatment goal rather than prolapse-related symptoms such as feeling of a bulge [14]. This may be due to the sensitive nature of symptoms, a patient's inability to clearly explain their main concerns, the constraints of a

conventional history and examination, or poor understanding of the interrelatedness of pelvic floor symptoms [15].

Patient-reported outcomes, either as a PRO or PRG, fill this gap by encouraging discussion and/or self-expression and disclosure of embarrassing or intimate conditions. They aid with the screening and detection of functional problems that may not be readily volunteered by patients. They also help with monitoring the treatment impact on patient functioning and inform clinical management of patient conditions.

PROs and PRGs can help with personalizing care planning and patient self-management. They facilitate patient involvement in their care and their decision-making and support patients in self-managing long-term conditions. Importantly, they also align surgeon's and patient's expectations.

Another important aspect of PROs and PRGs is their use in research, quality improvement projects, audits and clinical performance evaluations. By including PROs and PRGs in clinical trials, patients' everyday experiences of their condition and subsequent treatment are captured in an objective fashion, data that would not otherwise be captured by traditional physiologic measures. Health-related quality of life measures are important in POP where the goal is improved function (not survival) and treatments often have similar efficacy but may have differing effects on quality of life. Research studies with clinical primary outcomes should incorporate and control for PROs because self-rated health can affect risk behaviors, health utilization and general satisfaction.

## Materials and methods

International experts in the field of Urogynecology and PROs were selected through the IUC chairs and steering committee with input from the IUGA executive committee after a competitive application process and invitation. Regular group meetings took place from January 2020–July 2021 to determine the outline and content of the paper. A structured search of the literature from 1980 to May 2020 using Scopus, PubMed and Embase was performed to identify existing PROs for POP using the terms “(“Surveys and Questionnaires” [Mesh] OR patient reported outcome\* OR questionnaire OR questionnaire\* OR survey OR surveys) AND (“Pelvic Floor Disorders” [Mesh] OR pelvic floor prolapse[tiab] OR pelvic floor disorder\*[tiab] OR pelvic floor dysfunction[tiab] pelvic floor disorder' OR 'pelvic floor disorders' OR 'pelvic floor dysfunction' OR 'pop (prolapse)' OR 'colpoptosis' OR 'complete external prolapse (genital)' OR 'complete procidentia (genital)' OR 'complete prolapse (genital)' OR 'genital procidentia' OR 'genital prolapse' OR 'genital-urinary prolapse' OR 'genito-urinary prolapse' OR 'genitourinary prolapse' OR 'overt prolapse (vaginal)' OR

'pelvic descent' OR 'pelvic organ descent' OR 'pelvic organ prolapse' OR 'pelvic prolapse' OR 'procidentia, complete' OR 'prolapse, genital' OR 'prolapse, genitourinary' OR 'prolapse, vagina' OR 'total procidentia (genital)' OR 'uro-genital prolapse' OR 'urogenital prolapse' OR 'vagina eversion' OR 'vagina prolapse' OR 'vaginal descensus' OR 'vaginal descent' OR 'vaginal procidentia' OR 'vaginal prolapse' OR 'vaginal ptosis' OR 'vaginal wall descent' OR 'vaginal wall prolapse')

The structured review process was as follows. The initial search generated 3589 non-duplicated studies. After abstract review by 4 authors, 211 full texts were assessed for eligibility by 2 writing group members and 199 studies were reviewed in detail. Any disagreements on abstract or full-text articles were resolved by a third reviewer or during video meetings as a group. The list of POP PROs and information on PRGs was developed from these articles. Each PROM title was used to conduct an additional search in PubMed for validation and translation studies performed on the specific measure. The recommendations obtained from the writing group including PROs in this summative review were decided upon in an iterative process. The IUC peer review process involved four rounds of review including review by the IUC co-chairs, the IUC steering committee members, the IUGA general membership (through an online process) and finally the IUGA executive committee before being submitted for peer review to the International Urogynecology Journal.

## Overall objective of report

The aim of this working group was to evaluate and synthesize the existing evidence for PROs and PRGs in the initial clinical work-up/evaluation and research arena for patients with POP. This paper describes the development of clinical and research usage of PROMs, existing research gaps and current best practices for use of PROs and PRGs.

## Results

### Patient-reported Outcomes (PROs)

#### Generic or condition specific

Health-related quality of life measures fall into two major categories: generic and condition-specific. Generic measures are multi-dimensional, capture the overall health of a patient, transcend different specialties and assess a wide range of populations. Generic questionnaires compare health states between patients but are less able to assess patient concerns with specific disease states. Condition-specific measures more specifically assess a particular disease but are not able

to be compared across differing conditions across disease states. Condition-specific instruments can be further divided into screeners or in-depth questionnaires. Screening surveys allow providers to capture patients experiencing a specific condition and can be followed by in-depth questionnaires for further evaluation of the condition [16]. Condition-specific measures are more responsive inherently than generic PROs in detecting treatment effects [17]. Often, screening questionnaires are utilized to ascertain presence or absence of a condition and are followed by in-depth PROs to further gauge level of bother. Examples of condition-specific POP measures include the Pelvic Floor Distress Inventory (PFDI) and Pelvic organ prolapse/Incontinence Sexual Questionnaire-IUGA Revised (PISQ-IR) [18, 19]. Below is a more in-depth discussion of these classifications.

### Epidemiologic screening versus measurement in specific populations

Screening measures are an ideal method of assessing POP prevalence at the population level when a physical exam and completion of a detailed questionnaire may not be practical because of the sheer volume of subjects screened or the availability of practitioners to perform standardized exams. Tegerstedt et al. developed a five-item questionnaire to identify POP in population-based studies. Items in the questionnaire ask respondents about: (1) sensation of tissue protrusion/vaginal bulging; (2) vaginal pain/discomfort; (3) worsening of symptoms with stress/heavy lifting; (4) need to manually reduce the vagina to void; (5) urgency urinary incontinence along with the patient's age [20].

The second type of screening measure consists of complex questionnaires that evaluate multiple domains of pelvic floor disorders related to pelvic organ prolapse simultaneously, such as the Epidemiology of Prolapse and Incontinence Questionnaire (EPIQ). The EPIQ is a rigorously validated epidemiologic survey capable of screening for pelvic floor disorders in large populations of women, with a high likelihood of identifying women having a particular pelvic floor disorder. It collects a wide range of information on pelvic floor disorders' risk factors; thus, complete information about patients for detailed statistical analyses is obtained. The EPIQ assesses symptoms in the following six domains: SUI, overactive bladder, anal incontinence, vaginal bulge, defecation dysfunction and voiding dysfunction/pelvic pain. The EPIQ should not be used as a diagnostic instrument [21]. Some epidemiologists have used question #35 of EPIQ, a single question, to screen for pelvic organ prolapse in a general population [21].

Screening questionnaires may also be specific to certain populations. For example, pregnancy and the postpartum period are particular times in women's lives which can be associated with pelvic floor disorder symptom onset or

aggravation. Instruments that diagnose problems at this time of life would create an opportunity for early identification of symptoms to provide health promotion actions, thus potentially reducing the development of pelvic floor disorders later in life [22]. Examples of instruments used for this purpose include the International Consultation on Incontinence Questionnaire-Vaginal Symptoms (ICIQ-VS) [23] and the Australian Pelvic Floor Questionnaire [24].

### Multidimensional versus dimension-specific

Most generic and condition-specific instruments are multidimensional, i.e., they measure more than one aspect of health-related quality of life (HRQOL). In contrast, dimension-specific instruments are designed to assess a single component of HRQOL, e.g., emotional distress. The trend in assessing HRQOL outcomes has been toward the use of a multidimensional generic and/or condition-specific instrument, supplemented with dimension-specific instruments, as needed. Dimension-specific instruments should be used when more detail about a specific subdomain of HRQOL is desired. Primary domains of HRQOL include physical, psychological and social functioning, overall well-being and perceptions of health status. Secondary domains include symptoms, sleep disturbance, intimacy and sexual functioning and personal productivity (e.g., household, occupational or community activities).

POP, like all pelvic floor disorders, is a multidimensional phenomenon, and treatment outcomes should be evaluated based on patient-reported symptoms in multiple domains [25]. Patients with additional bowel and bladder symptoms may benefit from a global questionnaire like PFDI and PFIQ [6]. Other multidimensional tools include the Prolapse Quality of Life questionnaire (P-QOL) [26], or the electronic Personal Assessment Questionnaire-Pelvic Floor (ePAQ-PF) [27].

### Symptom measures versus function measures and bother

**Symptom measure** Symptom measures discriminate between women with and without POP and can be useful in accurately estimating prevalence and/or incidence of POP in the general population [28]. Symptom scales are considered condition-specific. Generally, these scales include measurement of a symptom's presence and whether or not it is bothersome. The symptom measures demonstrate spectrum bias. Some patients may present with "typical" or classic symptoms along the clinical spectrum of a condition, while others may present with less severe or even "atypical" symptoms or manifestations [28]. Screening for POP without a physical examination is subject to such spectrum bias and is likely

to only identify women with anatomically advanced POP. Therefore, screener sensitivity decreases in a population-based sample.

**Functional measure and bother** Symptom distress and life impact are two different aspects covered in questionnaires that measure function and bother. Health-related quality of life is assessed by measuring the degree to which bladder, bowel, or vaginal symptoms affect the daily activities, relationships, and emotions of women with pelvic floor disorders. Examples of function measures include the PFIQ, PFIQ-7 or Prolapse Quality of Life (P-QoL) scale. The P-QoL is a condition-specific instrument for measuring HRQOL in women with POP. The questionnaire consists of 20 items representing nine QoL domains of general health, prolapse impact, role physical and social limitations, personal relationships, emotional problems, sleep/energy disturbances and severity measures [26].

Symptom distress/bother scores usually serve the role of both a symptom inventory and a measure of the degree of bother and distress caused by the broad array of pelvic floor symptoms (i.e., PFDI-46, PFDI-20) [18]. Patients are asked whether they experience symptoms; if so, they indicate on a scale from 1 (not at all) to 4 (quite a bit) the degree to which they are bothersome. Those tools allow for some quantification of the degree of bother to patients from their POP symptoms and bladder and bowel dysfunction. Another instrument that measures the severity of POP symptoms (vaginal and sexual) and related bother is the ICIQ-VS. The bother rating is given on a scale from 0 to 10 [23].

### Patient-reported goals (PRGS)

Women with pelvic floor disorders have a wide range of personal goals before a treatment or intervention. Achievement of these goals is a primary reason for undergoing treatment. Patient's treatment goals are broadly categorized into:

1. Symptom goals: specific symptom relief: prolapse, urinary, bowel and pain/discomfort symptoms;
2. Function goals: general lifestyle improvement: physical, social, emotional and sexual [29, 30].

Based on the literature, most patients' goals are symptom resolution goals [13]. Symptom resolution goals ranked the most important and were commonly achieved after surgery [30]. Function goals, such as lifestyle and emotional goals, accounted for only 30% of the goals. They were usually ranked as a lesser priority [13] and were also achieved less frequently [31].

### How are patient-reported outcomes and goals administered?

While generally self-administered, PROs can be administered in multiple formats. Questionnaires may be completed by paper/pen, electronically or telephonically. Different formats of PROM administration require separate validation studies.

To achieve seamless integration of patient-reported outcomes and/or goals in clinical practice, there should be planning, selection and engagement.

**Planning** for what dissemination strategy will be used (e.g., paper, electronic vs telephonic), how the integrated system will be governed, ethical and legal issues, and how data from multiple electronic health records can be pooled across organizations is important. Some PROM measures require permission and/or fees for their use.

**Selection** identifies the target patient population for patient-reported outcome data collection based on the intended use of the data in the health care system. Selection of PROs should include choosing specific outcomes and their measures to optimize applicability for a target population.

**Engagement** includes how, where and with what frequency patients will respond to patient-reported outcomes measures; how to display patient-reported outcomes data in electronic health records, how clinical teams will act upon patient-reported outcomes data; and how to train, support and encourage clinical teams and patients to incorporate patient-reported outcomes data into care [32].

### How do we track PROM and PRGs?

The questionnaire link or goal form should ideally be provided before clinical consultation to help the clinician understand patient symptomatology and expectations prior to the appointment. Completed patient data are required to be stored in a secure database through a contracted data supplier responsible for keeping protected information secure. Ideally women should be asked to complete post-treatment PROs, goal attainment scores, or list new goals (if applicable) [33].

### Validation of PROs

A discussion about the validity of a measure (PRO) must begin with the meaning of validity. Validity refers to the evidence and rationale available to make inference and actions in a specific population based on instrument scores [34]. There are several key components to this definition.

**Table 1** Validity of questionnaires

Validity type		Data source	Data methods	Evaluative criteria
Internal	Content or face	Target population (patients), experts, literature reviews	Focus groups, interviews, cognitive interviews, literature review, sorting or ranking	
	Internal consistency	Target population	Survey	Tau-equivalence, Cronbach's alpha Item total correlation
	Dimensional	Target population	Survey-factor analysis	Kaiser-Guttman rule, eigenvalues, scree plots, Kaiser-Meyer-Olkin residuals, structural equation models
	Reliability	Target population	Survey test-retest, split half	Correlation, chi-square, t-tests matched pairs, Bland-Altman,
External (construct)	Convergent, concurrent, discriminant, divergent, Predictive	Target population, external	Patient self-report (surveys, diaries, activity logs), external subjective, external objective, gold standard	Correlation across data source and data method, ROC, AUC
Responsiveness	Sensitivity to change	Target population	Survey baseline and follow-up	Effect size, (Cohen's), standardized response mean (SRM), Guyatt (requires MCID be identified)

First, the term “specific population” is the acknowledgment that any “validation” efforts may only support the assumption that the instrument is a valid measure for which to draw inference in a population that is comparable to the populations used to validate the measure [35]. For instance, a test that was developed with the intention of being a valid measure of sexual function for women with a prolapse may not be valid to measure sexual function in women with a primary and sole diagnosis of urinary incontinence.

Inference may be intended to be used as a population-based screen and to indicate only that further evaluation may or may not be warranted. Alternatively, a score may be intended as a clinical tool and indicative of a preferred treatment pathway for an individual patient.

A further consideration in validation approach is the intended use of the measure. The intended use dictates the level of evidence required for inferential validity of a measure [34]. For instance, a measure that is intended to be used as a population screen to discriminate between those considered at risk versus those not at risk is a standard need of public health. For valid measurement, the use of a measure to screen for potential risk requires a less stringent level of evidence than would a measure intended for use as a clinical diagnostic tool, which may require the ability to discriminate between presence and absence of the actual disease state.

The evidence standards that exist for a given measure must be sufficient to support the intended use of the measure, and standards of evidence may shift over time. Reviews

and judgment of the adequacy of a measure for its intended use must primarily consider the sufficiency of the level of evidence available to support the intended inference based on test score. The hierarchical levels of evidence may be grossly categorized as corresponding to internal and external validity and are briefly described below as well as described in Table 1.

### Minimally important difference (MID)

When using overall scores from PROs to compare two time points it is important to report whether the measured change in the score reflects a real change in the patient's clinical condition versus a mere statistical change between values. The minimally important difference (MID) is a measure of change in a PRO total score that suggests an important clinical change, of either improvement or worsening of the condition as measured by the PRO. If the change in the total score of a PRO is greater than the MID, it suggests a significant clinical change; if it is less than the MID then it suggests no change in the clinical condition of the subject/subjects. There are two main approaches for identifying MIDs: anchor based and distribution based. Anchor-based approaches are preferred and more reliable; however, not all PROs have studies that define the MID. The anchor-based approaches use an external indicator, called an “anchor,” and differences can be determined either cross-sectionally or longitudinally. The anchor can be either an objective (e.g.,

**Table 2** Validation properties for POP PROs

PRO	Citation	Further validations	Country and language	Intended use of PROM	Sample composition and size	Number items in initial validation sample/psychometrics	Content validity: patient focus group or interview, expert focus final patient review:	Internal-dimensions: EFA, CFA, PCA, FA, SEM, IRT, eigenvalues, factor loadings	Internal consistency	Reliability/agreement	Number of items in final PROMS	Sub-scales or domains	External validation: convergent, discriminative, discriminant, known-group, external criterion: correlation, t-test, ANOVA, IRT	MID, yes/no; responsiveness	Scoring/outcome data type
Body Image in the Pelvic Organ Prolapse Questionnaire: BIPOP	Lowder, Jerry L., et al. "Body image in the pelvic organ prolapse questionnaire: development and validation." <i>American Journal of Obstetrics and Gynecology</i> 211.2 (2014): 174-e1.		US English	Research tool	Women 18+ with POPQ stage ≥ II and self-report of symptom; N = 201	21	Patient focus groups; pt. cognitive interviews for item evaluation; expert input	EFA (PCA) with varimax	Cronbach's alpha on factors/sub-scales, with appropriate ranges reported	Paired t-tests; ICC	10	2: Attractiveness and Partner	Yes, primarily convergent, use validated self-administered instruments, correlations with reported p-value	Not reported	Mean range 1-5. Option for total also. Evaluated use of a summary score by combining partnered and non-partnered women; the Attractiveness scale does differ across partnered and nonpartnered
Australian Pelvic Floor Questionnaire: APQ	Baessler, K., et al. (2008). "An interviewer-administered validated female pelvic floor questionnaire for community-based research." <i>Menopause</i> 15(5): 973-977	Baessler, K., et al. (2009). "Australian pelvic floor questionnaire: a validated interviewer-administered pelvic floor questionnaire for routine clinic and research." <i>Int Urogynecol J Pelvic Floor Dysfunct</i> 20(2): 149-158. Baessler, K., et al. (2010). "A validated self-administered female pelvic floor questionnaire." <i>Int Urogynecol J</i> 21(2): 163-172	UK English	Research with further work (Baessler) for clinic use	Women 18+ with pelvic floor disorders (n = 495) from the Longitudinal Study of Ageing Women	Not reported	Initial question set tested and assessed by women. Interviews to remove "ambiguous questions"	Factor analysis (principal component analysis, varimax rotation)	Cronbach's alpha	Blind Altman plot	Not reported	Bladder function (Q1-15), bowel prolapse symptoms (Q26-32) and sexual function (Q33-42)	Spearman correlation and K	1.3 for bladder, 1.0 for POP, 2.2 for global score	Total score is out of 40 with each question scoring 0-3 based on response
Electronic Personal Assessment Questionnaire: FloorePAQ-PF	Computer interviewing in urogynecology: Concept, development and psychometric testing of an electronic pelvic floor assessment questionnaire (e-PAQ) in primary and secondary care. Radley et al. <i>BJOG</i> , 2006	1. Development and psychometric testing of a symptom index for pelvic organ prolapse. Bradshaw HD, Hilder L, Farkas AG, Radley S, Radley SC. <i>J Obstet Gynaecol. Apr 2006</i> ; 2. Responsiveness of the electronic Personal Assessment Questionnaire-Pelvic Floor (ePAQ-PF). Jones GL, Lumb J, Radley SC, Farkas AG. <i>Int Urogynecol J Pelvic Floor Dysfunct</i> , 2009	UK English, Italian	Clinical	Women 18+ with and without Pelvic floor disorders; N = 432	14 domains with 4 dimensions	Questionnaire uses BBU-SQ, SPS-Q and FSFI and questions developed with other experts. No patient input	Factor analysis	Cronbach's alpha on factors/sub-scales, with appropriate value ranges reported	Test-retest at 1 week in primary care population only using Wilcoxon rank sum	20 domains in current version	Urinary, Bowel, Vaginal, Sexual	Known-group difference	10	This is automatically calculated as a percentage

Table 2 (continued)

PRO	Citation	Further validations	Country and language	Intended use of PROM	Sample composition and size	Number items in initial validation sample/psychometrics	Content validity: patient focus group or interview, expert focus group or interview, final patient review	Internal-dimensionality: EFA, CFA, PCA, FA, SEM, IRT, factor loadings	Internal consistency	Reliability/agreement	Number of items in final PROMS	Sub-scales or domains	External validation: construct, convergent, divergent, predictive, discriminant, known-group, external criterion: correlation, t-test, ANOVA, IRT	MID: yes/no; responsiveness	Scoring/outcome data type
Sheffield Prolapse Symptoms Questionnaire: SPS-Q	Bradshaw HD, Hiller L, Farbas AG, Raley S, Raley SC. Development and psychometric testing of a symptom index for pelvic organ prolapse. <i>J Obstet Gynaecol</i> . 2016 Apr;26(3):241–52. doi: 10.1080/014436105001537989. PMID: 16698333		UK English	Clinical	Women 18+ with and without prolapse. N = 203	25	Patient review of questionnaire and modification of questionnaire	Factor analysis	Cronbach's alpha	Test-retest with kappa	25		Wilcoxon-rank sum; Kruskal-Wallis; discriminant or group validity	MID not reported; Pearson correlation for responsiveness	4-point ordinal response scale (never, occasionally, most of the time, all of the time) and, in common with the BFLUTS-Q, each item also includes a sub-question relating to bother: 'How much of a problem is this for you?' also recorded on a 4-point ordinal response scale (not a problem, a bit of a problem, quite a problem, a serious problem)
Prolapse and Incontinence Knowledge Quiz: PIKQ	Shah AD, Massagli MP, Kohli N, Rajan SS, Braaten KP, Hoyte L. A reliable, valid instrument to assess patient knowledge about urinary incontinence and pelvic organ prolapse. <i>Int Urogynecol J</i> . 2008 Sep;19(9):1283–9. doi: 10.1007/s00192-008-0631-x. Epub 2008 May 15. PMID: 18480958.		US English	Clinical	Women 18+, with prolapse (n = 133) and without prolapse (n = 61)	24	No	Principal components factor analysis	Cronbach's alpha > 0.8	Test/retest reliability	24	12 urinary, 12 POP	Test-retest Pearson's correlations	12-point perfect score for each section (1 point per correct answer)	



Table 2 (continued)

PRO	Citation	Further validations	Country and language	Intended use of PROM	Sample composition and size	Number items in initial item pool for validation sample/psychometrics	Content validity: patient focus group or interview, expert focus final patient review:	Internal-dimensionality: EFA, CFA, PCA, FA, SEM, IRT, eigenvalues, factor loadings	Internal consistency	Reliability/stability/agreement	Number of items in final PROMS	Sub-scales or domains	External (construct) validation: convergent, divergent, predictive discriminant, known-group, external criterion: correlation, t-test, ANOVA, IRT	MID: yes/no; responsiveness	Scoring/outcome data type
Birmingham Bowel, Bladder and Urinary Symptom Questionnaire: BBUSQ	Hiller L, Radley S, Mann CH, Radley SG, Begum G, Profovee SJ, Sulaman JH. Development and validation of a questionnaire for the assessment of bowel and lower urinary tract symptoms in women. <i>BJOG</i> . 2002 Apr; 109(4):412-23. doi: 10.1111/j.1471-0528.2002.01147.x. PMID: 12013162.	L. Hiller, HD Bradshaw, SC Radley, S Radley, A scoring system for the assessment of bowel and lower urinary tract symptoms in women. <i>BJOG</i> . 2002 Apr; 109(4):412-23. doi: 10.1111/j.1471-0528.2002.01147.x. PMID: 12013162.	UK English	Clinical	Women 18+ with (n = 379) and without (n = 131) bladder or bowel symptoms	22	Yes	Factor analysis with Varimax rotation	Cronbach's alpha exceeded the 0.7 level	Kappa coefficients (representing the proportion of agreement beyond chance alone); test-retest 18-52 days apart	22	Constipation (Q1-2), Evacuation(Q7-13, 15), Incontinence (Q3-6), Urinary (q16-22, q14 is binary for constipation)	Wilcoxon rank sum or Kruskal-Wallis	Spearman's rank correlation coefficients baseline/6 months	For all individual questions, responses are coded as 1 to 4 from top to bottom of the response sets, with the exception of question one being coded as 1 to 6 and question 14 as 1 for 'yes' and 2 for 'no' (see Appendix 1). All missing responses are coded as 0. Except for a stand-alone binary constipation question (question 14), the questionnaire is composed entirely of multi-item domains with the composition of these domains shown in Table 1. Each domain score ranges from 0 to 100 where a high score is indicative of more severe symptoms
"Do you Feel a Bulge?"	Barber MD, Neuhauer NL, Klein-Olarte V. Can we screen for pelvic organ prolapse without a physical examination in epidemiologic studies? <i>Am J Obstet Gynecol</i> . 2006 Oct; 195(4):942-8. doi: 10.1016/j.ajog.2006.02.050. Epub 2006 May 8. PMID: 16681989.	1. Tan JS, Lukacz ES, Menefee SA, Powell CR, Naeger CW, San Diego Pelvic Floor Consortium. Predictive value of prolapse symptoms: a large database study. <i>Int Urogynecol J Pelvic Floor Dyfunct</i> . 2005 May-Jun; 16(3):203-9. discussion 209. doi: 10.1007/s00192-004-1243-8. Epub 2004 Oct 23. PMID: 15875236.	US English	Screening	Women 18+ with and without prolapse. N = 120	1	No	No descriptive study only	Spearman's 0.58 (P < 0.001)	Test/retest reliability at 1 week kappa 0.84	1	None	t-test	N/A	Binary
Pelvic Organ Prolapse Simple Screening Inventory: POPSSI	Tehrani et al. BMC Women's Health. 2011; 11:48. Screening of pelvic organ prolapse with a physical exam: (A community based study) <a href="http://www.biomedcentral.com/1472-6874/1148">http://www.biomedcentral.com/1472-6874/1148</a>		Iran Persian	Clinical screening	Women 18+ with and without prolapse. N = 945	4	No	No descriptive study only			4	None	Yes	In healthy population: Sens 46.5%, spec 87.4%, PPV 72.7, NPV 68%, in POP population: Sens 20%, Spec 20%, PPV 78%, NPV 66%	Numerical

Table 2 (continued)

PRO	Citation	Further validations	Country and language	Intended use of PROM	Sample composition and size	Number items in initial validation sample/psychometrics	Content validity: patient focus group or interview, expert focus final patient review	Internal consistency	Reliability/ agreement	Number of items in final PROMS	Sub-scales or domains	External validation: convergent, divergent, predictive, discriminant, known-group, external criterion: correlation, t-test, ANOVA, IRT	MID: yes/no; responsiveness	Scoring/outcome data type
International Consultation on Incontinence Questionnaire Vaginal Symptoms Module ICIQ-VS	Price, N, Jackson, SR, Avery, K, Brooks, ST, Abrams, P. 2006. Development and psychometric evaluation of the ICIQ Vaginal Symptoms Questionnaire: the ICIQ-VS. <i>BIOG Int. J. Obstet. Gynecol.</i> 113, 700–712.		UK English	Clinical	Women 18+ Symptomatic (N = 141) and without prolapse (N = 77)	27	Structured interviews with patients	Cronbach's alpha	Kappa	14	0-53 vaginal symptoms subscale 0-10 overall impact on quality of life subscale Bother scales are not incorporated in the overall score but indicate impact of individual symptoms for the patient	chi-square	MID not reported; responsive to surgical intervention for POP (Wilcoxon matched pairs signed rank test)	Each question is scored and then also assessed. Total score is reported and the website recommends against single item scores or assessments
Prolapse-Quality of Life: P-QoL	P-QoL: a validated questionnaire to assess the symptoms and quality of life of women with urogenital prolapse. <i>Digesu GA, Khullar V, Cardozo L, Robinson D, Salvatore S. Int Urogynecol J Pelvic Floor Dysfunct.</i> 2006 May-Jun;16(3):176-81; discussion 181. doi: 10.1007/s00192-004-1225-x. <i>Epub</i> 2004 Oct 21. PMID: 15875234		English	Clinical	Women 18+ with symptomatic POP (n = 140) and without POP (N = 75)	not reported	No patient input reported	Cronbach alpha and stability	2-week retest analysis	20	20	Spearman correlation	MID, responsiveness not reported	Subscale scores
Epidemiology of prolapse and incontinence questionnaire: EPIQ	Lukacz ES, Lawrence JM, Buckwalter JG, Burchette RJ, Nager CW, Lubner KM. Epidemiology of prolapse and incontinence questionnaire: validation of a new epidemiologic survey. <i>International Urogynecology Journal.</i> 2005 Aug;16(4):272-84.	Egger MJ, Lukacz E, Newhouse M, Wang J, Nygaard I, Web VS Paper-Based completion of the Epidemiology of Prolapse and Incontinence Questionnaire (EPIQ). <i>Female pelvic medicine &amp; reconstructive surgery.</i> 2013 Jan;19(1):17 electronic version	US English	Screen for PTDs	Symptomatic and nonsymptomatic "healthy" POP (N = 75)	22 "stem" questions,	Expert review, focus groups symptomatic and nonsymptomatic	Cronbach alpha	Test-retest 2-week interval Kappa and correlations or ICC	QoL, OPO, SUI, OAB, AI	Predictive for the following: POP, SUI, OAB, AI. Discriminant between general gyn and PFD patients	Not reported; this study did not evaluate responsiveness.	Positive and negative predictive values of the EPIQ to detect PFD were: POP = 76% and 97%; SUI = 88% and 87%; OAB = 77% and 90%; and AI = 61% and 91%, respectively	

**Table 2 (continued)**

<p>Pelvic Floor Distress Inventory (PFDI) and Pelvic Floor Impact Questionnaire (PFIQ)</p>	<p>Barber MD, Kadibhadda MN, Preper CF, Bump RC. Psychometric evaluation of 2 comprehensive condition-specific quality of life instruments for women with pelvic floor disorders. <i>Am J Obstet Gynecol.</i> 2001 Dec;185(6):1388-95. doi: 10.1067/mob.2001.1118659. PMID: 11744914.</p>	<p>US English</p>	<p>Research and Clinical</p>	<p>Women with pelvic floor dysfunction, n = 100</p>	<p>POPDI = 61 items; PFIQ = 93 items</p>	<p>No patient input; expert panel consisting of 4 urogynecologists, 1 female urologist, 1 colorectal surgeon and 2 psychometrists</p>	<p>Not reported</p>	<p>Overall PFDI and PFIQ scale and subscale Cronbach's alpha range from 0.84 to 0.98</p>	<p>Test-retest report interclass correlation (it is not stated but the statistic reported for interclass reliability should be Pearson's correlation coefficient, although authors label it ICC in summary table) with PFDI and PFIQ scale and subscale correlation coefficients ranging from 0.77 to 0.92</p>	<p>PFDI is 3 subscales: UDI, POPDI, CRADI; PFIQ is 3 subscales: POPIQ, UIQ, CRAIQ</p>	<p>Yes, Spearman's correlation comparing scales and subscales to clinical indicators of symptom severity and diagnostic criteria and bladder diary data</p>	<p>8-UDI scale (non-surgical SUI treatment)</p>	<p>Subscale scores for each scale are obtained by taking the mean value of all items answered within each subscale. These scores are then transformed by multiplying the mean score of each subscale by 25; subscale score - range of 0 to 100. Total scale score is calculated by summing the subscale scores. This gives a total possible score for the UDI (0-300); POPDI (0-300) each with 3 subscales; CRADI (0-400) has 4 subscales</p>
<p>1. Barber MD, Chen Z, Lukacz E, Markland A, Wei C, Bubbler L, Nygaard J, Weidner A, Janz NK, Spino C. Further validation of the short form versions of the Pelvic Floor Distress Inventory (PFDI) and Pelvic Floor Impact Questionnaire (PFIQ). <i>Neurourol Urodyn.</i> 2011 Apr;30(4):S11-6. doi: 10.1002/naa.20934. Epub 2011 Feb 22. PMID: 21344495; PMCID: PMC3759146.</p>	<p>US English</p>	<p>Clinical</p>	<p>Women with pelvic floor dysfunction, n = 100</p>	<p>POPDI = 61 items; PFIQ = 93 items</p>	<p>No patient input; expert panel consisting of 4 urogynecologists, 1 female urologist, 1 colorectal surgeon and 2 psychometrists</p>	<p>Not reported</p>	<p>Overall PFDI and PFIQ scale and subscale Cronbach's alpha range from 0.84 to 0.98</p>	<p>Test-retest report interclass correlation (it is not stated but the statistic reported for interclass reliability should be Pearson's correlation coefficient, although authors label it ICC in summary table) with PFDI and PFIQ scale and subscale correlation coefficients ranging from 0.77 to 0.92</p>	<p>PFDI is 3 subscales: UDI, POPDI, CRADI; PFIQ is 3 subscales: POPIQ, UIQ, CRAIQ</p>	<p>Yes, Spearman's correlation comparing scales and subscales to clinical indicators of symptom severity and diagnostic criteria and bladder diary data</p>	<p>8-UDI scale (non-surgical SUI treatment)</p>	<p>Subscale scores for each scale are obtained by taking the mean value of all items answered within each subscale. These scores are then transformed by multiplying the mean score of each subscale by 25; subscale score - range of 0 to 100. Total scale score is calculated by summing the subscale scores. This gives a total possible score for the UDI (0-300); POPDI (0-300) each with 3 subscales; CRADI (0-400) has 4 subscales</p>	
<p>2. Barber MD, Walters MD, Cundiff GW, PESSRI Trial Group. Responsiveness of the Pelvic Floor Distress Inventory (PFDI) and Pelvic Floor Impact Questionnaire (PFIQ) in women undergoing vaginal surgery, and pessary treatment for pelvic organ prolapse. <i>Am J Obstet Gynecol.</i> 2006 May;194(5):1492-8. doi: 10.1016/j.ajog.2006.01.076. PMID: 16647933.</p>	<p>US English</p>	<p>Clinical</p>	<p>Women with pelvic floor dysfunction, n = 100</p>	<p>POPDI = 61 items; PFIQ = 93 items</p>	<p>No patient input; expert panel consisting of 4 urogynecologists, 1 female urologist, 1 colorectal surgeon and 2 psychometrists</p>	<p>Not reported</p>	<p>Overall PFDI and PFIQ scale and subscale Cronbach's alpha range from 0.84 to 0.98</p>	<p>Test-retest report interclass correlation (it is not stated but the statistic reported for interclass reliability should be Pearson's correlation coefficient, although authors label it ICC in summary table) with PFDI and PFIQ scale and subscale correlation coefficients ranging from 0.77 to 0.92</p>	<p>PFDI is 3 subscales: UDI, POPDI, CRADI; PFIQ is 3 subscales: POPIQ, UIQ, CRAIQ</p>	<p>Yes, Spearman's correlation comparing scales and subscales to clinical indicators of symptom severity and diagnostic criteria and bladder diary data</p>	<p>8-UDI scale (non-surgical SUI treatment)</p>	<p>Subscale scores for each scale are obtained by taking the mean value of all items answered within each subscale. These scores are then transformed by multiplying the mean score of each subscale by 25; subscale score - range of 0 to 100. Total scale score is calculated by summing the subscale scores. This gives a total possible score for the UDI (0-300); POPDI (0-300) each with 3 subscales; CRADI (0-400) has 4 subscales</p>	
<p>3. Barber MD, Spino C, Janz NK, Bubbler L, Nygaard J, Nager CW, Wheeler TL, Pelvic Floor Disorders Network. The minimum important differences for the urinary scales of the Pelvic Floor Distress Inventory and Pelvic Floor Impact Questionnaire. <i>Am J Obstet Gynecol.</i> 2009 May;200(5):580.e1-7. doi: 10.1016/j.ajog.2009.02.007. PMID: 19375574; PMCID: PMC2688021.</p>	<p>US English</p>	<p>Clinical</p>	<p>Women with pelvic floor dysfunction, n = 100</p>	<p>POPDI = 61 items; PFIQ = 93 items</p>	<p>No patient input; expert panel consisting of 4 urogynecologists, 1 female urologist, 1 colorectal surgeon and 2 psychometrists</p>	<p>Not reported</p>	<p>Overall PFDI and PFIQ scale and subscale Cronbach's alpha range from 0.84 to 0.98</p>	<p>Test-retest report interclass correlation (it is not stated but the statistic reported for interclass reliability should be Pearson's correlation coefficient, although authors label it ICC in summary table) with PFDI and PFIQ scale and subscale correlation coefficients ranging from 0.77 to 0.92</p>	<p>PFDI is 3 subscales: UDI, POPDI, CRADI; PFIQ is 3 subscales: POPIQ, UIQ, CRAIQ</p>	<p>Yes, Spearman's correlation comparing scales and subscales to clinical indicators of symptom severity and diagnostic criteria and bladder diary data</p>	<p>8-UDI scale (non-surgical SUI treatment)</p>	<p>Subscale scores for each scale are obtained by taking the mean value of all items answered within each subscale. These scores are then transformed by multiplying the mean score of each subscale by 25; subscale score - range of 0 to 100. Total scale score is calculated by summing the subscale scores. This gives a total possible score for the UDI (0-300); POPDI (0-300) each with 3 subscales; CRADI (0-400) has 4 subscales</p>	

**Table 2 (continued)**

<p>Pelvic Floor Distress Inventory short form (PFDI-20) and PFIQ short form (PFIQ-7)</p>	<p>Barber MD, Walters MD, Bump RC. Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFDI-20 and PFIQ-7). <i>Am J Obstet Gynecol</i>. 2005 Jul;193(1):103-13. doi: 10.1016/j.ajog.2004.12.025.</p>	<p>Barber MD, Chen Z, Lukacz E, Markland A, Wai C, Brubaker L, Nygaard I, Weidner A, Janz NK, Spino C. Further validation of the short form versions of the Pelvic Floor Distress Inventory (PFDI) and Pelvic Floor Impact Questionnaire (PFIQ). <i>Neurourol Urodyn</i>. 2011 Apr;30(4):541-6. doi: 10.1002/nuu.20934.</p>	<p>US English</p> <p>Research + Clinical</p> <p>Women 18+, preoperative surgical patients for pelvic floor diagnosis. n = 45</p> <p>PFDI has 61 items PFIQ has 93 items</p> <p>No</p> <p>No</p> <p>No</p>	<p>Pearson correlation for test-retest reliability, labeled as ICC by authors</p> <p>20 - 3 scales: UDI (6 items), Pelvic Organ Pro-lapse Distress Inventory (POPDI), Colorectal-anal Distress Inventory (CRADI) 8 items</p> <p>Urinary Distress Inventory (UDI), Pelvic Organ Pro-lapse Distress Inventory (POPDI), Colorectal-anal Distress Inventory (CRADI)</p> <p>Correlation of short form with long form of original PFDI and PFIQ scales</p> <p>MID = 12; 3-6 months post-surgery. t-test for matched pairs of difference pre- and post-surgery PFDI and PFIQ scores, effect size, SRM</p> <p>Each of the 3 scales is scored from 0 (least distress) to 100 (greatest distress). The sum of the scores of these 3 scales serves as the overall summary score of the PFDI-20 (0-300)</p>
<p>Pelvic Floor Bother Questionnaire (PFBQ)</p>	<p>Peterson TV, Karp DR, Aguilar VC, Davila GW. Validation of a global pelvic floor symptom bother questionnaire. <i>Int Urogynecol J</i>. 2010 Sep;21(9):1129-35. doi: 10.1007/s00192-010-1148-7. Epub 2010 May 11. PMID: 20458467.</p>	<p>US English</p> <p>Clinical</p> <p>Women 18+ with pelvic floor disorders. N = 141</p> <p>9</p> <p>Not reported</p> <p>Not patient input; expert panel</p> <p>Cronbach's alpha</p> <p>Fixed effect with ICC, Kappa</p> <p>9</p> <p>Global, Urinary, Prolapse, Defecatory, Sexual Dysfunction</p> <p>Construct</p> <p>No MID reported; not tested for responsiveness</p> <p>Scores for each item range from 0 to 5. The total questionnaire score ranges from 0 to 45, with higher scores indicating more bother. The scores can be transformed by multiplying the mean score of the questionnaire by 20, which gives a total score varying between 0 and 100</p>		

Table 2 (continued)

	US Eng-lish	Research	Women 18+	41	No	Factor loading-MLC	Cronbach alpha	weighted kappa	31 items;	3 domains	T-test	A reasonable	Higher scores indi-
Pelvic Organ Pro-lapse/Urinary Incontinence Sexual Questionnaire; PISQ (full length)	Rogers, RG, et al. (2003). "A new instrument to measure sexual function in women with urinary incontinence or pelvic organ prolapse." Am J Obstet Gynecol 184(4): 552-558.	Research	Women 18+ symptomatic and healthy for internal validity phase 1, n = 83; Women with UI or POP and sexually active for internal and external validity phase 2, n = 99	41	No	Principal component analysis with Varimax rotation	Cronbach alpha	weighted kappa	31 items;	3 domains (Behavioral/Emotive, Physical, Partner-Related)	T-test	A reasonable estimate of MID for the PISQ total score is 6 points	Higher scores indicate better sexual function; scores were calculated by totaling the scores for each question, from 0 (always) to 4 (never), with the exception of question 5, which was scaled from 0 (always) to 5 (do not masturbate). Individual factor scores were calculated by adding the scores for the individual items in each factor. Reverse scoring was used for items 1, 2, 5, 6, 7, 8, 9, 10, 22, 23, 24, 26, 27 and 29; factor 1 contained questions 1, 2, 5, 6, 7, 8, 9, 10, 12, 22, 23, 24, 26, 27 and 29; factor 2 contained questions 11, 13, 16, 17, 18, 19, 20, 21, 25 and 30; factor 3 contained questions 3, 4, 14, 15, 28 and 31. To handle missing values, the researcher calculated the sum by multiplying the number of items by the mean of the answered items
Pelvic Organ Pro-lapse/Urinary Incontinence Sexual Questionnaire; PISQ-12	Rogers, RG, et al. (2003). "A short form of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12)." International Urogynecology Journal 14(3): 164-168. discussion 168.	Research	Women 18 + (n = 99) from primary PISQ validation cohort and additional women from TX (N = 46)	31	NA	None	Cronbach's alpha	test-retest	12	N	Correlation		
	Parnell, BA, et al. (2011). "Validation of web-based administration of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12)." International Urogynecology Journal 22(3): 357-361	Research											

Table 2 (continued)

	US Eng-lish	Research	Women 18+ with and without pelvic floor disorders	12	NA	None	Cronbach's alpha	Test-retest	9	N	Correlation
Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire: PISQ-9	Aeshkenazi, SO et al. (2010). "A Valid Form of the PISQ-12, the PISQ-9, for Use in Comparative Studies of Women With and Without Pelvic Organ Prolapse and/or Urinary Incontinence." <i>Female Pelvic Med Reconstr Surg</i> 16(4): 218-223.	Research	Women 18+ with and without pelvic floor disorders = 589	42							
Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire IUGA Revised: PISQ-IR	Rogers, RG, et al. (2013). "A new measure of sexual function in women with pelvic floor disorders (PPD): the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR)." <i>Int Urogynecol J</i> 26(5): 657-663. Constamine, ML, et al. (2017). "Validation of a single summary score for the Prolapse/Incontinence Sexual Questionnaire-IUGA revised (PISQ-IR)." <i>Int Urogynecol J</i> 28(12): 1901-1907. Grybowski, ME, et al. (2019). "Identification of the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire-IUGA Revised (PISQ-IR) Cutoff Scores for Impaired Sexual Function in Women with Pelvic Floor Disorders." <i>Journal of Clinical Medicine</i> 9(1): 19.	UK & US Eng-lish	Women 18+ with and without pelvic floor disorders. n = 589	42	Cognitive inter-views; expert panel	PCA with Varimax, threshold criteria given	Cronbach's alpha	Test-retest	19	For sexually inactive 2 domains: Sexuality Inactivity (NSA-CS, NSA-PR) Quality and Satisfaction (Global qualit-iv, Condition impact). For sexually active 2 domains: Sexual response (SA-AO, SA-PR, SA-CS) Quality, Satisfaction, Desire (SA-GOR, SA-CI, SA-D)	Correlation
											Not reported
											Either mean calculation or a transformed sum. For calculating subscale the respondent must answer more than one half of the items in the subscale.

**Table 3** POP PROs and available validated translations

Instrument	Citation	Language
Body Image in Pelvic Organ Prolapse Questionnaire (BIPOP)	Moroni, Rafael M., et al. "Assessment of body image, sexual function, and attractiveness in women with genital prolapse: a cross-sectional study with validation of the Body Image in the Pelvic Organ Prolapse (BIPOP) Questionnaire." <i>The journal of sexual medicine</i> 16.1 (2019): 126-136.	Portuguese-Brazilian
	Montoya, T. I., et al. "24: Validation of the body image in pelvic organ prolapse questionnaire in Spanish-speaking Latinas." <i>American Journal of Obstetrics &amp; Gynecology</i> 222.3 (2020): S789.	Spanish
Australian Pelvic Floor Questionnaire	Argirović, A., et al. (2015). "Cross-cultural adaptation and validation of the Serbian version of the Australian pelvic floor questionnaire." <i>Int Urogynecol J</i> 26(1): 131-138.	Serbian
	PDF not Available Saribrahim Astepe, B. and I. Köleli (2019). "Translation, cultural adaptation, and validation of Australian pelvic floor questionnaire in a Turkish population." <i>Eur J Obstet Gynecol Reprod Biol</i> 234: 71-74.	Turkish
	PDF Not Available Hou, Y. and D. Hou (2020). "Validation of the Australian Pelvic Floor Questionnaire in Chinese pregnant and postpartum women." <i>Eur J Obstet Gynecol Reprod Biol</i> 245: 102-106.	Chinese
	Malaekah, H., et al. (2021). "Arabic translation, cultural adaptation, and validation of Australian Pelvic Floor Questionnaire in a Saudi population." <i>BMC Womens Health</i> 21(1): 6.	Arabic
Prolapse and Incontinence Knowledge Quiz (PIKQ)	Toprak Celenay S, Coban O, Sahbaz Pirincci C, Korkut Z, Birben T, Alkan A, Avsar AF. Turkish translation of the Prolapse and Incontinence Knowledge Questionnaire: validity and reliability. <i>Int Urogynecol J</i> . 2019 Dec;30(12):2183-2190. doi: 10.1007/s00192-019-03962-5. Epub 2019 May 2. PMID: 31049644.	Turkish
Pelvic Organ Prolapse Simple Screening Inventory (POPSSI)	Kassa et al. Validation of the Pelvic Organ Prolapse Simple Screening Instrument (POPSSI) in a population of Ethiopian Women. <i>BMC Women's Health</i> (2019) 19:52	Ethiopian
Incontinence Questionnaire-VS	Banerjee, C., Banerjee, M., Hatzmann, W., Schiermeier, S., Sachse, K., Hellmich, M., Noé, G.K. (2010). The German Version of the 'ICIQ Vaginal Symptoms Questionnaire' (German ICIQ-VS): An Instrument Validation Study. <i>Urol. Int.</i> 85, 70–79	German
	Stavros, A., Themistoklis, G., Niki, K., George, G., Aristidis, A. (2012). The validation of international consultation on incontinence questionnaires in the Greek language. <i>Neurourol. Urodyn.</i> 31, 1141–1144	Greek
	Tamanini, J.T.N., Almeida, F.G., Girotti, M.E., Ricetto, C.L.Z., Palma, P.C.R., Rios, L.A.S. (2008). The Portuguese validation of the International Consultation on Incontinence Questionnaire—Vaginal Symptoms (ICIQ-VS) for Brazilian women with pelvic organ prolapse. <i>Int. Urogynecology J.</i> 19, 1385–1391	Portuguese
	Fonseca, C., et al. (2017). "Translation and cross-cultural adaptation of a standardized international consultation on incontinence modular questionnaire-vaginal symptoms (ICIQ-VS) to spanish." <i>International Urogynecology Journal</i> 28(1): S239-S240.	Spanish
	Silva, G. de, Furukan, R., Goonewardene, M., (2017). Validation of the Sinhala translation of the International Consultation on Incontinence Modular Questionnaire for female lower urinary tract symptoms among women in Sri Lanka. <i>Int. Urogynecology J.</i> 28, 1895–1899	Sinhala
	Ekanayake, C. D., et al. (2017). "Translation and validation of ICIQ-FLUTS for Tamil-speaking women." <i>International Urogynecology Journal</i> 28(12): 1875-1881.	Tamil
	Chattrakulchai, K., Manonai, J., Silpakit, C. et al. Validation of the Thai version of the International Consultation on Incontinence Questionnaire-Female Lower Urinary Tract Symptoms (ICIQ-FLUTS). <i>Int Urogynecol J</i> 31, 2603–2610 (2020).	Thai
	Arenholt, L. T. S., et al. (2019). "Translation and validation of the International Consultation on Incontinence Questionnaire Vaginal Symptoms (ICIQ-VS): the Danish version." <i>Int Urogynecol J</i> 30(1): 17-22.	Danish

**Table 3** (continued)

Instrument	Citation	Language
Prolapse Quality of Life (P-QoL)	Validation of the Malay version of the p-QOL questionnaire. Dasrilayah RA, Ng BK, Atan IK, Khong SY, Nusee Z, Lim PS. <i>Int Urogynecol J</i> . 2020 Jun 6. doi: 10.1007/s00192-020-04362-w. Online ahead of print.	Malay
	Validation of the Polish version of P-QoL questionnaire. Rzepka J, Zalewski K, Stefanowicz A, Khullar V, Swift S, Digesu GA. <i>Ginekol Pol</i> . 2016;87(7):477-83. doi: 10.5603/GP.2016.0029.	Polish
	Validation of the French version of the P-QoL questionnaire. Veit-Rubin N, Digesu A, Swift S, Khullar V, Kaelin Gambirasio I, Dällenbach P, Boulvain M. <i>Eur J Obstet Gynecol Reprod Biol</i> . 2015 Sep;192:10-6. doi: 10.1016/j.ejogrb.2015.05.028. Epub 2015 Jun 10. PMID: 26142910	French
	Quality of Life in POP: Validity, Reliability and Responsiveness of the Prolapse Quality of Life Questionnaire (P-QoL) in Spanish Women. Sánchez-Sánchez B, Yuste-Sánchez MJ, Arranz-Martín B, Navarro-Brazález B, Romay-Barrero H, Torres-Lacomba M. <i>Int J Environ Res Public Health</i> . 2020 Mar 5;17(5):1690. doi: 10.3390/ijerph17051690. PMID: 32150963	Spanish
	P-QOL questionnaire in Thai version./ Validation of the Prolapse Quality of Life (P-QOL) questionnaire in Thai version. Manchana T, Bunyavejchevin S. <i>Int Urogynecol J</i> . 2010 Aug;21(8):985-93. doi: 10.1007/s00192-010-1107-3. Epub 2010 Feb 11. PMID: 20148241	Thai
	Wiwanitkit V. <i>Int Urogynecol J</i> . 2010 Aug;21(8):1039; author reply 1041. doi: 10.1007/s00192-010-1166-5. Epub 2010 May 18. PMID: 20480141	
	Validation of the Slovakian version of the P-QOL questionnaire. Svihrova V, Digesu GA, Svihra J, Hudeckova H, Kliment J, Swift S. <i>Int Urogynecol J</i> . 2010 Jan;21(1):53-61. doi: 10.1007/s00192-009-0989-4. Epub 2009 Sep 11. PMID: 19763367	Slovakian
	Validation of a German version of the P-QOL Questionnaire. Lenz F, Stammer H, Brocker K, Rak M, Scherg H, Sohn C. <i>Int Urogynecol J Pelvic Floor Dysfunct</i> . 2009 Jun;20(6):641-9. doi: 10.1007/s00192-009-0809-x. Epub 2009 Feb 13. PMID: 19214361	German
	Response validity of Persian version of P-QOL questionnaire in patients with prolapse. / Validation of Persian version of the Prolapse Quality-of-Life questionnaire (P-QOL). Nojomi M, Digesu GA, Khullar V, Morovatdar N, Haghighi L, Alirezaei M, Swift S. <i>Int Urogynecol J</i> . 2012 Feb;23(2):229-33. doi: 10.1007/s00192-011-1529-6. Epub 2011 Aug 17. PMID: 22052441	Persian
	Morovatdar N, Hgghighi L, Najmi Z, Hashemi A, Nojomi M. <i>Eur J Obstet Gynecol Reprod Biol</i> . 2015 Oct;193:88-91. doi: 10.1016/j.ejogrb.2015.07.013. Epub 2015 Jul 31. PMID: 26262766	
	Validation of the traditional Chinese version of the prolapse quality of life questionnaire (P-QOL) in a Mandarin-speaking Taiwanese population. Chuang FC, Chu LC, Kung FT, Huang KH. <i>Taiwan J Obstet Gynecol</i> . 2016 Oct;55(5):680-685. doi: 10.1016/j.tjog.2016.02.018. PMID: 27751415	Mandarin
	Validity, reliability and responsiveness of a Dutch version of the prolapse quality-of-life (P-QoL) questionnaire. Claerhout F, Moons P, Ghesquiere S, Verguts J, De Ridder D, Deprest J. <i>Int Urogynecol J</i> . 2010 May;21(5):569-78. doi: 10.1007/s00192-009-1081-9. Epub 2010 Jan 16. PMID: 20082065	Dutch
	Validation of the prolapse quality of life questionnaire (P-QOL) in a Turkish population. Cam C, Sakalli M, Ay P, Aran T, Cam M, Karateke A. <i>Eur J Obstet Gynecol Reprod Biol</i> . 2007 Nov;135(1):132-5. doi: 10.1016/j.ejogrb.2007.06.009. Epub 2007 Aug 10. PMID: 17693011	Turkish
	Translation, transcultural adaptation, reliability and validation of the pelvic organ prolapse quality of life (P-QoL) in Amharic. Belayneh T, Gebeyehu A, Adefris M, Rortveit G, Genet T. <i>Health Qual Life Outcomes</i> . 2019 Jan 14;17(1):12. doi: 10.1186/s12955-019-1079-z. PMID: 30642346	Amharic
Validation of the Prolapse Quality-of-Life Questionnaire (P-QoL) in Portuguese version in Brazilian women. de Oliveira MS, Tamanini JT, de Aguiar Cavalcanti G. <i>Int Urogynecol J Pelvic Floor Dysfunct</i> . 2009 Oct;20(10):1191-202. doi: 10.1007/s00192-009-0934-6. Epub 2009 Jul 4. PMID: 19578803	Portuguese	



**Table 3** (continued)

Instrument	Citation	Language
	[Assessment of quality of life in women with pelvic organ prolapse: conditional translation and trial of P-QOL for use in Japan]. Fukumoto Y, Uesaka Y, Yamamoto K, Ito S, Yamanaka M, Takeyama M, Noma M. <i>Nihon Hinyokika Gakkai Zasshi</i> . 2008 Mar; 99(3):531-42. doi: 10.5980/jpnjurol1989.99.531. PMID: 18404882	Japanese
	Validation, reliability, and responsiveness of Prolapse Quality of Life Questionnaire (P-QOL) in a Brazilian population. Scarlato A, Souza CC, Fonseca ES, Sartori MG, Girão MJ, Castro RA. <i>Int Urogynecol J</i> . 2011 Jun;22(6):751-5. doi: 10.1007/s00192-010-1354-3. Epub 2011 Jan 28. PMID: 21274514	Portuguese
	Validation of the Spanish-language version of the Prolapse Quality of Life questionnaire in Chilean women. Flores-Espinoza C, Araya AX, Pizarro-Berdichevsky J, Santos V, Ferrer M, Garin O, Swift S, Digesu AG. <i>Int Urogynecol J</i> . 2015 Jan;26(1):123-30. doi: 10.1007/s00192-014-2484-9. Epub 2014 Sep 16. PMID: 25224147	Spanish in Chile
	Validation of an Italian version of the prolapse quality of life questionnaire. Digesu GA, Santamato S, Khullar V, Santillo V, Digesu A, Cormio G, Loverro G, Selvaggi L. <i>Eur J Obstet Gynecol Reprod Biol</i> . 2003 Feb 10;106(2):184-92. doi: 10.1016/s0301-2115(02)00229-4. PMID: 12551790	Italian
Epidemiology of prolapse and incontinence Questionnaire (EPIQ)	Pons ME, Crespo MF, Amorós MA, Álvarez PR, Soto MP. Validación de la versión en español del cuestionario "Epidemiology of Prolapse and Incontinence Questionnaire-EPIQ". <i>Actas urológicas españolas</i> . 2009 Jan 1;33(6):646-53.	Spanish
Pelvic Floor Distress Inventory (PFDI-46) & Pelvic Floor Impact Questionnaire (PFIQ)	Chan SS, Cheung RY, Yiu AK, Li JC, Lai BP, Choy KW, Chung TK. Chinese validation of Pelvic Floor Distress Inventory and Pelvic Floor Impact Questionnaire. <i>Int Urogynecol J</i> . 2011 Oct;22(10):1305-12. doi:10.1007/s00192-011-1450-z.	Chinese
	Omotosho TB, Hardart A, Rogers RG, Schaffer JI, Kobak WH, Romero AA. Validation of Spanish versions of the Pelvic Floor Distress Inventory (PFDI) and Pelvic Floor Impact Questionnaire (PFIQ): a multicenter validation randomized study. <i>Int Urogynecol J Pelvic Floor Dysfunct</i> . 2009 Jun;20(6):623-39. doi:10.1007/s00192-008-0792-7.	Spanish
	Young AE, Fine PM, McCreery R, Wren PA, Richter HE, Brubaker L, Brown MB, Weber AM; Pelvic Floor Disorders Network. Spanish language translation of pelvic floor disorders instruments. <i>Int Urogynecol J Pelvic Floor Dysfunct</i> . 2007 Oct;18(10):1171-8. doi: 10.1007/s00192-006-0297-1.	Spanish
Pelvic Floor Distress Inventory (PFDI-20) & Pelvic Floor Impact Questionnaire (PFIQ-7)	Arouca MA, Duarte TB, Lott DA, Magnani PS, Nogueira AA, Rosa-E-Silva JC, Brito LG. Validation and cultural translation for Brazilian Portuguese version of the Pelvic Floor Impact Questionnaire (PFIQ-7) and Pelvic Floor Distress Inventory (PFDI-20). <i>Int Urogynecol J</i> . 2016 Jul;27(7):1097-106. doi: 10.1007/s00192-015-2938-8	Brazilian Portuguese
	Ma Y, Xu T, Zhang Y, Mao M, Kang J, Zhu L. Validation of the Chinese version of the Pelvic Floor Distress Inventory-20 (PFDI-20) according to the COSMIN checklist. <i>Int Urogynecol J</i> . 2019 Jul;30(7):1127-1139. doi:10.1007/s00192-018-3847-4.	Chinese
	de Tayrac R, Deval B, Fernandez H, Marès P; Mapi Research Institute. Validation linguistique en français des versions courtes des questionnaires de symptômes (PFDI-20) et de qualité de vie (PFIQ-7) chez les patientes présentant un trouble de la statique pelvienne [Development of a linguistically validated French version of two short-form, condition-specific quality of life questionnaires for women with pelvic floor disorders (PFDI-20 and PFIQ-7)]. <i>J Gynecol Obstet Biol Reprod (Paris)</i> . 2007 Dec;36(8):738-48. French. doi:10.1016/j.jgyn.2007.08.002.	French
	Due U, Brostrøm S, Lose G. Validation of the Pelvic Floor Distress Inventory-20 and the Pelvic Floor Impact Questionnaire-7 in Danish women with pelvic organ prolapse. <i>Acta Obstet Gynecol Scand</i> . 2013 Sep;92(9):1041-8. doi:10.1111/aogs.12189.	Danish
	Goba GK, Legesse AY, Zelelow YB, Gebreselassie MA, Rogers RG, Kenton KS, Mueller MG. Reliability and validity of the Tigrigna version of the Pelvic Floor Distress Inventory-Short Form 20 (PFDI-20) and Pelvic Floor Impact Questionnaire-7 (PFIQ-7). <i>Int Urogynecol J</i> . 2019 Jan;30(1):65-70. doi:10.1007/s00192-018-3583-9.	Tigrigna

**Table 3** (continued)

Instrument	Citation	Language
	Grigoriadis T, Athanasiou S, Giannoulis G, Mylona SC, Lourantou D, Antsaklis A. Translation and psychometric evaluation of the Greek short forms of two condition-specific quality of life questionnaires for women with pelvic floor disorders: PFDI-20 and PFIQ-7. <i>Int Urogynecol J</i> . 2013 Dec;24(12):2131-44. doi:10.1007/s00192-013-2144-5.	Greek
	Grzybowska ME, Griffith JW, Kenton K, Mueller M, Piaszkowska-Cala J, Lewicky-Gaupp C, Wydra D, Bochenska K. Validation of the Polish version of the Pelvic Floor Distress Inventory. <i>Int Urogynecol J</i> . 2019 Jan;30(1):101-105. doi:10.1007/s00192-018-3715-2.	Polish
	Henn EW, Richter BW, Marokane MMP. Validation of the PFDI-20 and PFIQ-7 quality of life questionnaires in two African languages. <i>Int Urogynecol J</i> . 2017 Dec;28(12):1883-1890. doi: 10.1007/s00192-017-3318-3.	Afrikaans and Sesotho
	Kaplan PB, Sut N, Sut HK. Validation, cultural adaptation and responsiveness of two pelvic-floor-specific quality-of-life questionnaires, PFDI-20 and PFIQ-7, in a Turkish population. <i>Eur J Obstet Gynecol Reprod Biol</i> . 2012 Jun;162(2):229-33. doi: 10.1016/j.ejogrb.2012.03.004.	Turkish
	Toprak Celenay S, Akbayrak T, Kaya S, Ekici G, Beksac S. Validity and reliability of the Turkish version of the Pelvic Floor Distress Inventory-20. <i>Int Urogynecol J</i> . 2012 Aug;23(8):1123-7. doi: 10.1007/s00192-012-1729-8.	Turkish
	Mattsson NK, Nieminen K, Heikkinen AM, Jalkanen J, Koivurova S, Eloranta ML, Suvitie P, Tolppanen AM. Validation of the short forms of the Pelvic Floor Distress Inventory (PFDI-20), Pelvic Floor Impact Questionnaire (PFIQ-7), and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) in Finnish. <i>Health Qual Life Outcomes</i> . 2017 May 2;15(1):88. doi: 10.1186/s12955-017-0648-2.	Finnish
	Treszezamsky AD, Karp D, Dick-Biascoechea M, Ehsani N, Dancz C, Montoya TI, Olivera CK, Smith AL, Cardenas R, Fashokun T, Bradley CS; Society of Gynecologic Surgeons Fellows' Pelvic Research Network. Spanish translation and validation of four short pelvic floor disorders questionnaires. <i>Int Urogynecol J</i> . 2013 Apr;24(4):655-70. doi: 10.1007/s00192-012-1894-9.	Spanish
	Sánchez Sánchez B, Torres Lacomba M, Navarro Brazález B, Cerezo Téllez E, Pacheco Da Costa S, Gutiérrez Ortega C. Responsiveness of the Spanish Pelvic Floor Distress Inventory and Pelvic Floor Impact Questionnaires Short Forms (PFDI-20 and PFIQ-7) in women with pelvic floor disorders. <i>Eur J Obstet Gynecol Reprod Biol</i> . 2015 Jul;190:20-5. doi: 10.1016/j.ejogrb.2015.03.029.	Spanish
	Teig CJ, Grotle M, Bond MJ, Prinsen CAC, Engh MAE, Cvancarova MS, Kjøllesdal M, Martini A. Norwegian translation, and validation, of the Pelvic Floor Distress Inventory (PFDI-20) and the Pelvic Floor Impact Questionnaire (PFIQ-7). <i>Int Urogynecol J</i> . 2017 Jul;28(7):1005-1017. doi: 10.1007/s00192-016-3209-z.	Norwegian
	Teleman P, Stenzelius K, Iorizzo L, Jakobsson U. Validation of the Swedish short forms of the Pelvic Floor Impact Questionnaire (PFIQ-7), Pelvic Floor Distress Inventory (PFDI-20) and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12). <i>Acta Obstet Gynecol Scand</i> . 2011 May;90(5):483-7. doi: 10.1111/j.1600-0412.2011.01085.x.	Swedish
	Utomo E, Blok BF, Steensma AB, Korfage IJ. Validation of the Pelvic Floor Distress Inventory (PFDI-20) and Pelvic Floor Impact Questionnaire (PFIQ-7) in a Dutch population. <i>Int Urogynecol J</i> . 2014 Apr;25(4):531-44. doi: 10.1007/s00192-013-2263-z.	Dutch
	Wiegiersma M, Panman CM, Berger MY, De Vet HC, Kollen BJ, Dekker JH. Minimal important change in the pelvic floor distress inventory-20 among women opting for conservative prolapse treatment. <i>Am J Obstet Gynecol</i> . 2017 Apr;216(4):397.e1-397.e7. doi: 10.1016/j.ajog.2016.10.010.	Dutch
	Wijesinghe V, Amaradivakara P, Farukan R. Validation of the Sinhala translations of the Pelvic Floor Distress Inventory and the Pelvic Floor Impact Questionnaire in a Sri Lankan population. <i>Int Urogynecol J</i> . 2021 Mar 29. doi:10.1007/s00192-021-04695-0.	Sinhala
	Yoo EH, Jeon MJ, Ahn KH, Bai SW. Translation and linguistic validation of Korean version of short form of pelvic floor distress inventory-20, pelvic floor impact questionnaire-7. <i>Obstet Gynecol Sci</i> . 2013 Sep;56(5):330-2. doi:10.5468/ogs.2013.56.5.330.	Korea

**Table 3** (continued)

Instrument	Citation	Language
	Yoshida M, Murayama R, Ota E, Nakata M, Kozuma S, Homma Y. Reliability and validity of the Japanese version of the pelvic floor distress inventory-short form 20. <i>Int Urogynecol J</i> . 2013 Jun;24(6):1039-46. doi:10.1007/s00192-012-1962-1.	Japanese
	El-Azab AS, Abd-Elsayed AA, Imam HM. Patient reported and anatomical outcomes after surgery for pelvic organ prolapse. <i>Neurourol Urodyn</i> . 2009;28(3):219-24. doi: 10.1002/nau.20626.	Arabic Muslim
	Lowenstein L, Levy G, Chen KO, Ginath S, Condrea A, Padoa A. Validation of Hebrew versions of the Pelvic Floor Distress Inventory, Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire, and the Urgency, Severity and Impact Questionnaire. <i>Female Pelvic Med Reconstr Surg</i> . 2012 Nov-Dec;18(6):329-31. doi: 10.1097/SPV.0b013e31827268fa.	Hebrew
Pelvic Floor Bother questionnaire (PFBQ)	Peterson TV, Pinto RA, Davila GW, Nahas SC, Baracat EC, Haddad JM. Validation of the Brazilian Portuguese version of the pelvic floor bother questionnaire. <i>Int Urogynecol J</i> . 2019 Jan;30(1):81-88. doi: 10.1007/s00192-018-3627-1. Epub 2018 Mar 16. PMID: 29549393.	Brazilian Portuguese
	Bazi T, Kabakian-Khasholian T, Ezzeddine D, Ayoub H. Validation of an Arabic version of the global Pelvic Floor Bother Questionnaire. <i>Int J Gynaecol Obstet</i> . 2013 May;121(2):166-9. doi: 10.1016/j.ijgo.2012.12.006. Epub 2013 Mar 5. PMID: 23465855.	Arabic
	Badalian SS, Sagayan E, Simonyan H, Minassian VA, Isahakian A. The prevalence of pelvic floor disorders and degree of bother among women attending primary care clinics in Armenia. <i>Eur J Obstet Gynecol Reprod Biol</i> . 2020 Mar;246:106-112. doi: 10.1016/j.ejogrb.2020.01.029. Epub 2020 Jan 25. PMID: 32006916.	Armenian
Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-31)	Romero, A. A., et al. (2003). "Validation of a Spanish version of the Pelvic Organ Prolapse Incontinence Sexual Questionnaire." <i>Obstet Gynecol</i> 102(5 Pt 1): 1000-1005.	Spanish
	Grzybowska, M. E., et al. (2016). "Validation of the Polish version of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire." <i>Int Urogynecol J</i> 27(5): 781-786.	Polish
Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12)	Pons, E. M., et al. (2008). "[Questionnaire for evaluation of sexual function in women with genital prolapse and/or incontinence. Validation of the Spanish version of "Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12)]." <i>Actas Urol Esp</i> 32(2): 211-219.	Spanish
	Flores-Espinoza, C. C. and V. L. Santos (2017). "Validation of the spanish version pelvic organ prolapse/ urinary incontinence sexual questionnaire (PISQ-12) in Chilean women." <i>Quality of Life Research</i> 26(1): 114.	Spanish
	Mattsson, N. K., et al. (2017). "Validation of the short forms of the Pelvic Floor Distress Inventory (PFDI-20), Pelvic Floor Impact Questionnaire (PFIQ-7), and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) in Finnish." <i>Health Qual Life Outcomes</i> 15(1): 88.	Finnish
	Santana, G. W., et al. (2012). "The Portuguese validation of the short form of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12)." <i>International Urogynecology Journal</i> 23(1): 117-121.	Portuguese
	Teleman, P., et al. (2011). "Validation of the Swedish short forms of the Pelvic Floor Impact Questionnaire (PFIQ-7), Pelvic Floor Distress Inventory (PFDI-20) and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12)." <i>Acta Obstet Gynecol Scand</i> 90(5): 483-487.	Swedish
	Cam, C., et al. (2009). "Validation of the short form of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) in a Turkish population." <i>Eur J Obstet Gynecol Reprod Biol</i> 146(1): 104-107.	Turkish
	Bilgic Celik, D., et al. (2013). "Turkish adaptation of the short form of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12): a validation and reliability study." <i>Neurourology &amp; Urodynamics</i> 32(8): 1068-1073.	Turkish

**Table 3** (continued)

Instrument	Citation	Language
	Fatton, B., et al. (2009). "[Validation of a French version of the short form of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12)]." <i>J Gynecol Obstet Biol Reprod (Paris)</i> 38(8): 662-667.	French
	't Hoen, L. A., et al. (2015). "The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12): validation of the Dutch version." <i>International Urogynecology Journal</i> 26(9): 1293-1303.	Dutch
	Momenimovahe, Z., et al. (2015). "Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12): psychometric validation of the Iranian version." <i>Int Urogynecol J</i> 26(3): 433-439.	Iranian
	Su, T. H. and H. H. Lau (2010). "Validation of a Chinese version of the short form of the pelvic organ prolapse/urinary incontinence sexual questionnaire." <i>Journal of Sexual Medicine</i> 7(12): 3940-3945.	Chinese
	Kamińska A, Skorupska K, Kubik-Komar A, Futyma K, Filipczak J, Rechberger T. Reliability of the Polish Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) and Assessment of Sexual Function before and after Pelvic Organ Prolapse Reconstructive Surgery-A Prospective Study. <i>J Clin Med.</i> 2021 Sep 15;10(18):4167. doi: 10.3390/jcm10184167. PMID: 34575276; PMCID: PMC8467811.	Polish
	Zhu, L., et al. (2012). "Validation of the chinese version of the pelvic organ prolapse/urinary incontinence sexual questionnaire short form (PISQ-12)." <i>International Journal of Gynecology and Obstetrics</i> 116(2): 117-119.	Chinese
Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-IR)		
	Fatton, B., et al. (2013). "[French language validation of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire - IUGA revised (PISQ-IR)]." <i>Prog Urol</i> 23(17): 1464-1473.	French
	Tomoe, H., et al. (2014). "[Linguistic validation of Japanese version of Prolapse/Urinary Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR)]." <i>Nihon Hinyokika Gakkai Zasshi</i> 105(3): 102-111.	Japanese
	El-Azab, A. S., et al. (2015). "Arabic validation of the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR)." <i>Int Urogynecol J</i> 26(8): 1229-1237.	Arabic
	Al-Badr, A., et al. (2017). "Validation of the International Urogynecology Association's Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire in Arabic." <i>Int Urogynecol J</i> 28(3): 437-445.	Arabic
	Wang, H., et al. (2015). "Validation of a Mandarin Chinese version of the pelvic organ prolapse/urinary incontinence sexual questionnaire IUGA-revised (PISQ-IR)." <i>International Urogynecology Journal and Pelvic Floor Dysfunction</i> 26(11): 1695-1700.	Mandarin
	Farkas, B., et al. (2016). "Hungarian language validation of the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR)." <i>Int Urogynecol J</i> 27(12): 1831-1836.	Hungarian
	Grzybowska, M. E., et al. (2019). "Polish translation and validation of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR)." <i>Int Urogynecol J</i> 30(1): 55-64.	Polish
	Trutnovsky, G., et al. (2016). "German translation and validation of the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire-IUGA revised (PISQ-IR)." <i>International Urogynecology Journal</i> 27(8): 1235-1244.	German
	Mestre, M., et al. (2017). "Spanish version of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire IUGA-Revised (PISQ-IR): Transcultural validation." <i>International Urogynecology Journal</i> 28(12): 1865-1873.	Spanish
	Rušavý, Z., et al. (2017). "[Czech linguistic validation of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire - IUGA revised]." <i>Ceska Gynekol</i> 82(2): 129-138.	Czech
	Bunyavejchevin, S. and P. Ruanphoo (2018). "Validity and reliability of Thai version Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire, IUGA-Revised (PISQIR)." <i>International Urogynecology Journal</i> 29: S86.	Thai
	van Dongen, H., et al. (2019). "Dutch translation and validation of the pelvic organ prolapse/incontinence sexual questionnaire-IUGA revised (PISQ-IR)." <i>Int Urogynecol J</i> 30(1): 107-114.	Dutch

POPQ stage, pad count) or a subjective measure (e.g., PGI-I). Distribution-based approaches are based on statistical criteria from the PRO scores. When a PRO does not have an anchor-based MID, the MID can be estimated using a distribution approach as half the standard deviation of the baseline score of the measure of interest [36].

## PROs and PRGs for clinical practice

### Commonly used PRO and PRG measures

#### Patient-reported outcomes: function and symptom bother measures

Below is a list of instruments identified by our structured review of the literature. We aimed to be inclusive of measures specifically for POP or validated for use in this population. These measures are of varied quality and rigor in their validation and reliability testing; please refer to Table 2 for specific details of the PROs specific to POP. The overarching principle in choosing a PRO for clinical or research use is to understand what a PRO is designed to measure (severity, functional impact, sexual health, etc.) and in what population (post-menopausal women, community women, women with PFDs, etc.). Grading of PROs is an arduous process following the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) guidance and was outside the scope of this review [37]. Table 3 provides currently available validated languages for each PRO specific to POP.

The health-related quality of life (HRQOL) visual analog scale is a single validated health utility item that captures respondents' perceptions of their current state of health on a scale from 0 to 100 (0 represents death; 100 represents perfect health). This single question has been developed into three condition-specific HRQoL questions for evaluating POP treatment:

- (1) Overall, how satisfied are you with the care you have been getting for your pelvic floor condition? (Responses: very satisfied/somewhat satisfied/neither satisfied nor dissatisfied/somewhat dissatisfied/very dissatisfied).
- (2) In your opinion, has the treatment of your pelvic floor condition been very successful/moderately successful/somewhat successful/not at all successful?
- (3) Compared with how you were doing before your recent pelvic floor operation, would you say that now you are much better/a little better/about the same/a little worse/much worse?

Lower scores on the satisfaction items represent a better health state [38].

#### Patient Global Impression of Improvement (PGI-I)

Global impression, single-item scores are another option for measuring POP therapeutic success. Srikrishna et al. validated the Patient Global Impression of Improvement (PGI-I) in 2010 for patients with POP undergoing surgical management. Validation of this scale involved participants listing five goals prior to surgical management. Patient goal achievement measured by a visual analog scale (VAS) determined subjective satisfaction and PGI-I indicated overall satisfaction. The PGI-I correlated with anatomical changes in POP-Q and quality of life changes in the p-QoL [39].

#### Patient global impression of change PGI-C

The Patient Global Impression of Change (PGIC) is a single-item, self-report question that has been validated in women undergoing vaginal repair augmented with mesh. In this study, 88% of women who perceived “success” on the PGIC also showed improved POP-Q stage [40].

#### International consultation on incontinence questionnaire vaginal symptoms module (ICIQ-VS)

The ICIQ-VS is a 14-item scale with weighted scoring that was developed and validated in 2006 to assess the effect of POP on vaginal symptoms, quality of life and sexual function [23]. Instructions for use are maintained on-line at <https://icq.net/icq-vs> (accessed 01/01/2022).

#### Pelvic Floor Impact Questionnaire (PFIQ-31)/Pelvic Floor Impact Questionnaire short form-7 (PFIQ-7)/Pelvic Organ Prolapse Impact Questionnaire-7 (POPIQ-7)

The PFIQ is a commonly used condition-specific quality of life questionnaire that assess the impact of bladder, bowel and vaginal symptoms on a woman's daily activities, relationships and emotions [18]. It is psychometrically validated, reliable and responsive to change [41]. The PFIQ is a self-administered 31-item questionnaire with three subscales addressing bladder [Urinary Impact Questionnaire (UIQ)], bowel [Colorectal-Anal Impact Questionnaire (CRAIQ)] and POP [POP Impact Questionnaire (POPIQ)]. The short form of the PFIQ is shortened to seven questions, hence PFIQ-7.

The PFIQ-7 subscale scores range from 0–100, with a summary score of 0–300. Higher scores mean increased distress. Of note, compared to the PFDI, the PFIQ-7 requires a higher reading level (9th to 11th vs 6th to 8th, respectively) [42].

#### **Pelvic Floor Distress Inventory (PFDI)/Pelvic Organ Prolapse Distress Inventory (POP-DI)/single question for screening: do you feel a bulge?**

The PFDI is a 46-item form that evaluates urinary, colorectal and POP distress that asks about specific symptoms related to PFDs over the past 3 months [18]. In the PFDI-46, there are 16 items to evaluate POP distress (POP-DI). This is a complementary PRO to the PFIQ. Like the PFIQ, this was abridged to a short form, the PFDI-20. In the PFDI-20 there are 20 questions sub-divided into: urinary distress inventory (UDI), colorectal and anal distress (CRADI) and POP distress (POPDI). Subscale scores range from 0–100 and the summary score is from 0–300, with higher scores indicating increased distress. Their psychometric characteristics have been evaluated by Gelhorn et al., and the PFDI-20 has been validated by Barber et al. [18, 41, 43]. A mean difference of 24 points in the PFDI-20 or 11 points in the POPDI-6 can be used as a clinically relevant difference between groups [44]. It is written at a sixth to eighth grade reading level [42].

From the original study population a single question on the PFDI-20 accurately and reliably identified those women with POP "Do you usually have a bulge or something falling out that you can see or feel in your vaginal area?" An affirmative answer to this question was 96% sensitive (95% CI 92–100) and 79% specific (95% CI 77–92) for prolapse beyond the hymen, and it is commonly used for population-based screening [28].

#### **Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-IR, PISQ-9, PISQ-12, PISQ-31)**

The PISQ-31 was developed in 2001 as the first condition-specific instrument to assess sexual function in women with pelvic organ prolapse and/or urinary incontinence. The original questionnaire had 31 items but subsequently the short form (PISQ-12) was developed in 2003 [45, 46]. The MID for the PISQ-31 is 6 points, and improvements that meet this threshold may be considered clinically important [47]. The PISQ-31 has three domains that can be reported separately: Behavioral/Emotive, Physical and Partner-Related. PISQ-12 scores cannot be reported at the domain level.

The PISQ-9 is a shortened version and can be used in comparative studies assessing pelvic floor function in women with and without prolapse or incontinence [48].

The Pelvic Organ Prolapse/Incontinence Sexual Questionnaire-International Urogynecologic Association (IUGA) Revised (PISQ-IR) was designed to improve upon prior PISQ versions by including women who experience anal incontinence in its validation and evaluate potential PFD impact on women who are not sexually active [19]. Since 2013 the PISQ-IR has been validated and translated into over 25 languages.

#### **Pelvic Organ Prolapse Symptom Score (POP-SS)**

The POP-SS is a 7-item symptom index and requires participants to rate the frequency (never, occasionally, sometimes, most of the time or all of the time) of a POP symptom experienced in the 4 weeks before evaluation [49]. Co-existent urinary and bowel problems are not assessed.

This questionnaire was developed to cover symptoms caused or exacerbated by prolapse and was intended to be used as a supplement to other validated scales of urinary, bowel and sexual symptoms associated with POP. The final question asks which symptoms cause the most bother [49].

#### **Body Image in Pelvic Organ Prolapse Questionnaire (BIPOP)**

The BIPOP is validated to assess body image impact in women with POP and consists of ten items and two subscales: (1) general attractiveness and (2) partner-related POP reactions [50]. The BIPOP refers to an individual's perceptions of and attitudes towards her own body and is a dimension often incorporated with sexual function analyses.

#### **Prolapse Quality of Life (P-QOL)**

Designed to specifically assess the impact of POP on women's quality of life, the P-QOL is a specific multidimensional tool that has 20 questions over 9 domains: general health perceptions, prolapse impact, role limitations, physical limitations, social limitations, personal relationships, emotional problems, sleep, energy disturbance and measurement of symptom severity [26].

#### **Australian Pelvic Floor Questionnaire (APQ)**

The APQ is a comprehensive interviewer-administered questionnaire that integrates bladder, bowel and sexual function, pelvic organ prolapse, severity, bother and condition-specific quality of life [51]. It has been validated for self-administration [52].

### Electronic Personal Assessment Questionnaire-pelvic floor (ePAQ-PF)

The ePAQ-PF is a self-administered, interactive, web-based questionnaire that measures the impact of urinary, bowel, vaginal and sexual symptoms. The Birmingham Bowel and Urinary Symptoms Questionnaire (BBUS-Q), Sheffield Prolapse Symptoms Questionnaire (SPS-Q) and Female Sexual Function Index (FSFI) were the initial questionnaires to form the basis of the ePAQ-PF [27]. The core element of ePAQ-PF is standardized multiple-choice questions, which assess both the frequency and impact of pelvic floor symptoms across four dimensions [15, 27].

While there are no specific PROs for vaginal laxity, the ePAQ-PF patient response data have been used to identify the common concern for “vaginal laxity,” which shows a strong correlation with reduced vaginal sensation during intercourse [53].

The ePAQ-PF allows for free text to record PRGs. Previous data show 63% of patients (n = 1996) added PRGs. In evaluation of the goals, a potential deficit in the ePAQ-PF questionnaire was identified. Approximately 11% of patients listed goals related to body image. In view of this, body image was incorporated as a domain with the vaginal dimension of ePAQ-PF in the more recent versions (version 18) [15].

### Pelvic Floor Bother Questionnaire (PFBQ)

The PFBQ is a nine-item questionnaire that includes symptoms and bother related to (1) stress urinary incontinence, (2) urinary urgency, (3) urinary frequency, (4) urgency incontinence, (5) dysuria, (6) pelvic organ prolapse, (7) obstructed defecation, (8) fecal incontinence and (9) dyspareunia [54]. Each answer is scored in a range from 0 to 5 with higher scores indicating more severe bother. The scoring system gives the same weight for all questions [54].

### Surgical Satisfaction Questionnaire (SSQ)

The SSQ is an 8-item questionnaire validated for women after surgical repair of POP. Responses are recorded on a 5-point Likert-type scale with responses from 0 = “very unsatisfied” to 4 = “very Satisfied” [55].

### Improvement Satisfaction Scale (ISS)

The ISS a single validated item that assesses satisfaction in women following POP surgery. The item reads:

Check the number that best describes how you are currently compared to before surgery for incontinence/pelvic

organ prolapse? Response options are: (1) fixed; (2) greatly improved; (3) improved; (4) not improved; (5) worsened [56].

### SPS-Q Sheffield Prolapse Symptoms Questionnaire

The SPS-Q assesses symptoms related to POP and the impact they have on QoL. The original validation and development laid the groundwork for the more commonly used computer version (e-PAQ) [57].

### Patient-reported outcomes: screening

#### Epidemiology of Prolapse and Incontinence Questionnaire (EPIQ)

This questionnaire was developed to screen for pelvic floor disorders including POP in general populations. The positive predictive value to detect POP is 76% [21]. The questionnaire is valid for both paper and electronic (web-based) administration [58].

#### Pelvic Organ Prolapse Simple Screening Inventory (POP-SSI)

The POPSSI is a screening measure for POP and consists of four questions originally from the PFDI: (1) Do you experience urinary incontinence with laughing, sneezing, or coughing? (2) Do you experience urinary urgency? (3) Do you feel pain during defecation? (4) Do you feel or see a bulge in the vagina? [59]. According to the original validation study, the sensitivity and specificity of POPSSI for identification of pelvic organ prolapse in the general population are 45.5 and 87.4%, respectively.

#### POP Knowledge: Prolapse and Incontinence Knowledge Questionnaire (PIKQ) and the Pelvic Floor Awareness and Knowledge Survey (PFAKS)

The PIKQ and PFAKS are knowledge questionnaires. The PFAKS was developed through expert consensus using both qualitative and quantitative methods. Written at an eighth grade reading level, it demonstrates discriminant validity and can be used to uncover patient misconceptions about POP, SUI and OAB [60].

The PIKQ is a valid, reliable and self-administered instrument for assessing knowledge of POP and UI [61].

### Summary

In summary, the identified PROs for both screening and HRQoL in POP vary in their degree of rigor, utility and intended use. Some of the most widely used PROs still lack validation data in specific populations (such as pregnant women) and specific settings (e.g., community-based populations), and the minimally important clinical difference is still unknown. When choosing PROs for the initial

evaluation of POP, attention must be given to the validation and then confirming that the intended use of the PRO aligns with intended use in clinical practice or research.

### Limitations of patient-reported outcomes

PROs were originally developed for use in research methodology; their extrapolation to clinical practice may make data interpretation inaccurate. Importantly, women may be concerned about the impact of their answers on the care provided by health care providers and adjust responses accordingly. Questionnaires take time to complete, and the response burden may lead to a lower response rate. Clinicians' and researchers' knowledge and familiarity with PROs may also impact their use. Health care organizations often require funding to use PROs on a large-scale basis, potentially limiting usage.

### Patient-reported goals (PRGs)

In 2005, the term “EGGS” was created to facilitate communication about patient-centered treatment outcomes: E-expectations, G-goal setting, G-goal achievement and S-satisfaction [62]. Patient-reported goals can be used to provide patient-centered care and assess efficacy of treatments.

Patients may be asked to list their personal goals for treatment and prioritize their goals by indicating a rank order of importance from “most important to me” to “not very important” [13, 63]. Goal achievement can also be measured by a 5-point Likert scale (1 = strongly disagree, 5 = strongly agree) or by another 5-point scale (from -2 = strongly disagree that the goal had been met to +2 = strongly agree that the goal had been met) [64]. The 10-point Visual Analog Goal Attainment Scale is another option for reporting goal achievement [65, 66]. The visual analog scale can also be used to compare patients' and surgeons' goals [67].

Goal attainment scaling (GAS) is a technique for measuring goal achievement after therapy that has become commonly used to assess fulfillment of patient-centered goals and outcomes. GAS approaches allow any patient goal to be “anchored” prior to treatment. Patients can judge their own treatment outcomes during follow-up by rating their outcomes on a 5-point scale, with -2 assigned to the worst outcome and +2 to the best [12, 64]. A simpler option is the Global Impression of Improvement Questionnaire (PGI-I), which utilizes a single question and response to gauge goal attainment [29].

While patient goals correlate with satisfaction, they are also associated with improved condition specific QOL measures [68, 69]. Goal studies have also demonstrated that when patients seek care for pelvic organ prolapse they may desire

improvement in urinary symptoms illustrating the potential disconnect between anatomical improvement and patient expectations [63]. When evaluating patients with pelvic organ prolapse, overactive bladder symptoms remained a common reason for goal failure [70]. Mamik et al. also found that patient's pelvic organ prolapse surgical goals often centered on urinary symptom resolution while physician goals focused on anatomical correction of bulging illustrating the clinician/patient disconnect often found in surgical studies and outcome measures [71]. Pelvic organ prolapse symptom goals may include resolution of bulge, defecatory improvement, resolution of urinary tract infections, and sexual and emotional aspects. Importantly, symptom goals are often met with anatomical correction, and thus patient's report goal achievement [31, 65, 66]. Surgery has been found to attain greater goal achievement than non-surgical management of pelvic organ prolapse (pessary) [29, 71].

Patients' postoperative satisfaction with surgery is correlated with their goal achievement. Women whose personal goals were not met were often dissatisfied with their surgical outcomes, even though their surgery was considered “successful” based on objective findings [11]. Goal assessment is not identical to quality of life assessment; both provide complementary but independent indications of long-term subjective treatment success [72]. Goals that relate to social roles, sexuality and self-image may take longer to successfully achieve than other types of goals. Longer-term follow-up is crucial to determine whether initial improvements have been maintained [64].

Goals are stable over time; 83% of women continue to report goal achievement 10 years after surgery for pelvic floor disorders [3]. Research on goal setting has also included patient's fears related to surgery, providing insight into the concerns for new symptoms, pelvic organ prolapse recurrence and surgical complications that concern women choosing pelvic organ prolapse surgical management [73].

### Summary of patient-reported goals

Patient goals are broadly classified into symptomatic and functional goals. Symptomatic goals seem to be most common and are often achieved in pelvic organ prolapse treatment. Understanding patient goals may direct therapy, prevent misunderstanding and allow for effective shared decision making.

### Limitations of patient-reported goals

Patient-reported goals involve free text, and this can be difficult to track over time. Just like PROs, goals should be evaluated after treatment, and most systems lack simple ways to refer back to initial patient goals or measures of goal attainment.



## PRO/PRG research recommendations

The appropriate HRQoL instrument for a research study depends on the goals of the intervention and the primary outcomes studied. Important to consider are the concepts measured, target population, assessment frequency and administration. The measure used should be validated in the language and culture of the intended survey population, as these can confound responses. Multiple HRQoL measures can be included in a single study, but staff and participant burden, time constraints and resources are important to consider. HRQoL measures should be assessed, at minimum, at baseline and termination of the study. Additional assessments should be timed based on both the measurement properties of the instrument and the nature of the condition being studied (i.e., the expected changes in function due to the intervention, condition and disease process).

The use of validated HRQoL measures is preferred because it ensures the results obtained are clinically useful. Validation of a HRQoL measure involves a rigorous scientific process that ensures the instrument reliability measures what it is intended to measure for a specific population. The psychometric properties of an instrument are not transferable, and a new validation process must take place for each new language and culture in which it is administered.

Responses to HRQoL measures are on an ordered scale and include Likert scales, visual analog scales, categorized/anchored visual analog scales, pictorial scales and checklists [74]. Using statistical methods, weights can be added to questions or domains to reflect ideas that may be of greater importance. A validated scoring algorithm is predetermined for each HRQoL measure allowing for a numerical score to be computed based on each patient's responses. Various scoring mechanisms exist including: (1) single rating: single score obtained on a one concept; (2) index: single score obtained on multiple related domains or independent concepts; (3) profile: multiple scores on multiple related domains; (4) battery: multiple scores on an independent concept. Items on the instrument can also be reversed scored to accurately capture negatively worded questions specific to a concept or theme. To aid in the research analysis, Likert scales can be dichotomized although this does result in a loss of response granularity.

Responses to HRQoL instruments are highly variable because they are based on patients' own experiences. Interpretability of scores is enhanced by comparing them against published normative values for specific populations or the minimally important difference (MID). MIDs are the smallest change in score that suggests a benefit or detriment to an intervention and are specific to populations and context. The MID can usually be estimated as half the standard deviation of the baseline score of the measure of interest [36].

Incomplete HRQoL surveys decrease study sample size and potentially impose biased results. In some cases, missing

values make it impossible to generate a score. In the setting of missing survey items, statistical methods must be used to handle the missing data and depend on the missing mechanism. If the data can be assumed to be missing and random, then bias is less of an issue, and it can be presumed the available data may be representative of all data. For missing at random data, a complete case analysis using only available data, maximum-likelihood estimation or multiple imputation can be conducted. Often survey items are missing in patients with similar characteristics, and in these situations, data are considered missing not at random. For missing not at random data, sensitivity analyses should be conducted. Psychometrically, the number of allowed missing values can be determined where the remaining items no longer predict a global score. Some measures, such as the PISQ 12, provide this scoring advice.

More disease-specific HRQoL measures in FPMRS are needed. In particular, validated measures on vaginal laxity and its impact on relationship happiness and sexual function are lacking (Pauls 2013).

PRGs are also important to consider as a research outcome and represent individualized patient-centered outcomes. As previously discussed, there are validated ways to assess goal attainment or achievement; however, this is an area that needs further development and is an emerging field at this time.

## Translation/validation: considerations when validating a PROM in another language/cultural context

A clinical trial can be invalidated if proper data collection was not done because of ambiguous or incorrect translation of a PROM; for this reason, instruments must undergo a more rigorous translation process than simple translation.

The past decades have seen big changes in cross and multi-cultural research methods. Historically, translation work focused on establishing 'linguistic equivalence' or word-for-word translation. Linguistic equivalence does not always establish "cultural equivalence," and translation work has turned its' focus towards establishing cultural equivalence. The importance of cultural equivalence in translation means that the translation goal is to identify terminology which would convey a specific meaning; in some languages this might be achieved by a simple phrase, and in others this may require more detailed elaboration. On a practical level, for every item in a PROM an annotation is added that identifies the intent of the item as well as additional information around words or terminology that might be particularly problematic in the translation process [36].

Word-for-word translation is further verified for meaning with both forward and backward translation. Forward translation means the translation from the source language to the target language. Creating a minimum of two forward

translationsis recommended by professional translators able to read/write the source and the target language. The two translations must be “reconciled” in one final translation. Then, a new translator transforms the final translation “backward” or back into the original language to confirm content stability [75].

Prior to using the translated PROs, there should be qualitative research with the overall objective of linguistic validation to ensure that the translated documents are conceptually appropriate and linguistically accurate. By this process, the translated text is actively tested with patients to confirm conceptual equivalence and content validity based on clinician review and/or cognitive interviews (CI) in the target population. The general purpose of a CI is to find out how respondents understand questions and what they are thinking when they try to answer questions and perform the response tasks. The basic CI process involves reading the question to the respondent, or having the respondent read the question, and then using a strategy to find out what the respondent was thinking about the question. There are two basic strategies: think-aloud and verbal probing. Think-aloud typically requires a fair amount of interviewer training and is often conducted by cognitive psychologists, and respondents vary in their ability to perform the think-aloud task. Verbal probing is conducted by a member of the research team, not a professional interviewer. The person conducting the CI should be familiar with the objectives of the research and the specific questions recommended for CI for this questionnaire [75].

Once an instrument has been translated and linguistically validated, a study should be conducted to evaluate the psychometric properties of the translated questionnaire. Ideally, new PROs should be developed simultaneously in multiple languages to allow for inclusive research and clinical care.

## Conclusion

PROs and PRGs are essential in urogynecology clinical care and research. The challenge is integrating these tools into clinical care with the ability to track and obtain repeated measures over time. Research should focus on using PROs that are short, applicable to the study question and validated for the intended population. There remains a deficit in PROs for specific populations (such as post-partum people), languages/cultures and conditions (vaginal laxity). In addition, most of the PROs that have been developed for prolapse were developed for use in research, not clinical settings. Research aimed at identifying best practice use of PROs in a clinical setting for individual use would be helpful to establish their utility in clinical care.

## Summary of recommendations

All patients presenting for POP should be evaluated for vaginal, bladder, bowel and sexual symptoms including their goals for symptom treatment. Minimum recommendations for evaluation are as follows:

- (1) **Vaginal symptoms** including bulging, pressure, laxity, discomfort and digitation or splinting for urination or defecation.
- (2) **Bladder symptoms** including dysfunction (both storage/voiding) and incontinence.
- (3) **Bowel symptoms** including accidental bowel leakage, defecatory dysfunction, fecal urgency and constipation.
- (4) **Sexual function** including evaluation of sexual activity, presence of pain, concerns they would like to discuss and whether their pelvic floor dysfunction is affecting their sexual function or body image or preventing sexual relationships.

This screening can be facilitated by a validated PROM; however, most PROs provide more information than needed to provide clinical care and were designed for research purposes.

Based on the committee’s literature review and expertise, we make the following recommendations divided into clinical care for POP, research for POP and future directions for PRGs and PROs related to POP.

### I. PRGs and PROs for POP clinical care

- a. The most specific information needed for the initial evaluation of POP is patient-reported goals. The evaluation of POP requires investigation and questions into the multiple dimensions of the pelvic floor, and this complexity can be simplified with goals. Patient goals may or may not relate to POP and thus will align the clinician and patient, allowing for shared decision making and avoiding dissatisfaction with treatment plans.
  - i. Goals should be recorded in a way that allows for re-evaluation of goal attainment over time particularly after surgical or non-surgical management for POP.
  - ii. Goals may change over time as POP or symptoms related to POP are treated.
  - iii. As a main principle, the most bothersome symptom, as identified by the question “What bothers you most?,” can help guide goal-setting. However, the provider must consider that pelvic floor disorders tend to co-exist and patients

may have multiple equally important goals to address in a treatment plan.

- iv. Goals help delineate the primary expectation or concern for the patient of the clinical encounter. Examples include: “What problem do you hope the treatment will address?,” “What is your goal for bladder or bowel outcomes?,” and “What are your fears regarding bladder or bowel function after POP treatment?”

b. If PROs are used during the clinical encounter

- i. Use instruments validated for measurement of the patient’s specific symptoms (bowel, bladder, vaginal and/or sexual)
- ii. Use the instruments during the clinical encounter or inform the patient if these are being completed for research.
- iii. Choose short instruments to collect the minimum information necessary to decrease patient burden
- iv. If PROs are used to record the presence or absence of bowel, bladder, vaginal and sexual symptoms, the instrument(s) should include a bother score for symptoms.

iii. PROs offer standardized measurement of POP symptoms, quality of life, etc., but do not replace individualized patient goals.

iv. PROs may help unmask pre-existing PFDs prior to the treatment of POP.

## II. PROs and PRGs for POP Research

- a. Generally, PROs were developed for research rather than patient care.
- b. Understanding the population as well as the condition for which the PROM is valid for inference is essential when applying it to a given research project.
- c. Validated PROs should be used whenever possible and should be chosen based on project objectives.
- d. Be familiar with scoring and confirm accuracy in reporting PROM scores and interpretation. Identify rules for missing values and whether scores can be reported on the total measure, domain or individual item level.
- e. For some measures on-line scoring programs have been published and can help avoid errors. If you are scoring the measure yourself particular attention should be

paid attention to reverse scoring, weighted scoring or errors in scoring coding.

- f. In general, PROs should be administered and reported both before and after a research intervention.
- g. Evaluate the appropriateness and rigor of PROs including psychometric properties and compatibility with the project prior to initiating the project.
- h. In clinical research the primary objective should match primary outcome or endpoint. Example: If your research is about the approach of surgery (vaginal versus abdominal) and how it relates to sexual function then your main outcome needs to be a measure of sexual function.
- i. Minimum clinical important differences (MICDs) are more meaningful in reporting PROs after interventions than *p*-values.
- j. Patient-reported goals and goal attainment are also an important part of POP research.

## III. Gaps in current literature:

- a. New terms are emerging in patient description of vaginal symptoms such as laxity or openness, and PROs are needed to help quantify the impact of these symptoms on quality of life and bother.
- b. Most PROs are used for group-level research rather than assessing outcome on an individual level, and there is need to define MICD and responsiveness for most PROs.
- c. Few PROs assess the psychological distress associated with POP. This is a research gap.
- d. Few PROs assess patient-specific knowledge about POP, and this represents another research gap.
- e. There is need for more translations of PROs allowing for broader research populations.
- f. There are few POP screening questionnaires that could easily be used in primary care settings.
- g. POP PROs are generally designed for use in subspecialty clinics, and POP PROs for the general population need to be developed.

## Declarations

**Conflicts of interest** Rebecca Rogers receives stipend from UpToDate, travel and stipend from IUGA and travel and stipend from ABOG. All other authors declare no conflicts of interest.

## References

1. Barber MD, Maher C. Apical prolapse. *Int Urogynecol J*. 2013;24(11):1815–33.

2. Bump RC, Mattiasson A, Bø K, et al. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. *Am J Obstet Gynecol*. 1996;175(1):10–7.
3. Srikrishna S, Robinson D, Cardozo L, Thiagamoorthy G. Patient and surgeon goal achievement ten years following surgery for urogenital prolapse and urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*. 2015;26(1):S151–2.
4. Coyne K, Kelleher C. Patient reported outcomes: the ICIQ and the state of the art. *Neurourol Urodyn*. 2010;29(4):645–51.
5. Barber MD, Brubaker L, Nygaard I, et al. Defining success after surgery for pelvic organ prolapse. *Obstet Gynecol*. 2009;114(3):600–9.
6. Habashy E, Mahdy AE. Patient-Reported Outcome Measures (PROMs) in Pelvic Floor Disorders. *Current Urology Reports*. 2019;20(5):22.
7. Gray TG, Vickers H, Krishnaswamy P, Jha S. A systematic review of English language patient-reported outcome measures for use in urogynaecology and female pelvic medicine. *Int Urogynecol J*. 2021;32(8):2033–92.
8. Toozs-Hobson P, Freeman R, Barber M, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for reporting outcomes of surgical procedures for pelvic organ prolapse. *Neurourol Urodyn*. 2012;31(4):415–21.
9. Parker-Autry CY, Barber MD, Kenton K, Richter HE. Measuring outcomes in urogynecological surgery: "perspective is everything". *Int Urogynecol J*. 2013;24(1):15–25.
10. Rogers RG. Translating patient-reported outcomes to improve patient care and urogynecologic research. *Int Urogynecol J*. 2017;28(12):1765–6.
11. Elkadry EA, Kenton KS, FitzGerald MP, Shott S, Brubaker L. Patient-selected goals: a new perspective on surgical outcome. *Am J Obstet Gynecol*. 2003;189(6):1551–7 discussion 1557.
12. Bovbjerg VE, Trowbridge ER, Barber MD, Martirosian TE, Steers WD, Hullfish KL. Patient-centered treatment goals for pelvic floor disorders: Association with patient satisfaction. *J Pelvic Med Surg*. 2008;14(4):254.
13. Lowenstein L, FitzGerald MP, Kenton K, et al. Patient-selected goals: the fourth dimension in assessment of pelvic floor disorders. *Int Urogynecol J*. 2008;19(1):81–4.
14. Komesu YM, Rogers RG, Rode MA, et al. Pelvic floor symptom changes in pessary users. *Am J Obstet Gynecol*. 2007;197(6):620.e621–6.
15. Gray T, Strickland S, Pooranawattanakul S, et al. What are the concerns and goals of women attending a urogynaecology clinic? Content analysis of free-text data from an electronic pelvic floor assessment questionnaire (ePAQ-PF). *Int Urogynecol J*. 2019;30(1):33–41.
16. Habashy E, Mahdy AE. Patient-Reported Outcome Measures (PROMs) in Pelvic Floor Disorders. *Curr Urol Rep*. 2019;20(5):22.
17. Larsen MD, Lose G, Guldborg R, Gradel KO. Discrepancies between patient-reported outcome measures when assessing urinary incontinence or pelvic-prolapse surgery. *Int Urogynecol J*. 2016;27(4):537–43.
18. Barber MD, Kuchibhatla MN, Pieper CF, Bump RC. Psychometric evaluation of 2 comprehensive condition-specific quality of life instruments for women with pelvic floor disorders. *Am J Obstet Gynecol*. 2001;185(6):1388–95.
19. Rogers RG, Rockwood TH, Constantine ML, et al. A new measure of sexual function in women with pelvic floor disorders (PFD): the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR). *Int Urogynecol J*. 2013;24(7):1091–103.
20. Tegerstedt G, Miedel A, Maehle-Schmidt M, Nyren O, Hammarström M. A short-form questionnaire identified genital organ prolapse. *J Clin Epidemiol*. 2005;58(1):41–6.
21. Lukacz ES, Lawrence JM, Buckwalter JG, Burchette RJ, Nager CW, Lubner KM. Epidemiology of prolapse and incontinence questionnaire: validation of a new epidemiologic survey. *Int Urogynecol J Pelvic Floor Dysfunct*. 2005;16(4):272–84.
22. Zuchelo LTS, Bezerra IMP, Da Silva ATM, et al. Questionnaires to evaluate pelvic floor dysfunction in the postpartum period: a systematic review. *Int J Women's Health*. 2018;10:409–24.
23. Price N, Jackson SR, Avery K, Brookes ST, Abrams P. Development and psychometric evaluation of the ICIQ Vaginal Symptoms Questionnaire: the ICIQ-VS. *BJOG Int J Obstet Gynaecol*. 2006;113(6):700–12.
24. Baessler K, O'Neill SM, Maher CF, Battistutta D. An interviewer-administered validated female pelvic floor questionnaire for community-based research. *Menopause*. 2008;15(5):973–7.
25. Barber MD. Symptoms and outcome measures of pelvic organ prolapse. *Clin Obstet Gynecol*. 2005;48(3):648–61.
26. Digesu GA, Khullar V, Cardozo L, Robinson D, Salvatore S. P-QOL: a validated questionnaire to assess the symptoms and quality of life of women with urogenital prolapse. *Int Urogynecol J Pelvic Floor Dysfunct*. 2005;16(3):176–81 discussion 181.
27. Radley SC, Jones GL, Tanguy EA, Stevens VG, Nelson C, Mathers NJ. Computer interviewing in urogynaecology: concept, development and psychometric testing of an electronic pelvic floor assessment questionnaire in primary and secondary care. *BJOG*. 2006;113(2):231–8.
28. Barber MD, Neubauer NL, Klein-Olarte V. Can we screen for pelvic organ prolapse without a physical examination in epidemiologic studies? *Am J Obstet Gynecol*. 2006;195(4):942–8.
29. Sung VW, Wohlrab KJ, Madsen A, Raker C. Patient-reported goal attainment and comprehensive functioning outcomes after surgery compared with pessary for pelvic organ prolapse. *Am J Obstet Gynecol*. 2016;215(5):659.e651–7.
30. Pilzek AL, Raker CA, Sung VW. Are patients' personal goals achieved after pelvic reconstructive surgery? *Int Urogynecol J*. 2014;25(3):347–50.
31. Pilzek A, Raker CA, Sung V. Are patients personal goals achieved after pelvic reconstructive surgery? *Female Pelvic Med Reconstr Surg*. 2013;19:S2–3.
32. Gensheimer SG, Wu AW, Snyder CF. Oh, the Places We'll Go: Patient-Reported Outcomes and Electronic Health Records. *Patient*. 2018;11(6):591–8.
33. Kingsley CPS. Patient-reported outcome measures and patient-reported experience measures. *BJA Education*. 2017;17:137–44.
34. S M. Validity. Vol 2: Educational Test Serv Res Rep; 1987.
35. Hawkins M, Elsworth GR, Osborne RH. Application of validity theory and methodology to patient-reported outcome measures (PROMs): building an argument for validity. *Qual Life Res*. 2018;27(7):1695–710.
36. Revicki DHR, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. *J Clin Epidemiol*. 2008;61(2):102–9.
37. Prinsen CAC, Mokkink LB, Bouter LM, et al. COSMIN guideline for systematic reviews of patient-reported outcome measures. *Qual Life Res*. 2018;27(5):1147–57.
38. Wren PA, Janz NK, Brubaker L, et al. Reliability of health-related quality-of-life measures 1 year after surgical procedures for pelvic floor disorders. *Am J Obstet Gynecol*. 2005;192(3):780–8.
39. Srikrishna S, Robinson D, Cardozo L. Validation of the Patient Global Impression of Improvement (PGI-I) for urogenital prolapse. *Int Urogynecol J*. 2010;21(5):523–8.
40. Coyne K, Sikirica V, Gelhorn H, Robinson D, Hinoul P, Gauld J. Validation of the patient global impression of change (PGIC) in a patient population following vaginal prolapse repair with mesh. *Int Urogynecol J Pelvic Floor Dysfunct*. 2011;22:S801–2.
41. Barber MD, Chen Z, Lukacz E, et al. Further validation of the short form versions of the Pelvic Floor Distress Inventory (PFDI)

- and Pelvic Floor Impact Questionnaire (PFIQ). *Neurourol Urodyn.* 2011;30(4):541–6.
42. Spencer JE, Hadden K, Oliphant SS. The impact of health literacy on utilization of PFDI-20 and PFIQ-7. *Female Pelvic Med Reconstr Surg.* 2018;24(5):S27–8.
  43. Gelhorn HL, Coyne KS, Sikirica V, Gauld J, Murphy M. Psychometric evaluation of health-related quality-of-life measures after pelvic organ prolapse surgery. *Female Pelvic Med Reconstr Surg.* 2012;18(4):221–6.
  44. Karjalainen PK, Mattsson NK, Jalkanen JT, Nieminen K, Tolppanen AM. Minimal important difference and patient acceptable symptom state for PFDI-20 and POPDI-6 in POP surgery. *Int Urogynecol J.* 2021;32(12):3169–76.
  45. Rogers RG, Kammerer-Doak D, Villarreal A, Coates K, Qualls C. A new instrument to measure sexual function in women with urinary incontinence or pelvic organ prolapse. *Am J Obstet Gynecol.* 2001;184(4):552–8.
  46. Rogers RG, Coates KW, Kammerer-Doak D, Khalsa S, Qualls C. A short form of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12). *Int Urogynecol J.* 2003;14(3):164–8 discussion 168.
  47. Mamik MM, Rogers RG, Qualls CR, Morrow JD. The minimum important difference for the Pelvic Organ Prolapse-Urinary Incontinence Sexual Function Questionnaire. *Int Urogynecol J.* 2014;25(10):1321–6.
  48. Aschkenazi SO, Rogers RG, Beaumont J, Botros SM, Sand PK, Goldberg RP. A Valid Form of the PISQ-12, the PISQ-9, for Use in Comparative Studies of Women With and Without Pelvic Organ Prolapse and/or Urinary Incontinence. *Female Pelvic Med Reconstr Surg.* 2010;16(4):218–23.
  49. Hagen S, Glazener C, Sinclair L, Stark D, Bugge C. Psychometric properties of the pelvic organ prolapse symptom score. *Bjog.* 2009;116(1):25–31.
  50. Lowder JL, Ghetti C, Oliphant S, Skoczylas LC, Swift S, Switzer G. Body image in pelvic organ prolapse (BIPOP) questionnaire: Development and validation. *Female Pelvic Med Reconstruct Surg.* 2013;19:S50.
  51. Baessler K, O'Neill SM, Maher CF, Battistutta D. Australian pelvic floor questionnaire: a validated interviewer-administered pelvic floor questionnaire for routine clinic and research. *Int Urogynecol J Pelvic Floor Dysfunct.* 2009;20(2):149–58.
  52. Baessler K, O'Neill SM, Maher CF, Battistutta D. A validated self-administered female pelvic floor questionnaire. *Int Urogynecol J.* 2010;21(2):163–72.
  53. Campbell P, Krychman M, Gray T, et al. Self-Reported Vaginal Laxity-Prevalence, Impact, and Associated Symptoms in Women Attending a Urogynecology Clinic. *J Sex Med.* 2018;15(11):1515–7.
  54. Peterson TV, Karp DR, Aguilar VC, Davila GW. Validation of a global pelvic floor symptom bother questionnaire. *Int Urogynecol J.* 2010;21(9):1129–35.
  55. Haff RE, Stoltzfus J, Lucente VR, Murphy M. The surgical satisfaction questionnaire (SSQ-8): A validated tool for assessment of patient satisfaction following surgery to correct prolapse and/or incontinence. *J Minim Invasive Gynecol.* 2011;18(6):S49–50.
  56. Chinthakanan O, Davila G. Validation of the improvement satisfaction scale (ISS) for pelvic organ prolapse surgery. *Female Pelvic Med Reconstr Surg.* 2013;19:S151.
  57. Bradshaw HD, Hiller L, Farkas AG, Radley S, Radley SC. Development and psychometric testing of a symptom index for pelvic organ prolapse. *J Obstet Gynaecol.* 2006;26(3):241–52.
  58. Egger MJ, Lukacz ES, Newhouse M, Wang J, Nygaard I. Web versus paper-based completion of the epidemiology of prolapse and incontinence questionnaire. *Female Pelvic Med Reconstr Surg.* 2013;19(1):17–22.
  59. Tehrani FR, Hashemi S, Simbar M, Shiva N. Screening of the pelvic organ prolapse without a physical examination; (a community based study). *BMC Womens Health.* 2011;11:48.
  60. Burton C, Markowitz M, Kanji F, et al. Validation of the pelvic floor awareness and knowledge survey (PFAKS). *Neurourol Urodyn.* 2020;39:S138–9.
  61. Shah AD, Massagli MP, Kohli N, Rajan SS, Braaten KP, Hoyte L. A reliable, valid instrument to assess patient knowledge about urinary incontinence and pelvic organ prolapse. *Int Urogynecol J Pelvic Floor Dysfunct.* 2008;19(9):1283–9.
  62. Brubaker L, Shull B. EGGs for patient-centered outcomes. *Int Urogynecol J Pelvic Floor Dysfunct.* 2005;16(3):171–3.
  63. Adams SR, Dramitinos P, Dodge L, Elkadry E. Do patient goals vary with stage of prolapse? *J Pelvic Med Surg.* 2011;17(2):S17–8.
  64. Hullfish KL, Bovbjerg VE, Gibson J, Steers WD. Patient-centered goals for pelvic floor dysfunction surgery: what is success, and is it achieved? *Am J Obstet Gynecol.* 2002;187(1):88–92.
  65. Mamik M, Komesu Y, Qualls C, Rogers R. Goal attainment in patients that choose surgery versus pessary for treatment of symptomatic pelvic organ prolapse. *Female Pelvic Med Reconstr Surg.* 2013;19:S8.
  66. Kousgaard SJ, Bjork J, Glavind K. What are patient goals after an anterior colporrhaphy operation? *Eur J Obstet Gynecol Reprod Biol.* 2017;216:208–11.
  67. Srikrishna S, Robinson D, Cardozo L. Role of composite endpoints as an outcome assessment tool in urogenital prolapse. *J Obstet Gynaecol.* 2012;32(3):276–9.
  68. Bovbjerg VE, Trowbridge ER, Barber MD, Martirosian TE, Steers WD, Hullfish KL. Patient-centered treatment goals for pelvic floor disorders: association with quality-of-life and patient satisfaction. *Am J Obstet Gynecol.* 2009;200(5):568.e561–6.
  69. Glavind K, Bjoerk J, Kousgaard S. What are patient goals after an anterior colporrhaphy operation? *Int Urogynecol J.* 2017;28(1):S99–S100.
  70. Adams SR, Dodge LE, Dramitinos P, Elkadry EA. Do patient goals vary by stage of prolapse? a follow up study of goal achievement. *Female Pelvic Med Reconstr Surg.* 2012;18(5):S170.
  71. Mamik M, Komesu YM, Qualls C, Rogers RG. Does goal setting differ between women who choose surgery vs pessary for treatment of symptomatic prolapse? *Female Pelvic Med Reconstr Surg.* 2012;18(5):S67.
  72. Bovbjerg VE, Trowbridge ER, Barber MD, Martirosian TE, Steers WD, Hullfish KL. Patient-centered treatment goals for pelvic floor disorders: Association with PFD-specific and general quality of life. *J Pelvic Med Surg.* 2008;14(4):253–4.
  73. Lawndy SS, Withagen MI, Kluivers KB, Vierhout ME. Between hope and fear: patient's expectations prior to pelvic organ prolapse surgery. *Int Urogynecol J.* 2011;22(9):1159–63.
  74. Deshpande PR, Rajan S, Sudeepthi BL, Abdul Nazir CP. Patient-reported outcomes: A new era in clinical research. *Perspect Clin Res.* 2011;2(4):137–44.
  75. Eremenco S, Pease S, Mann S, Berry P. Patient-Reported Outcome (PRO) Consortium translation process: consensus development of updated best practices. *J Patient Rep Outcomes.* 2017;2(1):12.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.



## International Urogynecological Consultation Chapter 2.2: Imaging in the Diagnosis of Pelvic Organ Prolapse

Lioudmila Lipetskaia<sup>1</sup> · Ankita Gupta<sup>2</sup> · Rachel Y. K. Cheung<sup>3</sup> · Vik Khullar<sup>4</sup> · Sharif Ismail<sup>5</sup> · Megan Bradley<sup>6</sup> · Roopali Karmakar<sup>7</sup> · Shari Clifton<sup>8</sup> · Josephine Doo<sup>8</sup> · Lieschen Quiroz<sup>8</sup>

Received: 4 April 2024 / Accepted: 20 August 2024  
© The Author(s) 2025

### Abstract

**Introduction and Hypothesis** This section of Chapter 2.2 of the International Urogynecology Consultation on Pelvic Organ Prolapse (POP), reviews the literature on the role of imaging in the diagnosis of POP.

**Methods** An international group of nine urogynecologists and one university-based medical librarian adhered to the framework of the scoping review. The group performed a search of the literature using pre-specified search terms in Scopus, OVID Medline, and PubMed. Publications were eliminated if not relevant to the diagnostic value of POP imaging. The remaining articles were evaluated for quality using the Joanna Briggs Institute Checklist for Diagnostic Test Accuracy Studies. The resulting list of articles was used to perform a comprehensive narrative review of the diagnostic value of imaging modalities for the diagnosis of POP.

**Results** The original search yielded 3,289 references, 135 of which were used by the writing group.

**Conclusions** Most imaging studies utilized in the diagnoses of POP lacked standardization in the definition of POP. Most imaging studies lack standardization in the protocols used to diagnose POP within each imaging technique. Ultrasound- and MRI-related studies are most represented in the literature, compared with fewer CT- and X-ray-/fluoroscopy-related studies. Therefore, radiographic imaging is of limited value in the diagnosis of POP.

**Keywords** Imaging · Ultrasound · MRI · CT scan · Fluoroscopy · Pelvic organ prolapse · Diagnosis

### Abbreviations

AUGS	American Urogynecologic Society	POP	Pelvic organ prolapse
ICS	International Continence Society	POP-Q	Pelvic Organ Prolapse Quantification
IUC	International Urogynecological Consultation	SGS	Society for Gynecologic Surgeons
IUGA	International Urogynecological Association		

Handling Editor: Kaven Baessler  
Editor in Chief: Kaven Baessler

✉ Lioudmila Lipetskaia  
lipetskaia@rowan.edu; drmally2020@gmail.com

<sup>1</sup> Division of Urogynecology, Department of Obstetrics and Gynecology, Cooper Medical School of Rowan University, 402 E Oak Ave, Moorestown, USA

<sup>2</sup> Division of Urogynecology, Department of Obstetrics and Gynecology, University of Louisville, Louisville, USA

<sup>3</sup> Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong | CUHK, Ma Liu Shui, Hong Kong

<sup>4</sup> Department of Urogynaecology, Imperial College London, London, UK

<sup>5</sup> University Hospitals Sussex National Health Service (NHS) Foundation Trust/Brighton and Sussex Medical School, Brighton, UK

<sup>6</sup> Division of Urogynecology, Department of Obstetrics and Gynecology, University of Pittsburgh, Pittsburgh, PA, USA

<sup>7</sup> Department of Obstetrics and Gynaecology, Chelsea and Westminster NHS Foundation Trust, West Middlesex University Hospital, Isleworth, UK

<sup>8</sup> Division of FPMRS, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA


## Introduction

This report is part of the series of articles that are produced by the International Urogynecological Consultation (IUC), a project sponsored by the International Urogynecology Association (IUGA) on the management of pelvic organ prolapse (POP). This is a four-chapter project with 16 reports. The present article is from the second chapter reporting on the evaluation of POP. It focuses on the role of imaging in the diagnosis of POP. POP is defined as the descent of any one or more of the vaginal walls, cervix, or vaginal vault after hysterectomy [1]. The correlation of this examination finding with the symptom of being able to see or feel a vaginal bulge is necessary for the diagnosis of POP. This relationship mostly happens at or below the level of the hymenal plane. Chapter 1.1 of the IUC evaluated the definition of POP and stressed that it should only be made in a patient with the complaint of a vaginal bulge or in a patient with a medically morbid condition directly related to POP [2]. As symptoms play a major role in the diagnosis it can be difficult to appreciate various symptoms and the diagnosis becomes more complex when the patient's symptoms are disproportionate to the level of descent seen on examination. It has been postulated that imaging techniques, such as ultrasound or magnetic resonance imaging (MRI), can provide additional information to assist in those instances where the diagnosis is not straightforward [3, 4]. Imaging techniques can show and measure the degree of the displacement of pelvic organs and their descent against a defined reference point. Hence, imaging can assist in both the diagnosis and quantification of prolapse. For example, the reference points commonly used to assess POP on MRI are the pubo-coccygeal line (PCL) and midpubic line (MPL), which are fixed bony lines [3, 5, 6]. Translabial/transperineal ultrasound (TPUS) uses a transverse line along the inferior border of pubic symphysis as a reference line for diagnosing POP in different compartments [7–9]. On the other hand, the reference plane of the hymen, which is used for clinical examination, is a soft-tissue plane, which moves with the movement of the pelvic floor. The findings of clinical examination and imaging techniques may or may not correlate with each other or with the patient's symptoms [10–12]. The variation in landmarks used for reference lines also means that different methods of imaging are not comparable. Imaging, however, can be used to understand how POP and associated symptoms interact. As an example, it is commonly used to assess anorectal symptoms, especially bowel evacuation disorders. The dilation and anterior ballooning of the rectum seen on MRI may not cause descent of the posterior vaginal wall and POP by physical examination. Indeed, the term “rectocele,” which is used to describe this MRI finding, is also commonly used to describe posterior vaginal wall prolapse. This often

leads to confusion in the diagnosis and management of the conditions by different specialties. Clinical examination can visualize the vaginal wall descent, but it might be difficult to assess the visceral involvement [13]. Imaging techniques can identify the organs within the vaginal wall prolapse and hence improve the diagnostic accuracy of what the POP represents from an organ-based pathology. For example, it can help to differentiate the small bowel versus rectal descent in the settings of the clinically diagnosed posterior vaginal wall prolapse. The stage of POP may vary in the sitting up or standing position [12]. The non-invasive nature of imaging and convenience of assessment in a weight-bearing position are additional advantages of imaging for POP [3, 5, 6, 14]. Another question that arises is whether clinical examination or imaging might be more efficient in diagnosing POP of a particular compartment [15–17]. For example, a prolapse of the upper vagina, which may not be seen easily on clinical examination, may be better diagnosed using imaging techniques [18]. On the other hand, clinical examination may diagnose POP more accurately than imaging alone, and, more importantly, physical examination has been shown to correlate with POP symptoms [4, 17].

The value of any diagnostic testing is traditionally assessed by non-experimental cross-sectional or cohort studies, which compare a test's classification of a diagnosis with that of a reference standard. The conceptual starting point of a diagnostic test study is to apply the reference (or gold) standard to determine which study participants have the prolapse and which participants do not. In the case of prolapse, the Pelvic Organ Prolapse Quantification (POP-Q) examination is considered the gold standard among the urogynecology scientific community. However, although this view is widely accepted, it is not universally agreed upon. For example, in the colorectal literature, some studies call for other imaging modalities as a gold standard in assessing POP [19, 20]. The diagnosis of POP is further complicated by the fact that not all prolapse diagnosed by POP-Q is bothersome. Typically, the presence of symptoms is required to identify prolapse as clinically significant. Therefore, diagnostic studies should consider the fact that not all forms of prolapse identified on physical examination or imaging are symptomatic (Fig. 1).

A well-designed POP imaging accuracy study will need to include a clear definition of prolapse by POP-Q and symptoms, set up clear definitions of radiological findings identified as positive, calculate sensitivity and specificity, and ideally report likelihood ratio and receiver-operating curves (ROCs), which will allow the derivation of evidence-based cut-offs for this particular diagnostic modality. The area under the curve (AUC) on ROCs defines the accuracy of the test: the closer the AUC approaches 1, the more discriminatory value the test carries in distinguishing prolapse from normal controls. This chapter reviews different imaging



**Fig. 1** Venn diagram of pelvic organ prolapse (POP) physical findings, symptoms, and imaging findings. *POP-Q* Pelvic Organ Prolapse Quantification

techniques available for assessing POP and compares them with the clinical examination findings using a clinical diagnosis of prolapse according to either the POP-Q system or the Baden–Walker (BW) grading system. The BW half-way system preceded POP-Q and consisted of four grades: grade 0, no prolapse; grade 1, halfway to the hymen; grade 2, to the hymen; grade 3: halfway past the hymen; grade 4, maximum

descent. It was included in the review to avoid exclusion bias, as the colorectal literature was late to adopt POP-Q and continued using the BW system long after it was introduced in 1994 into the urogynecology community.

## Materials and Methods

This manuscript is a narrative review. Nine international urogynecology experts in radiographic imaging in POP were assembled. The chair of the writing group was selected by the IUC chairs, the IUC steering committee with input from the IUGA Executive Committee. A competitive application process and invitation were developed for the other members (authors) of the writing group.

To complete an in-depth literature search on this topic, the authors assembled the search terms that they found most relevant to the imaging of POP. This list of terms was presented at the IUGA annual scientific meeting in 2020 for input from the membership. The additions from membership input made at that meeting were incorporated in the final search terms presented in Table 1. Regular meetings allowed for the group to collaborate on the outline and layout components of this narrative review. The PubMed, OVID Medline, and Scopus Databases were queried for the search terms noted in Table 1, between January 1990 and July 2020. The initial search, performed on 29 July 2020, produced 2,961 unique references. The references were uploaded into Covidence software and divided among the authors for

**Table 1** MeSH search terms

Section 1 Introduction	ultrasound, pelvic organ prolapse imaging, fluoroscopy, pelvic floor disorders, pelvic floor imaging, mri pelvic floor, vaginal prolapse, rectocele, cystocele, defecography, proctography, radiology pelvic prolapse
Section 2 Role of Imaging in Prolapse	ultrasound, pelvic organ prolapse imaging, fluoroscopy, pelvic floor disorders, pelvic floor imaging, mri pelvic floor, vaginal prolapse, rectocele, cystocele, defecography, proctography, radiology pelvic prolapse
Section 3 MRI—Technique and Evaluation of Prolapse	mri pelvic prolapse, magnetic resonance imaging prolapse, mri pelvic floor, mri pelvic laxity, mri pelvic relaxation, mri cystocele, mri rectocele, mri anterior compartment, mri posterior compartment
Section 4 Role of X-ray and CT scan	x-ray abdomen, barium, computed tomography pelvis, CT scan pelvis, CT scan uterovaginal prolapse, radiologic imaging prolapse, radiographic imaging pelvis, fluoroscopy pelvis, contrast imaging, cysto-urethrography
Section 5 Ultrasound—Overview of Techniques: Transperineal, Introital, Transvaginal	transperineal ultrasound, translabial ultrasound, transvaginal ultrasound, pelvic prolapse, three dimensional ultrasound pelvic floor, 3 D ultrasound, 4 D ultrasound pelvic floor, introital ultrasound
Section 6 Ultrasound Anterior Compartment	ultrasound bladder, ultrasound urethra, bladder imaging, ultrasound anterior compartment, ultrasound cystocele, urethrocele, anterior vaginal defect, levator hiatus
Section 7 Ultrasound Middle Compartment	uterine prolapse, vaginal vault prolapse, levator hiatus, levator ani muscle, posthysterectomy prolapse, ultrasound vaginal prolapse, ultrasound uterovaginal prolapse, ultrasound vaginal vault prolapse, apical prolapse, cervical prolapse, ultrasound genital hiatus, levator ballooning
Section 8 Ultrasound Posterior Compartment	transperineal ultrasound, introital ultrasound, rectocele, ultrasound posterior compartment, levator ani imaging, ultrasound levator hiatus, enterocele, rectocele, posterior vaginal defect, perineal hypermobility



initial screening. Each reference underwent an inclusion or exclusion criteria assessment by two independent reviewers (writing group members), with a third reviewer as a referee for tie-breaking inconsistencies. The Joanna Briggs Institute (JBI) scoping review guidelines were followed.

Following the initial review, all abstracts were reviewed by two reviewers independently, and conflicts were resolved by a third team member, with the aim of eliminating the studies where the primary focus of imaging use was not the diagnosis of POP and where physical examination (POP-Q or other prolapse grading system) was not used as a gold-standard reference for POP diagnosis. This process resulted in 581 manuscripts relevant to the goal of the narrative review. The full-text manuscript reviews were performed by two reviewers independently rated for inclusion or exclusion, according to the JBI checklist. The final inclusion list consisted of 112 manuscripts and was made as a consensus discussion among all reviewers. Figure 2 shows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram of the article selection process.

Next, the data extraction from the manuscripts was performed, using a standardized data extraction sheet developed specifically for this project. The data collected included study geographic location, study design, number of participants, relevant imaging technique details, types of reference lines used (if any), prolapse compartment (anterior, apical, posterior), and testing validation methods. The sections were divided into different imaging techniques and included X-ray/fluoroscopy, CT scan, MRI, and ultrasound. At least two team members contributed to the data synthesis of each section.

The writing group members produced versions of the manuscript incorporating the edits provided by all members until a final first draft was achieved. This was then circulated to several chosen referees before undergoing peer review. The IUC peer review process involved four rounds of review, including review by the IUC co-chairs, the IUC steering committee members, the IUGA general membership (through an online process), and finally the IUGA board

members. The manuscript was then submitted for peer review to the *International Urogynecology Journal*.

## Results

### X-Ray/Fluoroscopy

A total of 4 cohort studies met the inclusion criteria. Three studies used the POP-Q system for the diagnosis of prolapse [13, 21, 22] and one study used the BW grading system [23]. Three studies focused on posterior wall compartment prolapse (defecography) [13, 22, 23] and one addressed the anterior compartment [21].


### Variation in Technique

All studies were performed in the sitting position on a commode, with maximum straining, squeezing, and at rest



Fig. 3 Normal fluoroscopy with rectal barium opacification

Fig. 2 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISM) diagram of the studies reviewed



(Fig. 3). The biggest variation in the technique was evident in the methods used for opacification of the rectum, vagina, bladder, and small bowel. For posterior prolapse imaging, Altman et al. used oral barium contrast medium, intraperitoneal and intravesical omnipaque solution, and barium paste contrast medium in the vagina and the rectum during defecoproctography (DCP) [13]. Finco et al. also used barium paste opacification of the rectum and vagina but added barium paste to the perianal skin, and used iohalamic acid for bladder opacification [23]. Groenendijk et al. limited opacification to the small bowel and rectum by using barium sulfate suspension meal and barium enema [22]. The only study reporting on anterior compartment prolapse described the extensive opacification technique involving intraperitoneal and intravesical omnipaque administration in addition to vaginal and rectal barium paste [21].

### Definition of Cases and Controls and Radiographic Markers

Three studies reported on symptoms associated with prolapse but did not use those symptoms in defining clinically significant prolapse. The clear clinical definition of prolapse was used only in one study: Groenendijk et al. defined clinically significant prolapse of the posterior wall as  $\geq$  POP-Q stage II [22]. The clear definition of an abnormal radiographic finding in the anterior compartment was reported by Altman et al., describing the descent of opacified urinary bladder below the pubococcygeal line as abnormal [21]. Studies focusing on the posterior compartment used definitions of abnormal radiographic findings describing the apex of the rectocele as a common reference point. Groenendijk et al. measured the distance from the rectocele apex to the expected rectal lining of the anterior rectal wall [22]. Finco et al. and Altman et al. measured the distance between the rectocele apex and the line extended through the anal canal axis [13, 23]. In addition, Finco et al. classified radiographic findings of rectocele as grades I, II, and III, using this distance, and defined radiographic rectocele as grade I when it was less than 2 cm long, grade II for 2–4 cm, and grade III when it was over 4 cm [23].

### Diagnostic Accuracy Reporting

There were no studies clearly reporting on the sensitivity or specificity of fluoroscopic testing, in relationship to clinical examination. Studies examined only the correlation between clinical and radiological findings. There was a moderate correlation between the clinical and radiological diagnosis of anterior wall prolapse (degree of correlation  $r=0.67$ ) [13]. There was poor correlation between fluoroscopic imaging of the posterior compartment and clinical examination for posterior vaginal prolapse (degree of correlation  $r=0.49$ ) [21]. Although increasing the size of the rectocele on

defecography moderately correlated with difficulty in rectal emptying ( $r=0.59$ ), there were no other significant associations between symptoms and anatomical findings on imaging [23].

### Computerized Tomography

Only one study was identified reporting on the diagnostic value of computerized tomography (CT) [24]. The study included only seven patients and commented on all compartments. The authors did not use POP-Q as the gold standard for POP diagnosis but rather identified the presence or absence of prolapse in specific compartments during surgical correction as an ultimate reference point. They used extension of the bladder base past the PCL as a radiographic marker for anterior prolapse, and the distance between the line from the anterior margin of the anal canal and the anterior wall of the rectum greater than 2 cm as the radiographic definition of posterior prolapse. CT findings were false negative for all three sites of prolapse in one patient. There were no false-positive cases on CT, when compared with surgical findings.

Because of the small number of studies identified using search terms specific to fluoroscopic and CT imaging of prolapse, the original search was extended past January 2000 to include manuscripts published as early as January 1990. The extended search added no additional manuscripts for CT and one additional manuscript in fluoroscopy [25]. Brubaker et al. evaluated 30 women with prolapse beyond introitus straining in a sitting position with oral contrast medium, and vaginal, rectal, and bladder opacification [25]. The specific radiographic findings consistent with prolapse were not clearly defined and cystocele and rectoceles were reported as present or absent. Radiographic markers were described as heterogeneous with comments on their appearance such as “hour glass shaped.” The study did not report on the sensitivity or specificity of testing but the authors concluded that 11 patients had a modification of their surgical plan based on the information obtained from imaging.

### Conclusion

There is no standardization in CT and fluoroscopic imaging techniques with regard to diagnosing POP. Opacification modalities vary greatly, and the definitions of radiographic findings consistent with prolapse are often unclear. There are no appropriately designed studies describing the diagnostic accuracy of fluoroscopy or CT in the diagnosis of POP. The summary of studies is presented in Table 2.

### Magnetic Resonance Imaging

A total of 25 studies met the inclusion criteria for assessing prolapse via MRI. Most studies were cohort cross-sectional,

**Table 2** Computerized tomography (CT) and fluoroscopy

Reference	Technique	Physical examination	POP symptoms considered in the analysis	Main reported outcome
Altman et al. [13]	Cystodefecoperitoneography, video	BW	UDI, DDI	History of pelvic surgery, size of prolapse of the posterior vaginal wall, and the presence of constipation (assessed by a questionnaire) are predictors of the presence of abnormal defecography
Altman et al. [21]	Cystodefecoperitoneography, video	BW	None	Moderate correlation between clinical and radiological findings in patients with anterior vaginal wall prolapse. New definition of cystocele with lead markers at the introitus did not improve the correlations
Finco et al. [23]	Colpocystodefecography	BW	KESS	Proportions of patients diagnosed with rectocele radiographically and with BW did not differ before surgical intervention, but they did differ after surgery for POP
Groenendijk et al. [22]	Defecography	POP-Q	DDI, UDI, CRADI	Two groups with rectocele (stage II and higher and stage I and lower) were compared. Symptoms were compared in groups defined by PE and by defecography. No relation was found between bowel complaints and posterior wall prolapse evaluated by clinical examination ( $p=0.33$ ), nor between bowel complaints and rectocele ( $p=0.19$ ) assessed by defecography
Brubaker et al. [25]	Dynamic fluoroscopy	Physical examination	None	Dynamic fluoroscopy improved pre-surgical evaluation by identifying enterocele in 26 out of 30 patients
Pannu et al. [24]	CT	Surgical exploration	None	CT findings were false negative for all three sites of prolapse in one patient. There were no false-positive cases on CT when compared with surgical findings

*BW* Baden–Walker, *POP-Q* Pelvic Organ Prolapse Quantification, *UDI* Urinary Distress Inventory, *DDI* Defecatory Distress Inventory, *KESS* Knowles Eccersley Scott Symptom Score, *CRADI* ColoRectal-Anal Distress Inventory, *POP* pelvic organ prolapse, *PE* physical examination, *CT* computerized tomography

with 5 out of 19 describing cohorts of patients planning surgical intervention for prolapse. All but two studies [18, 26] used POP-Q for describing patient prolapse type and severity.


### Variation in Technique

With the exception of one study, all studies used a T2-weighted basic pulse sequence, which enhances the signal of water (Figs. 4, 5) [26]. The strength of a magnetic field in an MRI machine varied from 0.25 to 3 Tesla with approximately half of studies reporting on the 1.5-Tesla

MRI technique. All studies were performed in the supine position and images obtained at rest and during straining. Some studies added images obtained during squeezing and contraction of the pelvic floor muscles [6, 17, 27]. One study examined patients in the supine position during defecation [18]. Delaney et al. hypothesized that prolapse in one vaginal wall can be obscured by a competing defect in the opposite vaginal wall in cases of multicompartamental prolapse. The authors examined the effect of the reduction of the opposing vaginal wall with the vaginal speculum blade and concluded that in cases of advanced POP, the speculum pressing onto the most dependent portion of



**Fig. 4** Magnetic resonance image at rest with no prolapse



**Fig. 5** Magnetic resonance image demonstrating a posterior defect with enterocele containing small bowel and small bowel mesentery

the vaginal wall prolapse reveals additional prolapse in the opposing compartment in 59% of the patients [28]. Abdulaziz et al. evaluated the effect of positioning (standing, sitting, and supine) on the diagnostic accuracy of MRI in POP quantification and concluded that the maximal extent of prolapse is best evaluated in the standing position [29]. Tumbarello et al. established that 95% of women extended their prolapse further in the supine position with repetitive Valsalva maneuvers [30]. About half of the studies used vaginal and/or rectal gel to enhance opacification and one study was specifically aimed at assessing the effect of the addition of vaginal and rectal gel on POP

MRI imaging by comparing opacified and non-opacified imaging techniques [31]. Oral contrast medium was used only in the study with T1-weighted images [26]. One study reported on the use of intramuscular butylscopolamine to reduce intestinal mobility [32] and one study described gadolinium solution infused into the bladder in addition to using vaginal and rectal gel. [33]

#### Definition of Cases and Controls and Radiographic Markers

Only four studies collected data on the symptoms of prolapse and used validated questionnaires [32, 34–36]. The most commonly used questionnaires were the Urinary Distress Inventory (UDI), the Defecatory Distress Inventory (DDI), the Incontinence Impact Questionnaire (IIQ), and the ColoRectal-Anal Distress Inventory. One study included correlation of prolapse and symptoms, but did not use a validated questionnaire [37]. All but one of the studies did not utilize questionnaires in defining POP as symptomatic or clinically significant [36]. The biggest variation existed in definitions of MRI findings: multiple midsagittal pelvic reference lines were described to quantify prolapse using MRI (Table 3). An attempt was made to standardize MRI lines, by introducing the sacrococcygeal–inferior pubic point line; however, this proposed reference line was not universally accepted. Subsequently, radiographic definitions of prolapse in reference to multiple lines varied greatly. Largely, studies reported either on distances between the pre-determined or leading portions of the prolapsing organ and the selected reference line or on different radiographic stages of prolapse using arbitrary cut-off values (Table 4). Xie et al. introduced the term “exposed vaginal length,” measured from the point where the posterior vaginal wall separates from the anterior wall to the ventral tip of the perineal body, as a potential tool to diagnose posterior compartment prolapse [36]. Rodrigues Jr et al. explored the value of estimated levator ani volume (LASV) in prolapse staging and found that LASV can be estimated using MRI and shows good correlation with 3D images on MRI; the clinical relevance of this finding needs to be studied [38]. Lammers et al. used pubovisceral muscle avulsions on MRI to correlate with prolapse in different compartments and found that pubovisceral avulsions, presence, and severity correlated with signs and symptoms of prolapse. [32]

#### Diagnostic Accuracy Reporting

The majority of the studies reported on the association or correlation of prolapse with physical examination findings but did not have sensitivity or specificity calculated or ROC reported. Findings of advanced prolapse stages appear to correlate better with MRI POP diagnosis than POP-Q stages I and II. The correlation of POP-Q prolapse diagnosis is

**Table 3** Magnetic resonance imaging reference lines

Line	Definition	References
Pubococcygeal line	Extending from the inferior-most portion of the symphysis pubis to the tangent of the last coccygeal joint. Points of interest are measured as a vertical distance to the reference line corresponding to the levator muscles	Abdulaziz et al. [29], Agildere et al. [26], Broekhuis et al. [17], Delaney et al. [28], Ethik et al. [14], Grob et al. [3], Hodroff et al. [33], Lakeman et al. [34], Lin et al. [18], Pannu et al. [31], Pollock et al. [68], Siegmann et al. [37], Singh et al. [61], Torricelli et al. [62]
Midpubic line	Drawn across the midsagittal aspect of the pubic bone through the approximate level of the vaginal hymen corresponding to the level of the hymen	Abdulaziz et al. [29], Barakat et al. [16], Cortes et al. [63], Fauconnier et al. [64], Lakeman et al. [34], Pannu [31], Singh et al. [61], Woodfield et al. [65], Xie et al. [36]
Horizontal line	Measures the width of the pelvic floor hiatus in the anteroposterior dimension. Measured from the inferior tip of the pubic symphysis to the posterior circular fibers of the anorectal junction	Xie et al. [36], Lin et al. [18], Lakeman et al. [34], Gupta et al. [16], Broekhuis et al. [17], Abdulaziz et al. [29]
Mid-anal line	Line extending through the middle of the anal canal in a resting position of the anorectal junction 2 cm above the plane of the ischial tuberosities	Xie et al. [36], Lin et al. [18], Abdulaziz et al. [29], Sayed et al. [66]
Internal anal sphincter line	Reference line placed through the ventral aspect of the internal anal sphincter	Xie et al. [36]
Hiatus line	Measures the distance from the pubis to the posterior anal canal	Xie et al. [36], Comiter et al. [67]
Perineal line	Reference line from the inside of the pubic symphysis to the front tip of the perineal body	Xie et al. [36], Lakeman et al. [34], Fauconnier et al. [64], Abdulaziz et al. [29]

slightly better in the anterior compartment than in the apical and posterior compartments. Only one study reported ROCs for different radiographic markers assessing posterior compartment prolapse [36]. The study compared the diagnostic value of eight existing reference lines and a new parameter, the “exposed vaginal length,” in the diagnosis of posterior compartment prolapse. The study focused on the ability of MRI to detect the size and not the POP-Q stage of prolapse, as the authors believed that POP-Q is not designed to assess the prolapse size, which is the parameter that the authors felt most consistently correlated with bothersome symptoms. The exposed vaginal length outperformed the traditional reference lines in diagnosing prolapse size, with an AUC of 0.95. This measurement can discriminate large posterior compartment prolapse from small, with a cut-off value of 2.9 cm. The “perineal line-internal pubis” showed the highest sensitivity and specificity among traditional lines, with an AUC of 0.91 [36].

## Conclusion

Magnetic resonance imaging findings appear to correlate somewhat better with POP-Q staging in the anterior compartment and in more advanced stages of prolapse. The lack of standardized definitions for reference lines and a lack of reporting on test accuracy made it difficult to compare study results.

## Ultrasound

Out of the 50 studies that met the inclusion criteria for assessing POP via ultrasound, 44 explored the perineal ultrasound technique, consistent with AIUM/IUGA practice guidelines [39]. The remainder of the studies focused on endovaginal, endoanal, and trans-abdominal ultrasound.

## Transperineal Ultrasound

The vast majority of the TPUS studies were cohort cross-sectional, with only 10 studies designed as case-control cross-sectional. Two studies used the BW or the Green classification of cystoceles, with the remainder reporting POP according to the POP-Q. The Green classification of cystocele takes into account the urethrovesical angle and the level of urethral involvement in anterior vaginal wall descent [40]. Three studies included patients planning surgery for prolapse.

**Variation in Technique** Technique variation in transperineal ultrasound was minimal in the studies published after 2004 following a standardized protocol popularized by Dietz et al. (Figs. 6, 7) [41, 42]. Most of the studies were performed in supine position with no organ opacification. The transducer

**Table 4** Radiographic definitions of prolapse

Radiographic distance to the reference line	Reference	Radiographic staging of POP	Reference
Difference between the coordinates of maximal prolapse for anterior and posterior vaginal wall and apex and reference line	Barakat et al. [6], Fauconnier et al. [64], Lakeman et al. [34], Tumbarello et al. [30], Xie et al. [36]	Stages of prolapse ranging from I to IV as referenced by the distance from the mid-pubic line: stage I MPL < -1 cm (less than 2-cm descent); stage II between -1 and +1 distance from the MPL (between 2- and 4-cm descent); stage III more than +1 cm from the MPL but less than + (TVL-2) (more than 4-cm descent), stage IV more than + (TVL-2) or more than 4-cm descent	Cortes et al. [63]
In the anterior compartment, the postero-caudal-most point of the anterior vaginal wall was used; in the central compartment, the distal-most point of the cervix or the vaginal vault; and in the posterior compartment, the antero-caudal-most point of the posterior vaginal wall using reference	Broekhuis et al. [17]	Modified Sigh et al.: 1st 0.5–2 cm movement of the pelvic organs during straining, 2nd 2–4 cm movement, but not below the PCL, 3rd > 4 cm movement or below the PCL, 4th > 10 cm movement below the PCL	Etilik et al. [14]
The positions of the bladder neck, bladder base, and uterine cervix (or vaginal apex) were recorded as positive if above and negative if under the PCL	Delaney et al. [28]	HMO classification for MRI grading of pelvic organ prolapse: 0 above the H line; 1, 0–2 cm below the H line; 2, 2–4 cm below the H line; 3, more than 4 cm below the H line	Gupta et al. [16]
Distances to the anterior part of the cervix, bladder neck, and pouch of Douglas were measured to the PCL	Grob et al. [3]	Stage I: all organs lying above the MPL; stage II: pelvic organs lying < 1 cm proximal to or distal from the MPL; stage III: distal-most portion of the prolapse is > 1 cm below the MPL but protrudes no further than 2 cm less than the total vaginal length; stage IV: complete eversion	Singh et al. [61]
Measures bladder neck height or the perpendicular distance from the bladder neck to the reference line, the posterior urethrovaginal angle, and the posterior levator plate angle relative to the PCL	Hodroff et al. [33]	Mild: organ descended < 3 cm below the PCL, moderate: between 3 and 6 cm below the PCL; severe: if more than 6 cm below the PCL. Rectocele was classified as mild if protruding less than 2 cm past the line tangential to the anterior wall of the anal canal, moderate if protruding 2–4 cm, and severe if protruding more than 4 cm	Torricelli et al. [62]
Cystocele: any portion of the bladder herniated below the PCL. Rectocele anterior bulging (> 1 cm) of the anterior rectal wall compared with static imaging	Lin et al. [18]	Anterior compartment, the reference point was the posterior- and inferior-most aspect of the bladder base. In the apical compartment, the reference point was the anterior cervical lip or the posterior superior vaginal apex if the woman was post-hysterectomy. In the posterior compartment, the anterior aspect of the anorectal junction served as the point of reference. Organ prolapse < 3 cm below the PCL small, 3 to 6 cm below moderate, and > 6 cm below the PCL large prolapse	Woodfield et al. [65]
Bladder: cystocele defined as 1) below the PCL, 2) below the MPL or < = 3 cm above the MPL; apical POP: 1) below the PCL, 2) below the MPL or < = 5 cm above the MPL; small bowel: 1) below the apical third of the vagina; rectum: more than 3-cm anterior bulge relative to the anal canal	Pannu et al. [31]	No staging system proposed	

Table 4 (continued)

Radiographic distance to the reference line	Reference	Radiographic staging of POP	Reference
Organ prolapse (O line) was used to categorize cystocele, when a portion of the bladder prolapsed below the PCL. Apical prolapse was measured with respect to the PCL. Rectocele was defined as anterior bulging > 1 cm of the anterior wall of the rectum compared with static imaging	Pollock et al. [68]	No staging system proposed	
Cystocele was diagnosed if the bladder base descended below the PCL on straining. Rectocele was present if the anterior rectal wall was pouching out $\geq 2$ cm at defecation	Siegmann et al. [37]	No staging system proposed	
Anterior compartment—the distal-most part of the bladder. Apical compartment—the leading edge of the vaginal cuff or the location of the cervix. Posterior compartment—the anorectal junction in relation to the PCL	Van der Weiden et al. [35]	No staging system proposed	


PCL pubo-coccygeal line, MPL midpubic line, POP pelvic organ prolapse, TVL total vaginal length, HMO H line, M line, organ prolapse, MRI magnetic resonance imaging

was applied to the perineum lightly placed to minimize pressure so as not to reduce maximal descent. The technique's sensitivity to positional changes was examined by Rodriguez-Mias et al. who studied the effect of standing position on US accuracy, to assess if established diagnostic cut-offs for POP need to be changed. The authors concluded that parameters describing organ descent are not affected by the standing position but hiatal diameters change enough to consider a new cut-off [43]. Braverman et al. demonstrated that diagnostic performance of sonographic markers predicting prolapse is only marginally better in standing position [12].


**Definition of Cases and Controls and Radiographic Markers** Two thirds of the studies included assessments of symptoms, but only five used validated questionnaires. The most commonly used questionnaire was the Pelvic Floor Distress Inventory (PFDI-20) [44]. Most of the studies did not use symptoms or validated questionnaires in the definition of clinically significant prolapse, but rather explored the association between ultrasound diagnosis of POP and the presence of clinical symptoms, without quantifying severity. However, several studies focused on the diagnostic accuracy of ultrasound in relationship to POP symptoms, rather than the POP-Q, and attempted to define cut-offs for significant pelvic organ descent on the basis of prolapse symptoms [7]. Ten studies used the definition of POP-Q stage II as clinically significant. There were two main categories of sonographic markers utilized to predict POP: the measurements of descent describing organ position relative to the inferior margin of the symphysis pubis and measurements relative to the levator plate (Table 5). The most frequently quoted topographic organ descent cut-offs were  $\geq 10$  mm and  $\geq 15$  mm below the symphysis pubis for the bladder and rectal ampulla [7]. In studies focusing on uterine prolapse, the clinical definition of prolapse was defined as descent of the cervix to 15 mm above the symphysis pubis or lower. The highest variation was amongst the cut-off values describing the apical compartment. They varied between 15 mm above the symphysis pubis to 0 mm (symphysis pubis level). However, some studies explored other sonographic markers such as tenting of the paravaginal fornices in the axial plane (presumably describing a paravaginal defect) [45], discontinuity in the anterior anorectal muscularis that resulted in a diverticulum of the rectal ampulla extending into the vagina (“true rectocele”) [46], vaginal canal shape described as H, U, and eye shaped [47] or morphology and axial orientation variations of the levator plate [48].

**Diagnostic Accuracy Reporting** Fifteen out of 44 studies commenting on the value of transperineal ultrasound in the diagnosis of POP reported measures of diagnostic test accuracy (area under the curve for ROC analysis). Five studies reported on topographic sonographic markers and eight

**Fig. 6** Transperineal ultrasound at rest



**Fig. 7** Transperineal ultrasound at rest with Valsalva demonstrating anterior compartment prolapse



focused on the measures of the levator plate, with two studies exploring both measures. Although the sonographic definitions were fairly consistent across the literature, the studies used heterogeneous definitions of prolapse as reference standards. Some studies focused on detecting the symptoms of prolapse and some attempted to report on diagnostic test discrimination between POP-Q stages. Others defined clinically significant prolapse as  $\geq$  POP-Q stage II (Table 6). The definition of clinically significant prolapse by POP-Q varied by compartment, with the majority of studies making the distinction for  $\geq$  POP-Q stage II for anterior and posterior compartments and  $\geq$  POP-Q stage I for the apical compartment. None of the studies used validated questionnaires to define clinically significant POP. All studies were cohort cross-sectional by design and included a large number of participants, but were limited to two populations: predominantly white in Australia and Asian in China. AUCs ranged from 0.59 for an ultrasound topographic marker predicting

uterine POP symptoms in the case of uterine prolapse, to 0.94 for hiatal area at Valsalva predicting POP-Q stage III. It is worth noting that an AUC of 0.5 carries no diagnostic value in detecting a pathological condition and indicates that the test is performing no better than flipping a coin.

Receiver-operating characteristic curves appear to be similar for both anterior and posterior compartments, although the relationship between organ descent and symptoms was slightly stronger for the anterior compartment. Topographic markers appear to detect symptoms of POP only slightly better than the marker of the levator plate. ROC analysis indicates that the probability of transperineal ultrasound (TPUS) in detecting symptomatic prolapse increases with increasing POP stage [49]. Studies reporting the diagnostic value of TPUS in an Asian Chinese population report slightly better diagnostic accuracy than studies originating in Australia. The sensitivities and specificities of TPUS in detecting symptoms of POP and physical evidence of POP



**Table 5** Sonographic markers for pelvic organ prolapse

Topographic imaging of organ descent	References	Measurements of the levator plate	References
Anterior: bladder descent below the symphysis	Xuan et al. [69], Lone et al. [4, 70], Dietz et al. [18, 11, 71], Kluivers et al. [72], Lai et al. [73], Rodriguez-Mias et al. [43], Wen et al. [53], Bu et al. [74], Chantarasorn and Dietz [9], Najjari et al. [75], Schettino et al. [76], Barakat et al. [6], Braverman et al. [12], Broekhuis et al. [17], Zhu et al. [77]	Levator muscle avulsion]	Trutnovsky et al. [78], Dietz and Beer-Gabel [79], Lai et al. [73], Pattillo Garnham et al. [80], Ying et al. [48], Zhuang et al. [50], Huang et al. [60], Zhu et al. [77]
Posterior: the antero-caudal-most point of the anterior rectal wall below the symphysis	Xuan et al. [69], Volloyhaug et al. [15], Lone et al. [4, 70], Dietz et al. [11, 71, 81], Dietz and Steensma [82], Dietz and Lekskulchai [7] Dietz and Korda [83], Barakat et al. [6], Rodrigues et al. [38], Kluivers et al. [84], Lai et al. [73], Rodriguez-Mias et al. [43], Wen et al. [53], Braverman et al. [12], Broekhuis et al. [17], Zhu et al. [77]	Levator diameter (vertical and horizontal)	Majida et al. [85], Kozma et al. [86], Dietz and Beer-Gabel [79], Pineda et al. [87], Huang et al. [60], Wen and Zhou [51], Ying et al. [48], Zhuang et al. [50], Wen et al. [88]
Apical: uterine descent in relation to the symphysis	Xuan et al. [69], Volloyhaug et al. [15], Lone et al. [4, 70], Dietz et al. [8, 11, 71], Kluivers et al. [84], Lai et al. [73], Rodriguez-Mias et al. [43], Wen et al. [47, 53], Wu et al. [49], Barakat et al. [6], Braverman et al. [12], Broekhuis et al. [17], Shekand Dietz [89], Zhu et al. [77]	Levator hiatal area (also described as levator ballooning)	Xuan et al. [69], Abdool et al. [90], Athanasiou et al. [57], Dietz and Beer-Gabel [79], Lai et al. [73], Pattillo Garnham et al. [80], Rodriguez-Mias et al. [43], Speksnijder et al. [91], Zhuang et al. [50]

**Table 6** Accuracy reporting for transperineal ultrasound studies

Reference	Ultrasound marker	Details	Prolapse reference standard definition	ROC statistics
Trutnovsky et al. [78]	Levator plate	Scoring system for puborectalis avulsion: 6-point and 12-point systems	Symptoms and signs of POP in all compartments dichotomized as presence or absence	AUCs were 0.619 and 0.633 for the 6-point and the 12-point scales respectively. The discrete variable "avulsion" a cut-off value of "6" was chosen for the 12-point scale on the basis of these ROC curves. This resulted in 32.8% sensitivity and 86.0% specificity for predicting significant POP on ultrasound. The association between avulsion and physical findings of POP (POP-Q) was stronger than the association of avulsion with ultrasound findings of POP
Dietz et al. [81]	Topographic	Measurement of rectal descent relative to the symphysis, rectocele depth measurement	Posterior compartment prolapse associated with symptoms of vaginal digitation and incomplete bowel emptying	AUCs are 0.61 for detecting vaginal digitation and 0.614 for incomplete bowel emptying on the one hand and rectocele depth on the other. The cut-off depth of 15 mm provides sensitivities of 66% for vaginal digitation and 63% for incomplete emptying, and specificities of 52 and 57% respectively
Dietz and Leksukulchai [7]	Topographic	Measurement of rectocele and cystocele descent below the symphysis pubis	Dominant compartment POP associated with the feeling of a vaginal lump or bulge, or a dragging sensation	AUCs 0.857 vs 0.821 for anterior vs posterior compartment for predicting symptoms of POP
Kluiwers et al. [72]	Topographic	Maximum descent of the leading edge of the bladder, the cervix or vaginal vault and rectum in millimeters	Symptomatic prolapse confirmed by POP-Q or BW and associated with the feeling of a vaginal lump or bulge, or a dragging sensation	AUCs indicating the probability of symptoms of prolapse with increasing stages, was 0.778 for the POP-Q, 0.783 for BW ordinal stages and 0.715 for ultrasound quantification. The cut-off point, with equal costs of misclassification, was at the hymen (0 cm) in the POP-Q, stage 2 in the ordinal stages and 14 mm below the reference line through the symphysis pubis for ultrasound
Lai et al. [73]	Levator plate	The depth of discontinuity between the insertion of the muscle and the rami pubis in the case of abnormal insertion of the puborectalis muscle. Measured in the plane of minimal hiatal dimension	POP symptoms were defined as a vaginal lump/bulge or a dragging sensation. Significant clinical prolapse was defined as POP stage II or higher	AUC 0.82 for POP stage II or higher, 0.84 for POP symptoms, 0.77 for significant POP on ultrasound, and 0.79 for hiatal ballooning. ROC showed that a cut-off depth for levator muscle injury of 7 mm yielded sensitivity of 62% and specificity of 80% for POP symptoms

Table 6 (continued)

Reference	Ultrasound marker	Details	Prolapse reference standard definition	ROC statistics
Pineda et al. [87]	Levator plate	Midsagittal diameter of the hiatus on Valsalva	Significant clinical prolapse was defined as POP stage II or higher	AUC of 0.637 for AP diameter on Valsalva. AUC 0.71 for the relationship between midsagittal AP diameter and clinical findings of significant prolapse, 0.751 for significant prolapse diagnosed on ultrasound. A cut-off of 6 cm of the AP hiatal diameter on Valsalva yielded a specificity of 0.64 and a sensitivity of 0.7 for detecting significant prolapse on ultrasound
Rodriguez-Mias et al. [43]	Topographic and levator plate	Maximum descent of the leading edge of the bladder, the cervix or vaginal vault and rectum in millimeters in the standing position. Levator hiatus area in the standing position	Symptoms of POP with clinically significant POP as POP-Q stage II and above for the anterior and posterior compartments and POP-Q stage $\geq$ I for the apical compartment	AUCs 0.698 for cystocele, 0.593 for uterine descent, 0.635 for the rectal ampulla, and 0.706 for levator hiatal area respectively vs symptoms of POP. A hiatal area on Valsalva of 29 cm <sup>2</sup> was found to be the optimal cut-off when imaging is performed in the standing position
Wen et al. [47]	Topographic	Maximal uterine descent and shape of the vaginal canal	Symptoms of POP with clinically significant POP as POP-Q stage II and above	The AUC was 0.69 for apical prolapse. The ROC curve proposed a cut-off of 10 mm above the symphysis pubis for uterine prolapse (POP stage $\geq$ I) with sensitivity of 74% and specificity of 64%. An eye-shaped vaginal canal with an AP diameter of greater than 10 mm in the rendered axial plane was a sign of uterine prolapse
Wen et al. [53]	Measures of levator plate	Hiatal area, AP diameter of hiatal area and width of hiatal area measured in centimeters at rest, on Valsalva maneuver, and on pelvic floor muscle contraction. All measures transformed in Z-score. Z-score 5 (measured value – predicted mean value)/predicted standard deviation	POP-Q stage II or higher defined as symptomatic prolapse. Symptomatic POP is defined as subjective symptoms of the bulge. Substantial POP on translabial ultrasound defined as a cystocele to at least 10 mm below the symphysis, uterine descent to 15 mm above the symphysis or lower, rectal ampulla/enterocele descent to at least 15 mm below the symphysis, or a combination thereof	AUCs of 0.69, 0.87, and 0.86 for Z-scores for POP-Q stage II or higher substantial POP on translabial ultrasound, and symptomatic POP. The levator hiatal area cut-off was 20 cm <sup>2</sup> with sensitivity of 81% and specificity of 58% for POP-Q stage II or higher, sensitivity of 86% and specificity of 70% for symptomatic POP, and sensitivity of 87% and specificity of 73% for substantiate POP on translabial ultrasound. ROC analysis illustrated that no diagnostic cut-off value can be used to distinguish the normal state and POP stage I. Patients with POP stage I were always clinically asymptomatic

Table 6 (continued)

Reference	Ultrasound marker	Details	Prolapse reference standard definition	ROC statistics
Wen et al. [52]	Measures of levator plate	Hiatal area, AP diameter of the hiatal area and width of the hiatal area measured in centimeters at rest, on Valsalva maneuver, and on pelvic floor muscle contraction. All measures transformed into Z-score	POP-Q stages I, II, III dichotomized as present or absent	AUCs of 0.65 and 0.69 for hiatal area at Valsalva and hiatal length at Valsalva respectively for POP stage I. AUC of 0.77 and 0.72 for hiatal area at Valsalva and hiatal length at Valsalva respectively for POP stage II. AUC of 0.94 for hiatal area at Valsalva and 0.86 for hiatal length at Valsalva for POP stage III. ROC illustrated that no ideal cut-off to distinguish between "normal" and POP stage I. If we consider women who had no POP or had asymptomatic POP (stage I) to be "normal" and those with symptomatic POP (stage II or more) to be "abnormal," the ROC proposes a maximal hiatal area of 20 cm <sup>2</sup> or an AP of 6 cm (Z-score of 1.0) as cut-off with sensitivity of 79% and specificity of 65% for hiatal area and sensitivity of 71% and specificity of 58% for hiatal length
Wen and Zhou [51]	Measures of levator plate	AP diameter was measured in the midsagittal plane as the minimal distance between the hyperechoic inferoposterior aspect of the pubic symphysis and the hyperechoic anterior border of the pubovisceral muscle. The hiatal area was measured in the minimal axial plane with minimal dimensions	POP-Q stage II or higher defined as clinically significant prolapse. Symptomatic POP is defined as subjective symptoms of a bulge	AUCs 0.63 for the AP diameter and 0.66 for the hiatal area according to POP-Q stage II and higher. AUCs 0.75 for the AP and 0.82 for the hiatal area against prolapse symptoms. A cut-off of 6.0 cm for the AP diameter against POP-Q stage II and higher yielded sensitivity of 73% and specificity of 52%. A cut-off of 20 cm <sup>2</sup> for the hiatal area against POP-Q stage II and higher produced sensitivity of 76% and specificity of 54%. For prolapse symptoms, the cut-off of 6.0 cm for the AP diameter had sensitivity of 74% and specificity of 64%, and the cut-off of 20 cm <sup>2</sup> for the hiatal area had sensitivity of 78% and specificity of 68%

Table 6 (continued)

Reference	Ultrasound marker	Details	Prolapse reference standard definition	ROC statistics
Wu et al. [49]	Topographic	Uterine descent was measured relative to the horizontal line positioned through the posteroinferior margin of the symphysis pubis on maximal Valsalva	POP-Q stages I and above and stage II and above for the apical compartment. Symptomatic POP is defined as subjective symptoms of the bulge	AUCs for POP symptoms 0.75. AUCs for POP-Q stage I and above 0.83; for POP-Q stage II and above 0.85. Cut-off values: 4.79 mm above the symphysis pubis for POP symptoms; cut-off 6.63 mm above the symphysis pubis for POP-Q stage I+; cut-off 8.42 mm below the symphysis pubis for POP-Q stage II+. Likelihood ratio + 1.91 for symptoms; 2.72 for POP-Q stage I+; 8.67 for POP-Q stage II+. Likelihood ratio 0.34 for symptoms; 0.25 for POP-Q stage I+; 0.39 for POP-Q stage II+
Braverman et al. [12]	Topographic and levator plate	Maximal caudal displacement of pelvic organs in relation to the symphysis pubis on maximal Valsalva maneuver supine and standing. Hiatal area on maximum Valsalva maneuver	Clinically significant prolapse defined as POP-Q stage II or higher in the anterior and posterior compartments or stage I or higher in the central compartment	AUCs for the anterior compartment: 0.64 supine and 0.67 standing; for uterine descent: 0.64 supine and 0.67 standing; for the posterior compartment: 0.57 supine and 0.6 standing; for the hiatal area: 0.68 supine and 0.72 standing
Shekand Dietz [89]	Topographic	Apical descent was measured relative to the posteroinferior margin of the symphysis pubis	Symptomatic POP is defined as subjective symptoms of the bulge	AUC 0.68 with sensitivity 0.7 and specificity 0.57 for a cut-off of -15 mm (15 mm above the symphysis pubis). AUC 0.74 with sensitivity 0.7 and specificity 0.64 for a cut-off of -15 mm (15 mm above the symphysis pubis) after patients with anterior- and posterior-dominant prolapse were excluded
Zhuang et al. [50]	Levator plate	Levator-urethra gap, levator-symphysis gap, and puborectalis attachment	MRI diagnosis of unilateral or bilateral avulsion	AUC 0.906 by levator-urethra gap for the diagnosis of levator avulsion with a cut-off of 23.65 mm (sensitivity, 92%; specificity, 95%). AUC 0.906 by levator-symphysis for the diagnosis of levator avulsion with a cut-off of 28.7 mm (sensitivity, 84.6%; specificity, 69.7%)

AP anteroposterior, POP pelvic organ prolapse, POP-Q Pelvic Organ Prolapse Quantification, BW Baden-Walker, ROC receiver-operating characteristic, AUC area under the curve

range from high 60 to low 80 and depend on the population, definition of POP, POP compartment assessed in the study, and POP severity [47, 49–53]. Only one study reported a likelihood ratio, the parameter that allows the assessment of an individual patient's probability of having POP [49]. The likelihood ratio (LR) describes the chance of a positive sonographic marker being expected in a patient with POP compared with the likelihood of the same result being expected in a patient without POP. LR close to 1 means that the test result does not appreciably change the likelihood of POP. Ideally, the LRs should be either above 10 or below 0.1 to provide strong evidence to rule POP in or out. The positive LRs were 1.91 for ultrasound detecting symptoms of POP, 2.72 for detecting  $\geq$  POP-Q stage I, and 8.6 for detecting  $\geq$  POP-Q stage II. The negative LRs were 0.34, 0.25, and 0.39 respectively, indicating that ultrasound performs marginally better in ruling in advanced-stage POP than ruling in it out. LRs showed a rather small effect in predicting symptoms of POP or less advanced POP. This study focused on detecting uterine prolapse only [49].

**Conclusion** The standardized technique of TPUS for POP detection is generally accepted; however, the accuracy of transperineal ultrasound in detecting symptoms or the anatomical finding of POP is moderate at best. The accuracy slightly improves in the standing position and with increasing POP severity. TPUS assessment in the standing position can be performed in cases where false-negative findings are suspected after a supine assessment. TPUS findings need to be interpreted with caution in patients with milder forms of POP. Reports on the diagnostic accuracy of TPUS findings are limited to two specific populations, as most studies originated in Australia and Asia. There is significant variation in diagnostic cut-offs for POP detection with regard to uterine descent between the two populations.

### Other Types of Ultrasound

Six studies evaluated the diagnostic significance of alternative ultrasound modalities for the diagnosis of POP. Three studies attempted to assess endoanal ultrasound, two studies commented on endovaginal ultrasound, and one study explored the value of transabdominal ultrasound.

**Endoanal Ultrasound** All three studies utilizing endoanal ultrasound in the diagnosis of POP were performed among patients awaiting surgical intervention for POP (Fig. 8). The technique was not standardized, and the ultrasound evaluations were performed in lithotomy, lateral decubital, or supine positions with the use of a tilting table. One study used a Foley balloon inserted in the bladder to better delineate the anterior compartment POP [54]. As POP-Q is not commonly accepted among colorectal surgeons as a gold



**Fig. 8** Endoanal ultrasound with internal and external anal sphincter defect

standard reference for POP diagnosis, the diagnostic accuracy of endoanal ultrasound was described in correlation with intraoperative findings during POP surgery. Vierhout et al. focused on the posterior compartment and identifying enteroceles [54]. The authors described a sonographic marker of peristaltic loops of small bowel protruding into the vagina as evidence of an enterocele herniation of the pouch of Douglas. They concluded that rectal ultrasonographic findings were in good accordance with intraoperative anatomical diagnosis of enterocele. In 27 out of 29 patients (93%), when an enterocele was diagnosed by endoanal ultrasound, it was confirmed during surgery. Karaus et al. also focused on diagnosing enterocele, and defined an enterocele sonographic marker as the opening of a cul-de-sac into the vagina [55]. Only 4 patients out of the entire cohort of 17 underwent surgery, and enterocele was confirmed for all of them. Minagawa et al. explored all compartments for prolapse using the endoanal technique and compared ultrasound against intraoperative findings in 31 patients. This study used postural change from supine to standing position on a tilting table and defined any descent of the bladder neck from the baseline supine position as cystocele, descent of the vaginal vault of more than 3 cm as apical prolapse, and descent of the posterior vaginal wall of more than 1 cm as rectocele. The authors reported sensitivity, specificity, and accuracy of 90%, 83%, and 74% for anterior, apical, and posterior prolapse respectively [56].

**Endovaginal Ultrasound** Two studies describing endovaginal ultrasound use in POP diagnosis focused on two different

aspects of POP. Lone et al. aimed to assess if ultrasound findings can aid in diagnosing additional POP, which would lead to a change in planned surgical intervention. They concluded that clinical examination is better at diagnosing cysto-urethrocele, rectocele, and uterine prolapse. In addition, endovaginal ultrasound also diagnosed two intussusceptions and a combined enterocele and intussusception in one woman, but overall did not have an impact in the planned management approach [4]. Athanasiou et al. reported on the ability of endovaginal ultrasound to assess the levator hiatal area and correlated it with POP-Q findings. The authors concluded that the hiatal area, and not levator thickness, is in strong correlation with POP-Q measurements in all compartments [57].

**Transabdominal Ultrasound** One study that utilized the transabdominal ultrasound technique, attempted to use it to diagnose paravaginal defects. The role of the paravaginal defect in POP is debated in the literature and the defect itself is not adequately reflected by the POP-Q measuring system [58]. The authors attempted to evaluate if the lateral bladder base “sagging” below level of the central bladder correlates with the physical examination diagnosis of a paravaginal defect established with the use of ring forceps reducing the apical prolapse. The authors concluded that the sonographic paravaginal defects identified in this study were artificially created by the ultrasound technique, utilizing a balloon placed in the vagina to enhance vaginal forces. Hence, this technique cannot accurately diagnose paravaginal defects.

**Conclusion** The diagnostic value of endovaginal and endoanal ultrasound is limited to the detection of enterocele, likely because insertion of the probe into the vaginal or rectal cavity distorts the descent of the prolapsing organs by adding a space-occupying effect. There is no adequately described transabdominal ultrasound technique that can aid the diagnosis of prolapse.

### Head-to-Head Comparison of Different Imaging Techniques

Seven studies included a second imaging technique in the assessment of patients' POP, while attempting to define the value of the index imaging technique in POP diagnosis. Some of the studies used another technique to define cases of POP, as they found POP-Q alone inadequate as a standard reference for testing accuracy. For example, Van Gruting et al. used a composite reference standard to define POP+ cases: DCP, MRI, and physical examination findings needed to agree in order to meet the definition of the positive reference case for POP [19]. Other studies provided insight

into how the techniques compare in POP detection. Martellucci and Naldini reported good correlation between DCP and ultrasound when assessing patients with rectocele (88% agreement) [20]. Beer-Gabel et al. demonstrated that DCP and the ultrasound techniques showed good concordance for the diagnosis of enterocele [59].

Broekhuis et al. aimed to evaluate agreement between MRI and TPUS in detecting prolapse in all compartments and concluded that the two imaging techniques correlate moderately to well only in the anterior compartment [17]. Barakat et al. performed a true blinded head-to-head comparison of MRI and TPUS in detecting POP defined via POP-Q, and concluded that both techniques perform similarly in POP detection in all three compartments, but these findings are limited only to high-grade (POP-Q stage III and IV) POP [6]. Finally, Zhuang et al. focused on the ability of MRI and TPUS to assess levator avulsion and reported 92% agreement, with a kappa of 0.79 between the two techniques [50].

### Conclusion

Transperineal ultrasound has a moderate correlation with DCP in diagnosing enteroceles. MRI and TPUS can be used interchangeably in the diagnosis of levator avulsion but differ in their detection of POP in individual compartments, especially in cases of mild POP.

### Role of Imaging Techniques in the Clinical Management of POP

In 6 studies (3 on MRI and 3 on TPUS) the authors attempted to evaluate the role of imaging in surgical or conservative POP management.

#### Magnetic resonance imaging

Van der Weiden et al. reported on MRI measurements before and 6 months after sacrocolpopexy and concluded that MRI only revealed significant improvement for the apical compartment, with no correlation between changes in MRI measurements, POP-Q measurements, and validated questionnaires [35]. Siegmann et al. reported on the MRI assessment of patients before and after pelvic floor repair with transvaginal mesh, demonstrating clinically occult POP cases in 73.3% of patients at 3 months after repair, but this finding did not correlate with clinical symptoms [37]. Attenberger et al. focused specifically on the ability of MRI to provide additional information not evident according to the physical examination [27]. The latter study evaluated if the MRI diagnosis of POP had an impact on the treatment strategy or altered the surgical procedure: the treatment plan was changed in 13 out of

50 cases (26%). In 12 cases, an enterocele was diagnosed by MRI, but was not detected on physical examination. In 4 cases, an enterocele and in 2 cases a rectocele were suspected clinically but were not confirmed by MRI. The study did not have a comparison group and did not provide any data on patient-centered surgical outcomes.

### Transperineal Ultrasound

Lone et al. studied whether baseline assessment with ultrasound in addition to routine physical examination added diagnostic value leading to management change in patients with POP in a prospective cohort study with normal controls [4]. Although TPUS enhanced the visualization of additional pelvic floor abnormalities and identified a higher number of additional ultrasound pathological conditions in the POP group (11.3% enteroceles and 3.4% intussusceptions), it did not lead to a change in the clinical treatment plan, as the majority of abnormalities (mainly enteroceles) were small. Huang et al. assessed the role of TPUS in patients undergoing transvaginal mesh and native tissue repair surgery for anterior compartment POP and commented on the ability of ultrasound parameters to predict surgical failure [60]. They reported that preoperatively, patients with and without POP recurrence were similar in the POP-Q staging and ultrasound measures of levator hiatus. On 12-month postoperative ultrasound, patients with POP recurrence in the anterior compartment demonstrated a higher rate of complete levator avulsion (OR 14.2; CI 4.8–42.2). Gillor et al. performed a similar study focusing on sonographic outcomes of posterior compartment correction with and without mesh augmentation [46]. They reported that clinical recurrent posterior vaginal wall prolapse (defined as point Bp  $\geq -1$ ) was seen in 20% of patients, whereas POP diagnosed by ultrasound (defined as descent of the rectal ampulla  $\geq 15$  mm below the symphysis pubis) was noted in 12% of patients. An additional 6% exhibited enterocele findings on ultrasound (diagnosed if an enterocele sac was seen at or below the level of the symphysis pubis on imaging) [46]. There was no difference in sonographic levator avulsion between the mesh-augmented and native tissue repair groups in this study [46]. In those without significant posterior compartment descent on clinical examination, a substantial minority still showed a “true rectocele,” (defined as defect of the rectovaginal septum). This was the case after both mesh (29%) and native tissue repair (18.5%).

### Conclusion

In comparison trials, no imaging modality appeared superior to another. Overall, the value of diagnostic imaging in POP management remains unclear and understudied.

### Recommendations

- Computerized tomography and fluoroscopic imaging such as defecography should not be used routinely to diagnose POP, as there are not enough well-designed studies reporting on their accuracy for POP detection.
- The value of defecography is in the detection of enterocele and intussusception.
- The value of MRI in diagnosing multicompartiment POP is unclear, as studies reporting diagnostic accuracy are very heterogeneous in technique, reference lines used, and definitions of POP reference standards.
- Exposed vaginal length with a cut-off value of 2.9 cm can be used to detect large rectocele on MRI with good accuracy.
- Transperineal ultrasound can be used to detect clinically significant POP and symptomatic POP with moderate accuracy. Accuracy decreases as POP-Q stages decrease.
- Cut-off values for uterine POP are population specific and need to be used with caution in populations other than white Australian or Asian Chinese women.
- The value of endovaginal and endoanal ultrasound in prolapse detection and quantification is limited to the detection of enteroceles.
- Both MRI and TPUS can be used in the diagnosis of levator ani avulsion.
- High-quality studies should be performed to evaluate the utility of imaging in the clinical management of POP.

### Discussion Points

The intended use of imaging test can be diagnosis, screening, staging, monitoring, surveillance, prediction, or prognosis. This narrative review focuses on the diagnostic value of different imaging modalities in POP. Our working group identified a significant gap in the current literature surrounding imaging use. There is a lack of well-designed studies with clear definitions of reference standard defining POP as disease. Largely, it is stemming from the lack of consensus of what defines “clinically significant POP.” Imaging techniques appear to perform moderately well in the diagnosis of advanced POP stages, but those POP cases are easily diagnosed on pelvic examination. An ideal study would be a large cohort focusing on low-grade POP, where the “clinically significant prolapse” is diagnosed as a combination of pelvic examination evidence of POP and the presence of symptoms determined by validated questionnaires. The studies with a similar design will need to be repeated in diverse patient populations. Only after this evidence is obtained can we gain a better insight into the diagnostic abilities of different imaging modalities.



**Authors' Contributions** L. Lipetskaia: writing group committee co-chair, primary writer, and editor of the manuscript; A. Gupta: literature search, writing, editing; R.Y.K. Cheung: literature search, writing, editing; V. Khullar: literature search, writing, editing; S. Ismail: literature search, writing, editing; M. Bradley: literature search, writing, editing; R. Karmakar: literature search, writing, editing; S. Clifton: coordinated the large-scale literature search and facilitated the Covidence management of manuscripts; J. Doo: literature search, writing, editing; L. Quiroz: writing group committee co-chair, primary editor of the manuscript.

**Funding** Open access funding provided by Rowan University.

## Declarations

**Financial Disclaimers/Conflicts of Interest** L. Quiroz: Miyazaki Enterprises research grant; UpToDate royalties; ABOG Board of directors for FPMRS.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

- Haylen BT, Freeman RM, Swift SE, Cosson M, Davila GW, Deprest J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint terminology and classification of the complications related directly to the insertion of prostheses (meshes, implants, tapes) and grafts in female pelvic floor surgery. *Neurourol Urodyn*. 2011;30(1):2–12. <https://doi.org/10.1002/nau.21036>.
- Collins SA, O'Shea M, Dykes N, Ramm O, Edenfield A, Shek KL, et al. International Urogynecological Consultation: clinical definition of pelvic organ prolapse. *Int Urogynecol J*. 2021;32(8):2011–9. <https://doi.org/10.1007/s00192-021-04875-y>.
- Grob ATM, Olde Heuvel J, Futterer JJ, Massop D, Veenstra van Nieuwenhoven AL, Simonis FFJ, et al. Underestimation of pelvic organ prolapse in the supine straining position, based on magnetic resonance imaging findings. *Int Urogynecol J*. 2019;30(11):1939–44. <https://doi.org/10.1007/s00192-018-03862-0>.
- Lone F, Sultan AH, Stankiewicz A, Thakar R. The value of pre-operative multicompartiment pelvic floor ultrasonography: a 1-year prospective study. *Br J Radiol*. 2014;87(1040):20140145. <https://doi.org/10.1259/bjr.20140145>.
- Friedman B, Stothers L, Lazare D, Macnab A. Positional pelvic organ prolapse (POP) evaluation using open, weight-bearing magnetic resonance imaging (MRI). *Can Urol Assoc J*. 2015;9(5–6):197–200. <https://doi.org/10.5489/cuaj.2767>.
- Barakat B, Afzal A, Schweda D, Laali A. Comparison of magnetic resonance defecography with pelvic floor ultrasound and vaginal inspection in the urogynecological diagnosis of pelvic floor dysfunction. *Urology Ann*. 2020;12(2):150–5. [https://doi.org/10.4103/UA.UA\\_78\\_19](https://doi.org/10.4103/UA.UA_78_19).
- Dietz HP, Leksukulchai O. Ultrasound assessment of pelvic organ prolapse: the relationship between prolapse severity and symptoms. *Ultrasound Obstet Gynecol*. 2007;29(6):688–91.
- Dietz HP, Kamisan Atan I, Salita A. Association between ICS POP-Q coordinates and translabial ultrasound findings: implications for definition of “normal pelvic organ support.” *Ultrasound Obstet Gynecol*. 2016;47(3):363–8. <https://doi.org/10.1002/uog.14872>.
- Chantarasorn V, Dietz HP. Diagnosis of cystocele type by clinical examination and pelvic floor ultrasound. *Ultrasound Obstet Gynecol*. 2012;39(6):710–4. <https://doi.org/10.1002/uog.10156>.
- Ginath S, Garely A, Luchs JS, Shahryarinejad A, Olivera C, Zhou S, et al. MRI pelvic landmark angles in the assessment of apical pelvic organ prolapse. *Arch Gynecol Obstet*. 2011;284(2):365–70. <https://doi.org/10.1007/s00404-010-1648-1>.
- Dietz HP, Haylen BT, Broome J. Ultrasound in the quantification of female pelvic organ prolapse. *Ultrasound Obstet Gynecol*. 2001;18(5):511–4.
- Braverman M, Kamisan Atan I, Turel F, Friedman T, Dietz HP. Does patient posture affect the ultrasound evaluation of pelvic organ prolapse? *J Ultrasound Med*. 2019;38(1):233–8. <https://doi.org/10.1002/jum.14688>.
- Altman D, Lopez A, Kierkegaard J, Zetterstrom J, Falconer C, Pollack J, et al. Assessment of posterior vaginal wall prolapse: comparison of physical findings to cystodectoperitoneography. *Int Urogynecol J*. 2005;16(2):96–103.
- Etlík O, Arslan H, Odabasi O, Odabasi H, Harman M, Celebi H, et al. The role of the MR-fluoroscopy in the diagnosis and staging of the pelvic organ prolapse. *Eur J Radiol*. 2005;53(1):136–41.
- Volloyhaug I, Rojas RG, Morkved S, Salvesen KA. Comparison of transperineal ultrasound with POP-Q for assessing symptoms of prolapse. *Int Urogynecol J*. 2019;30(4):595–602. <https://doi.org/10.1007/s00192-018-3722-3>.
- Gupta S, Sharma JB, Hari S, Kumar S, Roy KK, Singh N. Study of dynamic magnetic resonance imaging in diagnosis of pelvic organ prolapse. *Arch Gynecol Obstet*. 2012;286(4):953–8. <https://doi.org/10.1007/s00404-012-2381-8>.
- Broekhuis SR, Kluivers KB, Hendriks JC, Futterer JJ, Barentsz JO, Vierhout ME. POP-Q, dynamic MR imaging, and perineal ultrasonography: do they agree in the quantification of female pelvic organ prolapse? *Int Urogynecol J*. 2009;20(5):541–9. <https://doi.org/10.1007/s00192-009-0821-1>.
- Lin FC, Funk JT, Tiwari HA, Kalb BT, Twiss CO. Dynamic pelvic magnetic resonance imaging evaluation of pelvic organ prolapse compared to physical examination findings. *Urology*. 2018;119:49–54. <https://doi.org/10.1016/j.urology.2018.05.031>.
- Van Gruting IMA, Kluivers K, Sultan AH, De Bin R, Stankiewicz A, Blake H, et al. Does 4D transperineal ultrasound have additional value over 2D transperineal ultrasound for diagnosing posterior pelvic floor disorders in women with obstructed defecation syndrome? *Ultrasound Obstet Gynecol*. 2018;52(6):784–91. <https://doi.org/10.1002/uog.19105>.
- Martellucci J, Naldini G. Clinical relevance of transperineal ultrasound compared with evacuation proctography for the evaluation of patients with obstructed defaecation. *Colorectal Dis*. 2011;13(10):1167–72. <https://doi.org/10.1111/j.1463-1318.2010.02427.x>.
- Altman D, Mellgren A, Kierkegaard J, Zetterstrom J, Falconer C, Lopez A. Diagnosis of cystocele—the correlation between clinical and radiological evaluation. *Int Urogynecol J*. 2004;15(1):3–9.
- Groenendijk AG, van der Hulst VP, Birnie E, Bonsel GJ. Correlation between posterior vaginal wall defects assessed by clinical examination and by defecography. *Int Urogynecol J*. 2008;19(9):1291–7. <https://doi.org/10.1007/s00192-008-0632-9>.
- Finco C, Savastano S, Luongo B, Sarzo G, Vecchiato M, Gasparini G, et al. Colpocystodectography in obstructed defecation: is it

- really useful to the surgeon? Correlating clinical and radiological findings in surgery for obstructed defecation. *Colorectal Dis.* 2008;10(5):446–52.
24. Pannu HK, Genadry R, Kaufman HS, Fishman EK. Computed tomography evaluation of pelvic organ prolapse. *Techniques and applications. J Comput Assist Tomogr.* 2003;27(5):779–85.
  25. Brubaker L, Retzky S, Smith C, Saclarides T. Pelvic floor evaluation with dynamic fluoroscopy. *Obstet Gynecol.* 1993;82(5):863–8.
  26. Agildere AM, Tarhan NC, Ergeneli MH, Yologlu Z, Kurt A, Akgun S, et al. MR rectography evaluation of rectoceles with oral gadopentetate dimeglumine and polyethylene glycol solution. *Abdom Imaging.* 2003;28(1):28–35.
  27. Attenberger UI, Morelli JN, Budjan J, Herold A, Kienle P, Kleine W, et al. The value of dynamic magnetic resonance imaging in interdisciplinary treatment of pelvic floor dysfunction. *Abdom Imaging.* 2015;40(7):2242–7. <https://doi.org/10.1007/s00261-015-0476-y>.
  28. Delaney S, Fernandez P, N'Guyen A, Salomon L, Carbonne B, Laissy JP, et al. Effect of a speculum blade on dynamic MRI evaluation of pelvic organ prolapse. *Acta Obstet Gynecol Scand.* 2009;88(7):831–4. <https://doi.org/10.1080/00016340902883166>.
  29. Abdulaziz M, Kavanagh A, Stothers L, Macnab AJ. Relevance of open magnetic resonance imaging position (sitting and standing) to quantify pelvic organ prolapse in women. *Can Urol Assoc J.* 2018;12(11):E453–60. <https://doi.org/10.5489/cuaj.5186>.
  30. Tumbarello JA, Hsu Y, Lewicky-Gaupp C, Rohrer S, DeLancey JO. Do repetitive Valsalva maneuvers change maximum prolapse on dynamic MRI? *Int Urogynecol J.* 2010;21(10):1247–51. <https://doi.org/10.1007/s00192-010-1178-1>.
  31. Pannu HK, Scatarige JC, Eng J. MRI diagnosis of pelvic organ prolapse compared with clinical examination. *Acad Radiol.* 2011;18(10):1245–51. <https://doi.org/10.1016/j.acra.2011.05.010>.
  32. Lammers K, Futterer JJ, Inthout J, Prokop M, Vierhout ME, Kluivers KB. Correlating signs and symptoms with pubovisceral muscle avulsions on magnetic resonance imaging. *Am J Obstet Gynecol.* 2013;208(2):148.e1–7. <https://doi.org/10.1016/j.ajog.2012.12.006>.
  33. Hodroff MA, Stolpen AH, Denson MA, Bolinger L, Kreder KJ. Dynamic magnetic resonance imaging of the female pelvis: the relationship with the Pelvic Organ Prolapse quantification staging system. *J Urol.* 2002;167(3):1353–5.
  34. Lakeman MM, Zijta FM, Peringa J, Nederveen AJ, Stoker J, Roovers JP. Dynamic magnetic resonance imaging to quantify pelvic organ prolapse: reliability of assessment and correlation with clinical findings and pelvic floor symptoms. *Int Urogynecol J.* 2012;23(11):1547–54. <https://doi.org/10.1007/s00192-012-1772-5>.
  35. Van der Weiden RM, Rociu E, Mannaerts GH, van Hooff MH, Vierhout ME, Withagen MI. Dynamic magnetic resonance imaging before and 6 months after laparoscopic sacrocolpopexy. *Int Urogynecol J.* 2014;25(4):507–15. <https://doi.org/10.1007/s00192-013-2254-0>.
  36. Xie B, Chen L, Xue Z, English EM, Fenner DE, Gaetke-Udager K, et al. Comparison of measurement systems for posterior vaginal wall prolapse on magnetic resonance imaging. *Int Urogynecol J.* 2019;30(8):1269–77. <https://doi.org/10.1007/s00192-019-03939-4>.
  37. Siegmann KC, Reisenauer C, Speck S, Barth S, Kraemer B, Clausen CD. Dynamic magnetic resonance imaging for assessment of minimally invasive pelvic floor reconstruction with polypropylene implant. *Eur J Radiol.* 2011;80(2):182–7. <https://doi.org/10.1016/j.ejrad.2010.03.014>.
  38. Rodrigues Jr AA, Herrera-Hernandez MC, Bassalydo R, McCullough M, Terwilliger HL, Downes K, et al. Estimates of the levator ani subtended volume based on magnetic resonance linear measurements. *Neurourol Urodyn.* 2016;35(2):199–205. <https://doi.org/10.1002/nau.22691>.
  39. AIUM/IUGA Practice Parameter for the Performance of Urogynecological Ultrasound Examinations: developed in collaboration with the ACR, the AUGS, the AUA, and the SRU. *J Ultrasound Med.* 2019;38(4):851–64. <https://doi.org/10.1002/jum.14953>.
  40. Green TH Jr. Urinary stress incontinence: differential diagnosis, pathophysiology, and management. *Am J Obstet Gynecol.* 1975;122(3):368–400. [https://doi.org/10.1016/0002-9378\(75\)90186-6](https://doi.org/10.1016/0002-9378(75)90186-6).
  41. Dietz HP. Ultrasound imaging of the pelvic floor. I. Two-dimensional aspects. *Ultrasound Obstet Gynecol.* 2004;23(1):80–92. <https://doi.org/10.1002/uog.939>.
  42. Dietz HP. Ultrasound imaging of the pelvic floor. II. Three-dimensional or volume imaging. *Ultrasound Obstet Gynecol.* 2004;23(6):615–25. <https://doi.org/10.1002/uog.1072>.
  43. Rodriguez-Mias NL, Subramaniam N, Friedman T, Shek KL, Dietz HP. Prolapse assessment supine and standing: do we need different cutoffs for “significant prolapse”? *Int Urogynecol J.* 2018;29(5):685–9. <https://doi.org/10.1007/s00192-017-3342-3>.
  44. Barber MD, Walters MD, Bump RC. Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFDI-20 and PFIQ-7). *Am J Obstet Gynecol.* 2005;193(1):103–13. <https://doi.org/10.1016/j.ajog.2004.12.025>.
  45. Dietz HP, Pang S, Korda A, Benness C. Paravaginal defects: a comparison of clinical examination and 2D/3D ultrasound imaging. *Aust N Z J Obstet Gynaecol.* 2005;45(3):187–90.
  46. Gillor M, Langer S, Dietz HP. Long-term subjective, clinical and sonographic outcomes after native-tissue and mesh-augmented posterior colporrhaphy. *Int Urogynecol J.* 2019;30(9):1581–5. <https://doi.org/10.1007/s00192-019-03921-0>.
  47. Wen L, Li Y, Qing Z, Liu M. Detection of concealed uterine prolapse in the volume-rendering mode of 4-dimensional translabial ultrasound: a retrospective observational study. *J Ultrasound Med.* 2019;38(7):1705–11. <https://doi.org/10.1002/jum.14855>.
  48. Ying T, Li Q, Xu L, Liu F, Hu B. Three-dimensional ultrasound appearance of pelvic floor in nulliparous women and pelvic organ prolapse women. *Int J Med Sci.* 2012;9(10):894–900. <https://doi.org/10.7150/ijms.4829>.
  49. Wu M, Wang X, Lin X, Fu Y, Chen H, Guan X, et al. Defining cut-offs for uterine prolapse using transperineal ultrasound in Chinese women: a prospective multicenter study. *Ultrasound Obstet Gynecol.* 2020;23:23. <https://doi.org/10.1002/uog.23524>.
  50. Zhuang RR, Song YF, Chen ZQ, Ma M, Huang HJ, Chen JH, et al. Levator avulsion using a tomographic ultrasound and magnetic resonance-based model. *Am J Obstet Gynecol.* 2011;205(3):232.e1–8. <https://doi.org/10.1016/j.ajog.2011.03.052>.
  51. Wen L, Zhou Q. Can we evaluate hiatal ballooning by measuring the anteroposterior diameter with 2-dimensional translabial ultrasonography? *J Ultrasound Med.* 2018;37(4):1001–6. <https://doi.org/10.1002/jum.14445>.
  52. Wen L, Zhang J, Zeng S, Zhou Q. Using Z-scores to evaluate levator hiatal dimensions with four-dimensional translabial ultrasound. *J Obstet Gynaecol Res.* 2017;43(12):1840–7. <https://doi.org/10.1111/jog.13454>.
  53. Wen L, Liu M, Zhao B, Qing Z. Evaluating Z scores to quantify levator hiatal distensibility by 3-dimensional ultrasonography in nulliparas and women with pelvic organ prolapse. *J Ultrasound Med.* 2018;37(10):2363–9. <https://doi.org/10.1002/jum.14590>.
  54. Vierhout ME, van der Plas-de Koning YW. Diagnosis of posterior enterocele: comparison of rectal ultrasonography with intraoperative diagnosis. *J Ultrasound Med.* 2002;21(4):383–7.
  55. Karaus M, Neuhaus P, Wiedenmann TB. Diagnosis of enteroceles by dynamic anorectal endosonography. *Dis Colon Rectum.* 2000;43(12):1683–8.

56. Minagawa T, Ogawa T, Ishizuka O, Nishizawa O. Impact of dynamic transrectal ultrasonography on pelvic organ prolapse. *J Urol*. 2015;193(2):670–6. <https://doi.org/10.1016/j.juro.2014.06.094>.
57. Athanasiou S, Chaliha C, Toozs-Hobson P, Salvatore S, Khullar V, Cardozo L. Direct imaging of the pelvic floor muscles using two-dimensional ultrasound: a comparison of women with urogenital prolapse versus controls. *BJOG*. 2007;114(7):882–8.
58. Arenholt LTS, Pedersen BG, Glavind K, Glavind-Kristensen M, DeLancey JOL. Paravaginal defect: anatomy, clinical findings, and imaging. *Int Urogynecol J*. 2017;28(5):661–73. <https://doi.org/10.1007/s00192-016-3096-3>.
59. Beer-Gabel M, Assoulin Y, Amitai M, Bardan E. A comparison of dynamic transperineal ultrasound (DTP-US) with dynamic evacuation proctography (DEP) in the diagnosis of cul de sac hernia (enterocele) in patients with evacuatory dysfunction. *Int J Colorectal Dis*. 2008;23(5):513–9. <https://doi.org/10.1007/s00384-008-0440-1>.
60. Huang WC, Yang JM, Chen HF. Four-dimensional introital ultrasound in assessing perioperative pelvic floor muscle functions of women with cystoceles. *Ultraschall Med*. 2020;42(4):e31–41. <https://doi.org/10.1055/a-1109-2493>.
61. Singh K, Reid WM, Berger LA. Assessment and grading of pelvic organ prolapse by use of dynamic magnetic resonance imaging. *Am J Obstet Gynecol*. 2001;185(1):71–7.
62. Torricelli P, Pecchi A, Caruso Lombardi A, Vetrucchio E, Vetrucchio S, Romagnoli R. Magnetic resonance imaging in evaluating functional disorders of female pelvic floor. *Radiol Med*. 2002;103(5–6):488–500.
63. Cortes E, Reid WM, Singh K, Berger L. Clinical examination and dynamic magnetic resonance imaging in vaginal vault prolapse. *Obstet Gynecol*. 2004;103(1):41–6.
64. Fauconnier A, Zareski E, Abichedid J, Bader G, Falissard B, Fritel X. Dynamic magnetic resonance imaging for grading pelvic organ prolapse according to the International Continence Society classification: which line should be used? *Neurourol Urodyn*. 2008;27(3):191–7.
65. Woodfield CA, Hampton BS, Sung V, Brody JM. Magnetic resonance imaging of pelvic organ prolapse: comparing pubococcygeal and midpubic lines with clinical staging. *Int Urogynecol J*. 2009;20(6):695–701. <https://doi.org/10.1007/s00192-009-0865-2>.
66. El Sayed RF, Alt CD, Maccioni F, Meissnitzer M, Masselli G, Manganaro L, et al. Magnetic resonance imaging of pelvic floor dysfunction—joint recommendations of the ESUR and ESGAR Pelvic Floor Working Group. *Eur Radiol*. 2017;27(5):2067–85. <https://doi.org/10.1007/s00330-016-4471-7>.
67. Comiter CV, Vasavada SP, Barbaric ZL, Gousse AE, Raz S. Grading pelvic prolapse and pelvic floor relaxation using dynamic magnetic resonance imaging. *Urology*. 1999;54(3):454–7. [https://doi.org/10.1016/s0090-4295\(99\)00165-x](https://doi.org/10.1016/s0090-4295(99)00165-x).
68. Pollock GR, Twiss CO, Chartier S, Vedantham S, Funk J, Arif Tiwari H. Comparison of magnetic resonance defecography grading with POP-Q staging and Baden-Walker grading in the evaluation of female pelvic organ prolapse. *Abdom Radiol*. 2019;12:12. <https://doi.org/10.1007/s00261-019-02313-8>.
69. Xuan Y, Friedman T, Dietz HP. Does levator ani hiatus area configuration affect pelvic organ prolapse? *Ultrasound Obstet Gynecol*. 2019;54(1):124–7. <https://doi.org/10.1002/uoq.20210>.
70. Lone FW, Thakar R, Sultan AH, Stankiewicz A. Accuracy of assessing Pelvic Organ Prolapse Quantification points using dynamic 2D transperineal ultrasound in women with pelvic organ prolapse. *Int Urogynecol J*. 2012;23(11):1555–60. <https://doi.org/10.1007/s00192-012-1779-y>.
71. Dietz HP, Stankiewicz M, Atan IK, Ferreira CW, Socha M. Vaginal laxity: what does this symptom mean? *Int Urogynecol J*. 2018;29(5):723–8. <https://doi.org/10.1007/s00192-017-3426-0>.
72. Kluivers KB, Hendriks JC, Shek C, Dietz HP. Pelvic organ prolapse symptoms in relation to POPQ, ordinal stages and ultrasound prolapse assessment. *Int Urogynecol J*. 2008;19(9):1299–302. <https://doi.org/10.1007/s00192-008-0634-7>.
73. Lai W, Wen L, Li Y, Huang X, Qing Z. Concordance of tomographic ultrasound and multiplanar ultrasound in detecting levator ani muscle injury in patients with pelvic organ prolapse. *PLoS One*. 2018;13(7):e0199864. <https://doi.org/10.1371/journal.pone.0199864>.
74. Bu L, Yang D, Nie F, Li Q, Wang YF. Correlation of the type and degree of cystocele with stress urinary incontinence by transperineal ultrasound. *J Med Ultrason* (2001). 2020;47(1):123–30. <https://doi.org/10.1007/s10396-019-00972-0>.
75. Najjari L, Hennemann J, Larscheid P, Papatthemelis T, Maass N. Perineal ultrasound as a complement to POP-Q in the assessment of cystoceles. *Biomed Res Int*. 2014;2014:740925. <https://doi.org/10.1155/2014/740925>.
76. Schettino MT, Datol E, Rossi C, Panariello A, Vascone C, Coppola G, et al. Possible role of perineal ultrasound in the diagnosis of cystocele. *Clin Exp Obstet Gynecol*. 2015;42(3):321–6.
77. Zhu YC, Deng SH, Jiang Q, Zhang Y. Correlation between delivery mode and pelvic organ prolapse evaluated by four-dimensional pelvic floor ultrasonography. *Med Sci Monit*. 2018;24:7891–7. <https://doi.org/10.12659/MSM.911343>.
78. Trutnovsky G, Kamisan Atan I, Ulrich D, Martin A, Dietz HP. Levator ani trauma and pelvic organ prolapse—a comparison of three translabial ultrasound scoring systems. *Acta Obstet Gynecol Scand*. 2016;95(12):1411–7. <https://doi.org/10.1111/aogs.13018>.
79. Dietz HP, Beer-Gabel M. Ultrasound in the investigation of posterior compartment vaginal prolapse and obstructed defecation. *Ultrasound Obstet Gynecol*. 2012;40(1):14–27. <https://doi.org/10.1002/uoq.10131>.
80. Pattillo Garnham A, Guzman Rojas R, Shek KL, Dietz HP. Predicting levator avulsion from ICS POP-Q findings. *Int Urogynecol J*. 2017;28(6):907–11. <https://doi.org/10.1007/s00192-016-3214-2>.
81. Dietz HP, Zhang X, Shek KL, Guzman RR. How large does a rectocele have to be to cause symptoms? A 3D/4D ultrasound study. *Int Urogynecol J*. 2015;26(9):1355–9. <https://doi.org/10.1007/s00192-015-2709-6>.
82. Dietz HP, Steensma AB. Posterior compartment prolapse on two-dimensional and three-dimensional pelvic floor ultrasound: the distinction between true rectocele, perineal hypermobility and enterocele. *Ultrasound Obstet Gynecol*. 2005;26(1):73–7.
83. Dietz HP, Korda A. Which bowel symptoms are most strongly associated with a true rectocele? *Aust N Z J Obstet Gynaecol*. 2005;45(6):505–8.
84. Kluivers KB, Hendriks JC, Shek C, Dietz HP. Pelvic organ prolapse symptoms in relation to POPQ, ordinal stages and ultrasound prolapse assessment. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008;19(9):1299–302. <https://doi.org/10.1007/s00192-008-0634-7>.
85. Majida M, Braekken I, Bo K, Benth J, Engh M. Anterior but not posterior compartment prolapse is associated with levator hiatus area: a three- and four-dimensional transperineal ultrasound study. *BJOG*. 2011;118(3):329–37. <https://doi.org/10.1111/j.1471-0528.2010.02784.x>.
86. Kozma B, Larson K, Scott L, Cunningham TD, Abuhamad A, Poka R, et al. Association between pelvic organ prolapse types

- and levator-urethra gap as measured by 3D transperineal ultrasound. *J Ultrasound Med.* 2018;37(12):2849–54. <https://doi.org/10.1002/jum.14644>.
87. Pineda M, Shek K, Wong V, Dietz HP. Can hiatal ballooning be determined by two-dimensional translabial ultrasound? *Aust N Z J Obstet Gynaecol.* 2013;53(5):489–93. <https://doi.org/10.1111/ajog.12111>.
88. Wen L, Zhao B, Chen W, Qing Z, Liu M. Real-time assessment of the behaviour of the bladder neck and proximal urethra during urine leaking in the cough stress test (CST) in supine and standing positions using transperineal ultrasound. *Int Urogynecol J.* 2020;31(12):2515–9. <https://doi.org/10.1007/s00192-020-04273-w>.
89. Shek KL, Dietz HP. What is abnormal uterine descent on translabial ultrasound? *Int Urogynecol J.* 2015;26(12):1783–7. <https://doi.org/10.1007/s00192-015-2792-8>.
90. Abdool Z, Dietz HP, Lindeque BG. Prolapse symptoms are associated with abnormal functional anatomy of the pelvic floor. *Int Urogynecol J.* 2017;28(9):1387–91. <https://doi.org/10.1007/s00192-017-3280-0>.
91. Speksnijder L, Oom DM, Koning AH, Biesmeijer CS, Steegers EA, Steensma AB. Agreement and reliability of pelvic floor measurements during rest and on maximum Valsalva maneuver using three-dimensional translabial ultrasound and virtual reality imaging. *Ultrasound Obstet Gynecol.* 2016;48(2):243–9. <https://doi.org/10.1002/uog.15785>.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



## International Urogynecology consultation chapter 2 committee 3: the clinical evaluation of pelvic organ prolapse including investigations into associated morbidity/pelvic floor dysfunction

Heather Barbier<sup>1</sup> · Cassandra L. Carberry<sup>2</sup> · Päivi K. Karjalainen<sup>3,4,5</sup> · Charlotte K. Mahoney<sup>6</sup> · Valentín Manríquez Galán<sup>7</sup> · Anna Rosamilia<sup>8,9</sup> · Esther Ruess<sup>10</sup> · David Shaker<sup>11</sup> · Karishma Thariani<sup>12</sup>

Received: 1 May 2023 / Accepted: 22 July 2023 / Published online: 22 September 2023  
© The Author(s) 2023

### Abstract

**Introduction and hypothesis** This manuscript from Chapter 2 of the International Urogynecology Consultation (IUC) on Pelvic Organ Prolapse (POP) reviews the literature involving the clinical evaluation of a patient with POP and associated bladder and bowel dysfunction.

**Methods** An international group of 11 clinicians performed a search of the literature using pre-specified search MESH terms in PubMed and Embase databases (January 2000 to August 2020). Publications were eliminated if not relevant to the clinical evaluation of patients or did not include clear definitions of POP. The titles and abstracts were reviewed using the Covidence database to determine whether they met the inclusion criteria. The manuscripts were reviewed for suitability using the Specialist Unit for Review Evidence checklists. The data from full-text manuscripts were extracted and then reviewed.

**Results** The search strategy found 11,242 abstracts, of which 220 articles were used to inform this narrative review. The main themes of this manuscript were the clinical examination, and the evaluation of comorbid conditions including the urinary tract (LUTS), gastrointestinal tract (GIT), pain, and sexual function. The physical examination of patients with pelvic organ prolapse (POP) should include a reproducible method of describing and quantifying the degree of POP and only the Pelvic Organ Quantification (POP-Q) system or the Simplified Pelvic Organ Prolapse Quantification (S-POP) system have enough reproducibility to be recommended. POP examination should be done with an empty bladder and patients can be supine but should be upright if the prolapse cannot be reproduced. No other parameters of the examination aid in describing and quantifying POP. Post-void residual urine volume >100 ml is commonly used to assess for voiding difficulty. Prolapse reduction can be used to predict the possibility of postoperative persistence of voiding difficulty. There is no benefit of urodynamic testing for assessment of detrusor overactivity as it does not change the management. In women with POP and stress urinary incontinence (SUI), the cough stress test should be performed with a bladder volume of at least 200 ml and with the prolapse reduced either with a speculum or by a pessary. The urodynamic assessment only changes management when SUI and voiding dysfunction co-exist. Demonstration of preoperative occult SUI has a positive predictive value for de novo SUI of 40% but most useful is its absence, which has a negative predictive value of 91%. The routine addition of radiographic or physiological testing of the GIT currently has no additional value for a physical examination. In subjects with GIT symptoms further radiological but not physiological testing appears to aid in diagnosing enteroceles, sigmoidoceles, and intussusception, but there are no data on how this affects outcomes. There were no articles in the search on the evaluation of the co-morbid conditions of pain or sexual dysfunction in women with POP.

**Conclusions** The clinical pelvic examination remains the central tool for evaluation of POP and a system such as the POP-Q or S-POP should be used to describe and quantify. The value of investigation for urinary tract dysfunction was discussed and findings presented. The routine addition of GI radiographic or physiological testing is currently not recommended. There are no data on the role of the routine assessment of pain or sexual function, and this area needs more study. Imaging studies alone cannot replace clinical examination for the assessment of POP.

**Keywords** Pelvic organ prolapse · Clinical evaluation · Urinary tract dysfunction · Gastrointestinal dysfunction

✉ Anna Rosamilia  
annarosamilia@urogyn.com.au

Extended author information available on the last page of the article

## Introduction

This report is part of a series of articles that are the product of the International Urogynecology Consultation (IUC), which is sponsored by the International Urogynecological Association (IUGA). This is a 4-year, four-chapter project, with 16 reports dedicated to reviewing and summarizing the world's literature on pelvic organ prolapse (POP).

This report is from the 2nd year and chapter of the project, which is dedicated to the evaluation of POP. This year/chapter is divided into three reviews, the other two involve the radiographic evaluation of POP and the use of patient-reported outcomes (POP condition-specific quality-of-life questionnaires) in the evaluation of POP. This report focuses on the clinical evaluation of women with POP and describe how to use the physical examination to describe pelvic organ support or prolapse. In addition, the associated testing to evaluate comorbid conditions of the urinary and gastrointestinal tracts (GITs) is described and evaluated. Radiographic testing to evaluate comorbid lower urinary tract and gastrointestinal conditions is part of this report.

It is recommended that every patient with POP has a thorough clinical examination. Describing and evaluating the patient for POP, although it at first seems straightforward, is in fact very complex. First, there are several classification systems currently in use to describe and quantify POP. The clinician is then left to determine the relative benefits of using one system over another. In addition, it is recognized that many patients with POP often have pelvic floor comorbidities involving other pelvic/abdominal organ systems [1]. Choosing how best to use clinical resources to properly investigate these conditions in patients with POP can be confusing. In addition, the interpretation of test results in a patient with POP may be different than interpretation of the same studies in a patient with normal pelvic organ support. Finally, this paper addresses the question as to which additional testing is necessary and should be routine versus which testing should only be performed if there are associated symptoms present. This review is not meant to be an exhaustive paper regarding the evaluation of lower urinary tract or gastrointestinal symptoms in women, except as they are uniquely influenced by POP.

In this review, the components of a clinical examination and the conditions under which they should be performed are assessed and the best practices described. Any additional testing of co-morbid conditions that should be routinely undertaken, and the conditions under which they are best performed, are evaluated and the best practices described. Knowledge gaps and areas that require further study are also noted.

## Materials and methods

This manuscript is a narrative review that includes a systematic search of the literature using terms from the PubMed and Embase databases (January 2000 to August 2020).

Only human studies involving adult women and limited to the English language were included. The terms for searching the literature were developed by the authors of this report and were presented to the IUGA membership at the annual scientific meeting in 2020; progress was reported at subsequent meetings. These are shown in Table 1 the titles and abstracts were reviewed using the Covidence database to determine whether they met the inclusion criteria. In the event of uncertainty, this was discussed at regularly scheduled meetings. The manuscripts were next reviewed for suitability using the Specialist Unit for Review Evidence checklists for cohort, cross-sectional, and case-control epidemiological studies. This was done to assess data presentation, population description, and bias. Only studies that included populations with clear definitions of patients with symptomatic POP, which described examination findings, were included. The full-text manuscripts were extracted and then reviewed. Those manuscripts that qualified were reviewed in depth and the process is summarized in the Results section (Fig. 1).

## Results

The search strategy found 11,242 abstracts, which were reviewed and led to the extraction of 940 full-text articles, of which 220 articles were used to inform this narrative review. The results and the PRISMA figure for each are reported in three areas:

1. Clinical physical examination
2. The urinary tract (LUTS), and
3. The gastrointestinal tract (GIT).

Other comorbid conditions such as pain and sexual dysfunction are better evaluated and recorded using patient-reported outcomes, which are covered in a separate manuscript of the IUC [2].

### Clinical physical examination of a woman with POP

A review of the existing literature on the examination of a patient with POP and the impact of various parameters on the examination findings was performed. The initial search identified more than 7,155 abstracts of which around 96 studies were included in the final review (Fig. 2) This review of the clinical examination is divided into four sections:

1. General aspects of examination of a woman with POP
2. Examination of the anterior compartment
3. Examination of the posterior compartment
4. Examination of the apical compartment

**Table 1** Keywords used for searching the literature

Number	Evaluation of POP	Evaluation of LUTS	Evaluation of GIT	Evaluation of pelvic floor muscle function, sexual function, and pelvic pain
1.	Genital prolapse	Assessment of urinary symptoms	Assessment of defecation symptoms	Assessment of sexual dysfunction
2.	Uterovaginal prolapse	Urinalysis	Proctoscopy	Vaginal laxity
3.	Cystocele	Urinary incontinence, stress/cough stress test	Digital anorectal examination	Pelvic floor muscle strength
4.	Cystourethrocele	Post-void residual	Anal sphincter tone	Oxford Scale
5.	Anterior wall prolapse	Uroflow	Digital rectal examination	Clitoral sensation
6.	Rectocele	Urodynamics or urodynamic studies	Bowel diary	Blood flow
7.	Posterior wall prolapse	Cystometry	Bristol Stool Chart	Assessment of pelvic pain
8.	Enterocele	Pressure-flow study	Sigmoidoscopy	Evaluation of pelvic pain
9.	Recto-enterocele	Occult stress incontinence	Anorectal manometry	Cotton-swab test
10.	Perineocele	Bladder diary	Defecography	Sensory examination
11.	Procidentia	Frequency volume chart	Defecography with MRI	Trigger points
12.	Apical prolapse	Pad-weight test	Rectal prolapse	Pelvic floor muscle tenderness
13.	Vault prolapse	Cystoscopy	Intussusception	Pelvic floor resting tone
14.	Cervical elongation	Urethral mobility		Neuromuscular examination
15.	Pelvic organ prolapse	Q-tip		
16.	Uterine prolapse	Cotton swab test		
17.	Anterior compartment prolapse	Pessary reduction test		
18.	Posterior compartment prolapse	Urethral pressure profilometry		
19.	Perineal descent	Leak point pressure		
20.	Joint hypermobility and prolapse	Detrusor overactivity		
21.	Striae	Non-obstructive voiding difficulty		
22.	Urethral mucosal prolapse			
23.	Paravaginal defect			

POP pelvic organ prolapse, LUTS lower urinary tract symptoms, GIT gastrointestinal tract

## General aspects of examination of a woman with POP

**Methods to describe/quantify examination of POP** A variety of systems have been devised to classify and quantify POP. Eight studies focused on assessing the reliability and reproducibility of various staging systems (Table 2). It was found that the Baden–Walker Halfway Grading System had moderate reproducibility, making it unsuitable for clinical care or research [3]. The Pelvic Organ Prolapse Quantification (POP-Q) system, on the other hand, was found to have good interobserver agreement and was found to be particularly useful in the research setting [4].

Owing to the complexity of the POP-Q, a simplified POP-Q (S-POP) system was devised. This system retains the ordinal stages of the POP-Q but simplifies the terminology and reduces the number of points measured. Three studies evaluated the validity, interobserver agreement, and inter-system agreement between the simplified POP-Q and POP-Q [5–7]. The authors concluded that a substantial intersystem

association exists between S-POP and POP-Q, and S-POP, being simpler, may be more applicable to clinical practice worldwide. It was also found that the simplified POP-Q system retains its inter-examiner agreement across centers of varying degrees of expertise and is a valid, user-friendly alternative to POP-Q. For a complete description of the POP-Q please refer to the article by Bump et al. [8]. For a complete description of the S-POP please refer to the article by Swift et al. [9].

One study described and evaluated the validity of the novel “eye-ball” POP-Q technique (POP-Q by estimation) [10]. In this technique, the points along the anterior and posterior vaginal walls (Aa, Ba, Ap, and Bp) and on the perineum genital hiatus (GH) and perineal body (Pb) were visually estimated. Determination of vaginal depth (total vaginal length, or TVL) and apical descent (points C and D) were assessed by both visual estimation and palpation with the examiner’s dominant hand. The authors suggested that estimating POP-Q values provided comparable results to



**Fig. 1** Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram for prolapse and examination findings

**Fig. 2** Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram for lower urinary tract symptoms

measuring them when performed by physicians well versed with the standard POP-Q.

**Impact of various parameters on POP examination** When examining a patient with suspected POP, it is critical that the examiner sees and describes the maximal extent of the POP as experienced by the woman. This may be impacted by many variables including the patient's age, parity, body mass index (BMI), position, bladder volume, rectal fullness, the timing of the day of the examination, examination performed at rest or Valsalva/straining, and effect of anesthesia in the case of examination in operating rooms. The correlation of examination findings with these variables was examined separately in nine studies. The conclusions of these are summarized below.

1. Age, parity, and BMI: there is no literature on how any of these impacts the ability of a woman to aid in her examination to identify the bothersome extent of her POP.

2. Bladder volume and rectal fullness: the effect of bladder volume on examination of POP was evaluated by two studies [11, 12]. Both concluded that the maximal extent of POP should always be assessed with an empty bladder. This could be because a full bladder does not allow maximal straining and also distorts the anatomy of the vaginal wall, especially of the anterior and central compartments. Similarly, a full rectum may cause confounding of findings by competing for space. One study commented that all patients with POP should be examined with an empty rectum if possible [13]. However, there is a lack of evidence to support this.

3. Patient position: there is a lack of standardized recommendations regarding patient position during a POP examination. Three studies examined the effect of patient position on the staging of POP [14–16]. It was found that the severity of POP demonstrated is greater when the examination is done in the upright position on a birthing chair or in the standing position rather than



**Table 2** Results of studies assessing the different staging systems for pelvic organ prolapse

Staging system	Number of studies	Interobserver repeatability	Intersystem agreement with POP-Q	Validity	Simplicity/complexity
Baden–Walker	2	Moderate (kappa 0.50)	Fair to moderate	+	–
POP-Q	1	Good	–	+	Complex
Simplified POP-Q	3	Perfect (kappa 0.87)	Good	+	Simple
Eye ball POP-Q	1	Perfect (kappa 0.84)	Good	+	Simple for physicians well versed in standard POP-Q

*POP-Q* Pelvic Organ Prolapse Quantification

in the supine or lithotomy position. The inter-observer repeatability and correlation with the quality of life scores were also greater for examination findings in the upright position. In cases where the examination is not possible in an upright position, validation of POP-Q in a left lateral position was also assessed and the authors found a high degree of inter-observer reliability of POP-Q findings in this position [12].

- Time of examination: the effect of the time of the day (morning versus afternoon) on POP-Q measurements, was assessed in a prospective observational study on 32 subjects [17]. No correlation was found between time of the day and extent of POP on examination. The authors concluded that for patients complaining of POP extending beyond the hymen there is no need to repeat an examination late in the day to confirm the full extent of prolapse.
- Rest or straining: one study examined the predictive value of GH and Pb measurements obtained at rest and with straining for signs and symptoms of POP [18]. GH and Pb measured on straining were consistently stronger predictors of prolapse symptoms and objective prolapse (by clinician examination and by ultrasound) than at Gh and Pb measured at rest.
- Anesthesia/neuromuscular blockade: the effect of neuromuscular blockade on POP staging was examined by one study [19]. It was found that neuromuscular blockade during anesthesia led to a significant increase in POP-Q measurements, especially in the apical compartment. The authors highlighted that in asymptomatic women with up to stage II POP, the surgical procedure should be limited to that planned preoperatively rather than allowing intraoperative findings to affect surgical management.
- Role of cervical traction in prolapse examination: one study compared the degree of uterine prolapse between POP-Q with cervical traction and POP-Q in the standing position. They also assessed patient-reported pain and acceptability scores between the two examinations [20]. The median point C in the standing position was  $-4$  ( $-7$  to  $+2$ ) and with cervical traction  $-0.5$  ( $-3$  to  $+4$ ). Forty

percent reported visual analog scale (VAS) pain scores of  $\geq 5$  under examination with cervical traction. Surprisingly, there was no significant difference in acceptability scores between the groups.

**Relation of POP stage to GH length, Pb, and TVL** Two studies were aimed at describing the relationship between GH and Pb measurements with increasing POP stage [21, 22]. It was found that as the extent of POP increases, GH measurements also increased until stage 4 POP, where mean GH decreased. Also, the POP-Q measurement  $GH \geq 3.75$  cm is highly associated with and predictive of apical vaginal support loss. One study found that measurement of the TVL improved the correlation between the C-point measurement and POP symptoms [23].

**Evaluation of pelvic floor muscle function in women with POP** Different methods have been used to study the pelvic floor muscle function (PFMF) and its correlation with severity of POP and pelvic symptoms. One study assessed whether POP severity, pelvic symptoms, quality of life, and sexual function differ based on PFMF (assessed by the Brink scale score; Table 3) by re-analyzing preoperative assessments of 317 of the 322 women enrolled in the Colpopexy and Urinary Reduction Efforts (CARE) trial [24]. They found that women with the highest Brink scores ( $n=75$ ), suggesting enhanced pelvic floor muscle tone, had less advanced POP and smaller GH measurements, than those with the lowest Brink scores ( $n=56$ ), suggesting weak pelvic floor muscle tone.

Two other studies tested the correlation between the PFMF, using the Oxford grading scale (Table 4), and the severity of POP. In one study 1,037 women were evaluated by assessing the POP-Q and the Oxford assessment of the PFMF. The muscle contraction was graded according to the modified Oxford grading system (Table 4): 0 = no contraction, 1 = flicker, 2 = weak, 3 = moderate, 4 = good, 5 = strong [25]. The levator hiatus (LH) size and GH were measured by digital examination [26]. Severity of POP correlated moderately with GH ( $r = 0.5$ ,  $p < 0.0001$ ) and with LH (transverse  $r = 0.4$ ,  $p < 0.0001$ ; longitudinal  $r = 0.5$ ,  $p < 0.0001$ ), but

**Table 3** Brink scoring system

Muscle function dimension	Score
Squeeze pressure	1 = None 2 = Weak squeeze, felt as a flick at various points along the finger surface: not all the way around 3 = Moderate squeeze; felt all the way around the finger surface 4 = Strong squeeze; full circumference of fingers compressed
Muscle contraction duration	1 = None 2 = Less than 1 s 3 = Greater than 1 s but less than 3 s 4 = Greater than 3 s
Vertical displacement	1 = None 2 = Finger moves anteriorly 3 = Whole length of finger move anteriorly 4 = Whole fingers move anteriorly, are gripped, and pulled in
Total	Range 3–12

weakly with the modified Oxford grading scale ( $r = 0.16$ ,  $p < 0.0001$ ). In the second study, it was seen that POP stage had a significant influence on effective involuntary pelvic floor muscle contraction to counteract a sudden increase in intra-abdominal pressure during coughing. Women with POP stages II or more were significantly less able to achieve effective involuntary muscle contraction during coughing (which resulted in stabilization of the perineum; 37.7%) than women without POP (75.2%) [27].

**Neurological examination in women with POP** There are very few data on neurological assessment in patients with POP. In a case–control study, the vaginal and clitoral sensory thresholds were assessed in 66 women with ( $n=22$ ) and without POP ( $n=44$ ) using a thermal and vibration Genito-Sensory Analyzer [28]. They found that women with POP exhibited significantly lower sensitivity in the genital area to vibratory and thermal stimuli than women without POP.

**Association of spine curvature with POP and bony dimensions of the pelvis** Three studies evaluated the relationship of spinal curvature with POP. One study assessed the relationship of spinal curvature and POP, specifically, the loss of lumbar

lordosis or pronounced thoracic kyphosis in 363 patients with symptomatic POP [29]. They found that patients with abnormal spinal curvature were 3.2 times more likely to develop POP than patients with a normal curvature (odds ratio, 3.18; 95% confidence interval, 1.46 to 6.93;  $p=0.002$ ) and identified an abnormal change in spinal curvature as a significant risk factor in the development of POP. In the other two studies no differences in the mean T or L spine angles were found between women with and those without POP symptoms ( $p \geq 0.05$ ) and bony dimensions on MRI at the level of the pelvic floor in matched cohorts were similar [30, 31].

### Examination of different pelvic compartments in POP

**Examination of anterior vaginal wall compartment for paravaginal defects** With respect to the clinical examination of the anterior vaginal wall defects, using the standardized POP-Q examination and a clinically defined technique for describing the presence of paravaginal defects, right and/or left lateral, central or superior defects have been described. To differentiate a midline or central defect from a paravaginal defect, an index finger or ring forceps must be placed vaginally toward each ischial spine separately. If the prolapse becomes reduced, the woman is clinically diagnosed with a paravaginal defect on that side. In a prospective study, the sensitivity to detect left, right, and bilateral paravaginal defects was reported to be 48%, 40%, and 23.5% respectively, whereas the specificities for each side were 71%, 67%, and 80% respectively compared with intraoperative findings. The overall prevalence of paravaginal defects in patients with at least POP-Q stage II POP of the anterior vaginal wall was 38% [32].

Another study assessed the inter-examiner and intra-examiner reliability of the evaluation of the anterior vaginal wall, including the evaluation of paravaginal defects, using the POP-Q examination and a standardized evaluation of

**Table 4** Modified Oxford Grading scale for pelvic floor muscle (PFM) strength

Grading	Description
0	No discernible PFM contraction
1	Very weak PFM contraction
2	Weak PFM contraction
3	Moderate PFM contraction
4	Good PFM contraction
5	Strong PFM contraction

paravaginal defects [33]. The clinical examination of anterior vaginal wall support defects displayed poor inter-examiner and intra-examiner agreement. Overall inter-examiner agreement was 42%, with a kappa of 0.16.

**Correlation of anterior and apical compartment prolapse** The relationship or coexistence of anterior vaginal wall prolapse with apical prolapse was investigated in one study [34]. Women with a POP-Q Point Ba value  $\geq -1$  were retrospectively analyzed for the presence of apical POP defined as POP-Q point C value  $\geq -3$ . The finding of POP-Q stage II or greater anterior vaginal wall prolapse was highly suggestive of clinically significant apical vaginal descent to  $-3$  cm or greater. Furthermore, as the anterior vaginal wall POP-Q stage increased, the predictive value of apical POP increased. In women with POP-Q stage II anterior vaginal wall prolapse there was associated apical descent (defined as POP-Q point C  $\geq -3$ ) in 42%; in stage III anterior vaginal wall POP, apical descent was found in 85%; and in POP-Q stage IV anterior vaginal wall POP it was 100%.

#### Examination of the posterior compartment and the need for a rectovaginal examination

Three studies were identified that specifically evaluated the posterior vaginal wall and its relationship to GI dysfunction. A prospective cohort study used a variety of validated questionnaires and standardized examination measures, including Bp, AP, GH, and Pb, transverse GH, Pb at rest, with strain in addition to a “pocket” noted on rectal examination [35]. Inter- and intra-rater reliability for these were assessed by two independent examiners. This study demonstrated the reliability of these measurements of the posterior vaginal compartment and a weak association between obstructed defecation and pelvic organ prolapse.

Another study evaluated the association between defecatory symptoms such as constipation, painful defecation, fecal incontinence, and flatus incontinence and posterior vaginal wall examination using the POP-Q and by defecography [36]. The authors found no association between defecation disorders and posterior wall prolapse (evaluated by POP-Q) or rectocele (assessed by defecography) and that clinical examination missed most enteroceles. They concluded that most anatomical measures of posterior compartment prolapse are reliable and reproducible; however, they do not correlate well with defecatory symptoms.

One study assessed the evaluation of the rectovaginal septum (RVS) using a digital rectal examination [37]. The authors concluded that extending the clinical examination of prolapse to include rectal examination to palpate defects in the RVS may reduce the need for a defecatory proctogram or ultrasound for the assessment of obstructive defecation and may help to triage patients in the management

of posterior compartment prolapse. Larger rectoceles were easier to identify and true rectoceles may be best diagnosed by rectal examination.

#### Examination of the apical compartment

**Normal values for the apical component of the POP-Q** One study assessed normal values for the apical component of the POP-Q (points C, D, and TVL) in asymptomatic women by re-analyzing data from the original 2005 Pelvic Organ Support Study using a data set of 1,011 women [38]. In patients without POP defined as all POP-Q points above the hymenal remnants, they found mean POP-Q values to be: point C (vaginal cuff)  $-7.3 \pm 1.5$  cm, point C (cervix)  $-5.9 \pm 1.5$ , point D  $-8.7$  cm  $\pm 1.5$  cm, TVL (no hysterectomy)  $9.8$  cm  $\pm 1.3$  cm, and TVL (hysterectomy)  $8.9$  cm  $\pm 1.5$  cm.

**Clinical evaluation of cervical elongation** A study evaluating 39 consecutive patients who had a preoperative POP-Q and a pathology report that documented the cervical length was performed. The comparison was between estimated cervical length (eCL) on the preoperative POP-Q (by subtracting point D from point C) to the actual cervical length (aCL) reported in the pathology report. The authors found a statistically significant difference between the eCL (mean  $5.6 \pm 2.91$  cm) and the mean aCL ( $3.2$  cm  $\pm 0.99$ ;  $p < 0.0001$ ). However, there was not a statistically significant difference between the eCL and aCL in patients whose prolapse was proximal to the hymen ( $3.5 \pm 2.21$  cm vs  $3.1 \pm 1.06$  cm;  $p = 0.475$ ). The authors concluded that the cervical length measured using POP-Q may not be accurate at more advanced stages of prolapse [39].

**Apical descent in the office compared with evaluation in the operating room** One study compared the assessment of apical prolapse in the office and assessment in the operating room [40]. The office assessment was conducted using a standard POP-Q examination with measurement at straining. The intraoperative assessment was performed by placing traction on the cervix with a tenaculum. The mean difference in the C point between the two clinical settings was 3.5 cm with a difference of  $\geq 5$  cm in 33% of subjects. Of note, the mean difference was larger for women with lesser stages of prolapse: 5.8 cm at stage 1, 3.0 cm at stage 2, and 1.4 cm at stages 3/4 ( $p < 0.001$ ). A difference of  $\geq 5$  cm in point C with cervical traction was more commonly noted with lower stages of prolapse; it was noted in 70.3% of women with stage 1 versus only 9.3% of women with stage 2, and 8.5% in women with stage 3 ( $p < 0.001$ ).

**Association of posterior and anterior prolapse with apical support** Two studies evaluated the association of anterior and posterior compartment prolapse with apical support. In

the first study the authors found that the mean point C location was  $-6.9 \pm 1.5$  (mean  $\pm$  standard deviation) in control patients without POP. In patients with posterior prolapse point C was  $-4.7 \pm 2.7$  cm. In patients with anterior prolapse point C was  $-1.2 \pm 4.1$  cm,  $p$  values were  $<0.001$  for all comparisons [41]. The authors concluded that posterior-predominant prolapse involved threefold less apical descent than in patients with anterior-predominant prolapse. In the second study the authors analyzed 196 subjects and performed a standard POP-Q examination, and then assessed anterior and posterior prolapse in each subject before and following support of the apex using the posterior half of a Graves speculum [42]. Their POP-Q stages before apical support were stage 2 prolapse in 36% of patients, stage 3 in 55%, and stage 4 in 10%. With simulated apical support from the Graves speculum, point Ba changed to stage 0 or 1 in 55% and Bp changed to stage 0 or 1 in 30% ( $p < 0.001$  for both). The mean change in Ba with apical support was  $3.5 \pm 2.6$  cm and for point Bp the mean change was  $1.9 \pm 2.9$  cm ( $p < 0.001$ ). These findings suggest a greater relationship between the anterior vaginal wall and apical prolapse.

**Summary of clinical examination of a woman with POP** The clinical evaluation of a patient suspected of having POP by presenting symptoms should start with a thorough pelvic examination. The POP-Q system is the most studied POP classification system for describing and quantifying POP. It should be used clinically in settings where clinicians have extensive experience and comfort in its use. In clinicians with extensive experience, POP-Q values can often be reliably and adequately obtained by “eyeballing.” The POP-Q should be used in all research settings. In settings that do not have extensive experience with the POP-Q, or in settings that find it cumbersome to use, substituting the S-POP is acceptable as a means of describing and quantifying POP. The use of other systems currently in the literature should be discouraged unless more literature is published demonstrating their utility.

To optimally perform a physical examination on a patient with suspected POP several parameters should be met:

1. The subject should have an empty bladder (and empty rectum, if possible).
2. If the subject cannot confirm the extent of their POP by examination in the supine or left lateral position, the examination should be repeated in a more upright or standing position.
3. The time of day of the examination is not important in most cases.
4. The examination should be done during straining or coughing.
5. Cervical traction or examination under the effects of a neuromuscular blockade may overstate the degree of apical POP and should not be relied upon.

Other parameters of a thorough pelvic examination and imaging for pelvic anatomy are less well investigated but may provide some clinical assistance in planning therapy.

1. Noting the dimensions of the GH or vaginal introitus plays a role in the evaluation of a patient with POP. A large GH as documented by a POP-Q examination  $\geq 3.75$  cm is associated with greater degrees of POP. Understanding what information this provides to the clinician in staging and quantifying POP is less clear and requires more study. Of note, recording the size of the GH is part of the POP-Q but not the S-POP.
2. A greater pelvic floor muscle contraction strength has been associated with less severe POP by both POP-Q examination and various POP symptom scores. In addition, patients with POP appear to have some degree of neurological deficit in other pelvic structures. Therefore, evaluating and recording pelvic floor muscle contraction strength and the presence or absence of neurological deficits, although encouraged, does not currently play a recognized role in the evaluation or quantification of POP.
3. Evaluation of the spine in patients with POP may lead to better understanding of the epidemiology and pathophysiology of POP but does not play any specific role in the evaluation of patients with POP.
4. Clinical examination to identify and characterize site-specific defect of the anterior vaginal wall prolapse has not been studied enough to draw robust conclusions. However, although reporting these clinical findings may aid the individual surgeon in preoperative planning, is too nonspecific for widespread adoption into current clinical grading schemes.
5. Evaluation of posterior vaginal wall prolapse can be complemented by a rectovaginal examination as there is evidence that it can help to distinguish between true rectoceles and enteroceles. There is poor correlation between posterior vaginal prolapse by clinical examination and GI dysfunction.
6. Evaluation and grading of apical (cervical/vaginal vault) POP is complex and currently there is very little information from which to draw clinically relevant information. It appears that in normal subjects the cervix (POP-Q point C) is 4.5 to 7.5 cm above the hymenal remnants, the posterior vaginal fornix (POP-Q point D) is 7 to 10 cm above the hymenal remnants, and in hysterectomized patients the vaginal cuff (POP-Q point C in hysterectomized patients) is 6 to 8.5 cm above the hymen. The TVL in patients with a uterus is 8.5 to 11 cm and in hysterectomized patients it is 7.5 to 10.5 cm. The determination of a cut-off point beyond which apical values represent true POP or clinical symptomatic disease is unknown although any compartment prolapse at or beyond the hymen is more likely to be symptomatic.

7. Repeating a POP-Q examination under anesthesia often overestimates apical prolapse and although useful for surgical planning, currently should not be recommended. It is not known whether there is a long-term prognostic value for this apical assessment.
8. Using a tenaculum to provide traction on the cervix in the clinical setting can overestimate uterine prolapse, is deemed uncomfortable by patients, and therefore should be discouraged.

### Further research

1. Future research needs to determine the predictive value of a large GH as a sign of impending POP that may require prophylactic therapeutic measures. Further, is a large GH a risk factor for POP or a side effect of having the vaginal bulge protruding through and physically dilating the vaginal opening?
2. Future research on what represents true uterine or vaginal vault prolapse is critical. There are some data on the normal range of values for POP-Q points C and D. However, what is not known is if patients with POP-Q point C and D values below these ranges but still above the hymenal remnants have a type of POP that requires therapeutic measures, particularly if that patient is undergoing surgery to correct anterior or posterior vaginal wall prolapse.
3. If a paravaginal defect is detected what is the role of anterior vaginal repair? To what degree does a paravaginal defect contribute to anterior vaginal wall recurrence?
4. Further study on how physical examination under the effects of neuromuscular blockade (anesthesia) affects future outcomes. For example, if a subject has significant cervical or apical POP identified in the operating room that was not noted during clinical physical examination, are they at a greater risk of future apical POP, particularly if nothing is done to address this apparent apical defect at the time of surgery for another form of POP?
5. Future research should better define the role of weak pelvic floor muscle tone or contraction strength as a predictor of the subsequent development of POP. A complete discussion of the role of pelvic floor muscle strength training and its role in treating POP will be included under another report in the IUC that has been published as part of this series entitled “International Urogynecology Consultation chapter 3 committee 2; conservative treatment of patients with pelvic organ prolapse: pelvic floor muscle training” [43].

### Assessment of lower urinary tract function in women with POP

A review of the existing literature on the assessment of lower urinary tract function in women with POP was performed. The initial search identified 2,711 titles and abstracts, of

which 63 studies were included in the final review of this section (Fig. 2).

This section is presented in three sub-sections: the assessment of voiding dysfunction, assessment of detrusor overactivity (DO), and assessment of stress urinary incontinence (SUI).

#### Assessment of voiding dysfunction in women with POP

The prevalence of voiding dysfunction in women with prolapse varies depending on the definition but ranges from 6 to 60%. Assessment of voiding difficulty in women with prolapse was addressed in 11 papers. Six papers had voiding difficulty as the focus [44–49], 4 papers addressed voiding difficulty as part of LUTS assessment [50–53], and 1 paper addressed the accuracy of ultrasound in measuring bladder volume [54]. Six themes were identified in these studies.

**Post-void residual urine volume** Post-void residual urine volume (PVR) was the most utilized measure to define voiding dysfunction in the studies reviewed; however, there was no agreement on the cut-off value at which retention was diagnosed ranging from 50 to 200 ml, as shown in Table 5.

To find a cut-off value for PVR that could predict postoperative voiding trial results more accurately than a predetermined value of 100 ml, one study used a receiver operating curve, but no PVR value was better than 100 ml (the predetermined value used in the study) [49].

The accuracy of translabial ultrasound scan formulae used for PVR measurement in patients with prolapse was examined in one paper [54]. It found that the results obtained by the three published formulae correlated with the catheter-measured PVR.

**Urine flow studies** These included free-flow studies (non-instrumented flow studies) and pressure-flow studies (instrumented urodynamic flow studies). Different measurements were used to define voiding dysfunction, as shown in Table 5.

One study [46] examined the correlation between free-flow and pressure-flow studies. It concluded that the peak and average flow rates in women with POP are dependent on voided volume and the correlation between free-flow and pressure-flow studies decreases as the prolapse stage increases.

**Detrusor contractility measures** The concept of detrusor underactivity was addressed in two papers [45, 50] to predict the potential course of postoperative voiding difficulty. The Bladder Contractility Index (BCI), as defined by Abrams [55], was used in one paper [45]. BCI <100 was associated with higher PVR and a more severe stage of prolapse, but it failed to predict postoperative resolution of voiding difficulty. The second study [50] used a six-class grading of detrusor contractility based on Schafer’s nomograms [56].

**Table 5** Measures for the assessment of voiding difficulty

	Number of studies	Reference numbers of the studies
Post void residual volume	10	
>50 ml	1	(46)
>100 ml	6	(39, 41, 43–48, 47)
>150 ml	1	(38)
>200 ml	1	(42)
>25% of total bladder volume	1	(40)
Urin flow studies		
Q max	4	
<12 ml/s	1	(47)
<15 ml/s	3	(38, 42, 45)
Bladder outlet obstruction		
Pdet Max >40 cm H <sub>2</sub> O	1	(45)
Pdet Qmax >20 cm H <sub>2</sub> O with Qmax <12	1	(47)
Detrusor underactivity		
Bladder Contractility Index	1	(39)
Schafer's grading	1	(50)
Pdet Max <10 cm H <sub>2</sub> O	1	(42)
Prolapse reduction during voiding assessment	3	(41, 42, 46)

*Qmax* maximum flow rate, *Pdet Max* maximum detrusor pressure as measured during pressure flow studies, *Pdet Qmax* pressure detrusor at maximum flow rate, *DU* detrusor underactivity

They reported women with weak detrusor contractility having increased PVR in the immediate postoperative period, with resolution after 1 month.

**Bladder trabeculation on cystoscopy** One study addressed the cystoscopic finding of trabeculation in women with POP. Trabeculations were scored from 0 to 4, representing increasing severity from none, slight, moderate, severe, and severe with diverticula. They reported significantly higher prevalence of symptoms of voiding difficulty and increased PVR (>100 ml) in women with any degree of trabeculations compared with women with no trabeculations [53].

**Prolapse reduction in assessing voiding dysfunction** Prolapse reduction using a pessary or gauze pack was used to assess the impact of prolapse on voiding difficulty in three papers [47, 48, 52]. One study used pessary reduction of prolapse to predict postoperative resolution of voiding difficulties [47]. Authors reported that the resolution of voiding difficulty with pessary reduction of prolapse has 89% sensitivity and 80% specificity in predicting post-repair resolution [47]. In another study, pessary reduction of prolapse was used routinely in all patients while performing urodynamics [48] to assess voiding dysfunction and occult SUI. This resulted in the diagnosis of voiding dysfunction defined as post-void residual of >50 ml or 20% of voided volume in 27%, which reduced to 10% postoperatively. The authors did not test the value of pessary in predicting postoperative

voiding dysfunction. The third study used vaginal packing for prolapse reduction and found that PVR decreased significantly after vaginal packing [52].

**Risk factors for postoperative voiding dysfunction** Five studies looked at the assessment of potential risk factors to predict postoperative persistence of voiding dysfunction [45, 47–50]. In two studies, no potential risk factors were found [45, 50]. Three papers reported various potential risk factors to include history of diabetes, PVR >200 ml and detrusor pressure at maximum flow (*Pdet Max*) <10 cm H<sub>2</sub>O, all of which were found to have some impact on postoperative voiding dysfunction [48]. Persistence of voiding difficulty after pessary reduction of prolapse was associated with a 67% chance of persistent postoperative voiding difficulty [47]. Patient age was reported as the only risk factor for postoperative elevated PVR [49].

#### Assessment for detrusor overactivity in patients with POP

The effect of POP on detrusor overactivity (DO) was addressed in ten papers [50–53, 57–62]. Table 6 demonstrates the measures used to assess DO, the aim of assessment, and the use of prolapse reduction.

**Assessment methods for DO** Urodynamic assessment [50–55] trabeculation on cystoscopy [53] and artificial neural network analysis of clinical assessment [62] were used to assess for DO. However, even when other methods of

**Table 6** Studies addressing detrusor overactivity (DO) in patients with pelvic organ prolapse (POP)

	Number of studies	Reference numbers of the studies
Method of assessing for DO		
Urodynamics (cystometry)	8	(44–46, 51–55)
Trabeculations on cystoscopy	1	(47)
Artificial neural network analysis	1	(56)
Aim of assessing for DO <sup>a</sup>		
Assessment for DO as co-morbidity with POP	3	(46, 47, 56)
Assessing the value of urodynamics in patients with POP	5	(44, 45, 52, 53, 55)
Assessment for risk factors predicting DO post-repair	3	(44, 51, 54)
Prolapse reduction during assessment	2	(46, 54)

<sup>a</sup>Some papers had more than one aim and were included in more than one group

assessment of DO were used, urodynamic assessment was carried out as the gold standard for comparison, despite no evidence that urodynamics are the gold standard.

**The importance of urodynamic studies in the assessment of DO in patients with POP** Five studies were designed to evaluate the role of preoperative urodynamic assessment of DO (uninhibited detrusor contractions on a cystometrogram) in women with POP. Two studies examined the impact of urodynamic assessment on changing patient management [58, 59]. Two other studies examined the role of urodynamic assessment in predicting postoperative DO [50, 61] whereas the last study focused on the role of urodynamic assessment in diagnosing asymptomatic DO [51]. Not surprisingly, they came to different conclusions regarding the importance of preoperative urodynamic assessment in women with POP and two of the three found no benefit of urodynamic assessment in the preoperative evaluation of patients with POP.

**Predicting post-repair overactive bladder** Three papers considered the preoperative risk factors for persistent or de novo overactive bladder (OAB; symptom of urinary frequency and urgency with or without the complaint of urgency incontinence) following surgical repair. Two studies used symptoms to assess for postoperative OAB [50, 57], one used urodynamic assessment post-operatively to assess for DO [60]. Pre-operative DO was not predictive of post-repair OAB or DO; however, one study found that preoperative OAB symptoms are more likely to resolve in the absence of preoperative DO [50].

**Summary: assessment of voiding dysfunction in women with POP** Voiding dysfunction in patients with POP is common but evaluation techniques provide limited information.

1. The post-void residual volume estimation is commonly used for assessment of voiding dysfunction. The most commonly used value for diagnosing an elevated post-void residual is 100 ml by catheter or ultrasound.

2. Severity of POP is associated with reduced maximum and average flow rate, and voiding dysfunction is associated with the cystoscopic finding of trabeculation; however, there is no demonstrated benefit for using any of these methods in the routine assessment of the patient with POP.
3. Reduction of POP by pessary or packing often resolves voiding dysfunction and if this is noted on evaluation, it has a high predictive value for resolution of voiding difficulty after surgical POP repair.
4. Postoperative persistence of voiding dysfunction was found to be associated with diabetes, age, PVR >200 ml, P det max <10 and failure of a pessary to resolve voiding difficulty.
5. Preoperative urodynamic assessment was the most commonly utilized diagnostic tool for DO. Preoperative urodynamic diagnosis of DO did not change management, but the absence of preoperative urodynamic DO suggests that symptoms of OAB are more likely to resolve after surgery.

#### Further research

1. Further research is needed in the development of predictive models for persistence of voiding difficulty or DO postoperatively to aid in patient counseling.
2. Understanding how varying degrees of POP and how prolapse of different compartments affects voiding is poorly understood and needs further research.
3. Further study to assess the effect of voiding dysfunction on the patient both from a symptomatic and a morbidity perspective (recurrent UTIs, upper urinary tract disease) is not currently well understood

#### Assessment for SUI in women with POP

A substantial proportion of women presenting with POP report SUI symptoms. Preoperative SUI can either resolve or persist after POP surgery. Furthermore, a significant

proportion of preoperatively continent women develop de novo SUI after POP surgery. SUI was addressed, either exclusively or as part of LUTS assessment, in 47 papers. Three main themes were identified: assessment of preoperative SUI, prediction of postoperative SUI, and prediction of de novo SUI.

### Assessment of preoperative SUI

1. **Stress test:** the significance of patient position and prolapse reduction during the cough stress test was demonstrated in a study performed on 297 women waitlisted for POP surgery, with a third of them reporting SUI symptoms. Five different cough stress tests were performed with a subjectively full bladder (standing, semi-lithotomy, with and without reduction, reduction with speculum, and pessary). The test with the fewest positive results (34%) was the one performed without POP reduction in a semi-lithotomy position; the test with the most positive results (80%) was the one performed with pessary reduction in a semi-lithotomy position. With the full battery of tests, 93% of women with SUI symptoms demonstrated leakage; only 50% demonstrated leakage without reduction. Eighty-nine percent of the women with a positive stress test were diagnosed when performing at least two of the three tests with prolapse reduction, and 98% were diagnosed when performing all three tests with prolapse reduction (speculum and pessary reduction in the semi-lithotomy position, pessary reduction in the standing position). The authors also emphasized the importance of adequate bladder volume (200 ml) [63]. The findings were not compared with postoperative outcomes.
2. **Q-tip angle:** one study concluded that the Q-tip test is affected by POP. The angles were smaller with the prolapse reduced and with a full bladder [64]. A substantial correlation ( $r=0.68$ ) between POP-Q point Aa and Q-tip angle was noted in a study on women presenting predominantly with SUI and anterior wall prolapse [65].
3. **Importance of urodynamic studies in the assessment of preoperative SUI:** one study concluded that a computer-based model including preoperative symptoms and patient's baseline characteristics cannot predict preoperative urodynamic diagnosis and, as a consequence, cannot replace a preoperative urodynamic study [62]. In another retrospective study, preoperative urodynamic testing in patients with POP changed the management or counseling in only 3% (11 out of 316) in a cohort of women, with the indication for the study being OAB symptoms, mixed, or insensible urinary incontinence, or voiding difficulty (i.e., not occult SUI evaluation only). Major management alterations occurred mostly in women with SUI and concurrent voiding difficulty.

The authors inferred that it might be in these patients that preoperative urodynamic study has its greatest value [58]. These two studies did not correlate the preoperative examination with postoperative outcomes.

**Prediction of postoperative SUI** Postoperative SUI can represent persistent or de novo SUI. In this section, some studies approached postoperative SUI as persistent SUI [66] specifically, whereas some studies included women with any preoperative continence status and their results on postoperative SUI include both persistent and de novo SUI. De novo SUI specifically is addressed separately in the following section.

1. **Predictive value of preoperative stress test:** five studies provided data to calculate the predictive value of a negative stress test during preoperative urodynamic study for postoperative SUI in an unselected POP population (i.e., any preoperative continence status) [67–70]. All studies included stress tests with prolapse reduction. The negative predictive value ranged between 45 and 90% (median 78%; Table 7).
2. **Other predictors for postoperative SUI:**

Three studies looked at other predictors of postoperative SUI. One study included only women with preoperative urodynamic SUI and the predictive urodynamic parameters for persisting urodynamic stress incontinence were overt (versus occult) urodynamic SUI, below normal maximum urethral closure pressure (MUCP, defined by the authors as  $<60$  mmHg), and functional urethral length (FUL)  $< 2$  cm [71].

Two further studies included all women, regardless of preoperative incontinence status. The only two urodynamic parameters predictive of postoperative SUI in the one study were preoperative urodynamic stress incontinence and low P det Max [72]. In the other study, none of the investigated urodynamic parameters was associated with postoperative SUI [61].

**Prediction model for postoperative SUI** A model developed to predict postoperative SUI for women regardless of preoperative continence status considers subjective urinary incontinence symptoms, stress test with and without prolapse reduction, age, point Ba, vaginal parity, and insertion of a mid-urethral sling during surgery [73]. The strongest predictor for postoperative SUI was preoperative SUI. The model's ability to discriminate women at low or high risk for bothersome postoperative SUI or treatment for SUI during the first postoperative year was at a "useful level" (defined as area under the curve 0.76; interpretation: 0.5 not better than chance—1 perfect discrimination). However, the study does not report the extent to which the model correctly estimates the absolute risk (i.e., calibration), making it difficult to use it in counseling



**Table 7** Predictive value of a negative preoperative stress test for postoperative stress urinary incontinence after pelvic organ prolapse surgery

Reference	Type of surgery	Study design	Follow-up (months)	Baseline continence	<i>n</i> <sup>a</sup>	Preoperative test	Postoperative SUI outcome	Rate of postoperative SUI after a negative test, <i>n</i> (%)	NPV <sup>b</sup> %
Alas et al. [67]	Any	Retrospective	Median 53	Any	274	UDS up to capacity with and without reduction (speculum)	Subjective (non-validated) or objective SUI (not specified)	27/274 (10)	90
Jeon et al. [68]	SCP	Prospective	24	Any	112	UDS up to capacity with reduction (swab)	Bothersome subjective SUI (UDI-6) or objective SUI (CST) or additional SUI surgery	32/112 (29)	71
Kasturi et al. [69]	TVM	Retrospective	6	Any	60	UDS with reduction (speculum or pessary)	Subjective (non-validated) and objective SUI (CST or UDS)	15/60 (25)	75
Leruth et al. [66]	SCP	Retrospective	Mean 25	Any	55	Stress test at capacity with and without reduction (manual) and UDS up to capacity with reduction (swab)	Subjective SUI (nonvalidated) Need for sling surgery	30/55 (55) 9/55 (16)	45 84
Park et al. [70]	SCP	Retrospective	Mean 11	Any	70	UDS up to capacity with reduction (pessary or speculum)	Need for SUI surgery	13/70 (19)	81

SUI stress urinary incontinence, NPV negative predictive value, UDS urodynamic study, SCP sacrocolpopexy, CST cough stress test, TVM transvaginal mesh, UDI-6 Urinary Distress Inventory Short Form

<sup>a</sup>Only women without concomitant anti-incontinence surgery included

<sup>b</sup>Negative predictive value calculated based on numbers provided in the original studies

patients regarding operative options. Furthermore, our search did not identify any external validation studies for the model.

**Prediction of postoperative SUI (occult SUI)** Occult SUI is defined as urine loss observed during a cough stress test with the POP reduced in a patient with POP who reports no urinary incontinence [74]. It is used as a preoperative test with the intention to identify women at risk of developing de novo SUI after prolapse surgery. Table 8 summarizes the studies that address the predictive value of occult SUI for de novo SUI.

Twenty-five studies provided either the diagnostic accuracy measures or data enabling the calculation for positive and/or negative test [50, 67, 75–97]. Baseline continence status, diagnostic criteria for occult SUI, methods to reduce the prolapse, surgical procedures, and the definition of de novo SUI varied widely among the studies, making the comparison challenging. Most studies defined occult SUI clearly as

SUI demonstrated only during prolapse reduction, whereas some also included demonstrable urodynamic SUI without prolapse reduction in symptomatically continent women. The diagnostic accuracy of occult SUI differed greatly, likely because of the heterogeneity in the studies. The medians (and ranges) for sensitivity were 39% (5–100), for specificity they were 86% (57–97), for positive predictive value they were 40% (0–79), and for negative predictive value they were 91% (51–100).

**Importance of urodynamic studies for diagnosis of occult SUI** One study reported similar occult SUI rates with stress testing during physical examination and urodynamic studies. In 76%, occult SUI was identified with both tests, in 11% with urodynamic studies only, and in 13% during physical examination only (kappa 0.648). They did not correlate the findings with postoperative de novo SUI rates [98].

**Table 8** Diagnostic accuracy of occult stress urinary incontinence for de novo stress urinary incontinence after pelvic organ prolapse surgery without concomitant anti-incontinence surgery

Reference	Type of POP surgery	Study design	Follow-up (months)	Baseline continence	n <sup>a</sup>	Test for OSUI	Definition of de novo SUI	Rate of de novo SUI		Sensitivity, %	Specificity, %	PPV, %	NPV, %
								Test positive, n (%)	Test negative, n (%)				
Alas et al. [67]	Any	Retrospective	Median 53	No subjective (nonvalidated) or objective SUI (stress test, UDS)	210	UDS up to capacity; reduction with speculum	Subjective (nonvalidated) or objective SUI (not specified)	N/A	12/210 (4)	N/A	N/A	N/A	94
Araki et al. [50]	TVM	Retrospective	6	No subjective SUI (ICIQ-UI + pad usage)	62	CST at 300 ml; reduction with gauze pack or pessary	SUI symptoms + pad usage	8/13 (62)	2/49 (4)	80	90	62	96
Ballert et al. [75]	Any vaginal	Retrospective	Mean 17	No subjective (non-validated) or objective SUI (UDS)	24	UDS up to capacity; reduction with pessary or vaginal pack	Need for intervention for SUI	N/A	0/49 (0)	100	83	23	100
Costantini et al. [76]	SCP	RCT	6	No subjective (UDJ) or objective SUI (stress test, UDS)	32	Stress test with full bladder; reduction both with fingers and speculum	Subjective (UDI) + objective SUI (stress test)	N/A	3/32 (9)	N/A	N/A	N/A	91
Ellström Engh et al. [77]	Vaginal NTR	Prospective	12	No subjective (nonvalidated) or objective SUI	74	CST at 300 ml; reduction with speculum	Subjective SUI (nonvalidated)	3/7 (43)	5/67 (7)	38	94	43	93
Ennemoser et al. [78]	Any vaginal	Retrospective	Mean 68	No objective SUI (CST)	57	Quantification test and 48-h pad test; reduction with pessary	Subjective SUI (nonvalidated)	2/6 (33)	6/68 (9)	25	94	33	91
Goessens et al. [79]	Vaginal NTR	Retrospective	2	No bothersome subjective SUI (nonvalidated)	132	Stress test at 300 ml sitting and standing; reduction with speculum	Subjective (non-validated) and/or objective and/or treatment for SUI	16/57 (28)	N/A	N/A	N/A	28	N/A
Hafidh et al. [80]	Vaginal NTR	Retrospective	12	No subjective (non-validated) or objective SUI (UDS)	52	Subjective SUI (non-validated) revealed during ring pessary home test	Need for SUI surgery	3/57 (5)	N/A	N/A	N/A	5	N/A
Karateke et al. [81]	Vaginal NTR	Retrospective	20	No subjective SUI (UDI-6)	54	UDS; reduction with pessary/sponge stick	Bothersome subjective SUI (nonvalidated) warranting treatment	N/A	12/132 (9)	N/A	N/A	N/A	91
						UDS up to 200 ml; reduction with two ring forceps bilaterally	Subjective SUI warranting any treatment	N/A	2/52 (4)	N/A	N/A	N/A	96
							Objective SUI (UDS)	N/A	8/54 (15)	N/A	N/A	N/A	85

**Table 8** (continued)

Reference	Type of POP surgery	Study design	Follow-up (months)	Baseline continence	n <sup>a</sup>	Test for OSUI	Definition of de novo SUI	Rate of de novo SUI		Sensitivity, %	Specificity, %	PPV, %	NPV, %
								Test positive, n (%)	Test negative, n (%)				
Kleeman et al. [82]	Vaginal NTR	Retrospective	Mean 5	No subjective SUI (UDI)	53	CST, retrograde filling to subjectively full bladder; reduction with speculum	Subjective SUI (not specified)	N/A	1/53 (2)	N/A	N/A	N/A	98
Klutke and Ramos [83]	Vaginal NTR	Retrospective	Mean 42	No subjective SUI (nonvalidated)	20	UDS up to capacity; reduction with Gellhorn pessary	Subjective (non-validated) and objective SUI (UDS)	N/A	0/20 (0)	N/A	N/A	N/A	100
Liang et al. [84]	Vaginal NTR	Prospective	3–6	No subjective SUI (nonvalidated)	47	UDS up to capacity; reduction with pessary	Subjective SUI (nonvalidated)	11/17 (65)	0/30 (0)	100	83	65	100
Manodoro et al. [85]	Vaginal NTR	Retrospective	Mean 18	No subjective SUI (nonvalidated)	120	UDS up to capacity; reduction with ring pessary	Objective SUI (CST) or need for SUI surgery	10/43 (23)	15/77 (19)	40	65	23	81
Misraï et al. [86]	SCP	Retrospective	Mean 20	No subjective (non-validated) or objective SUI (UDS)	53	UDS; reduction with sponge-holding forceps	Need for SUI surgery	0/43 (0)	0/77 (0)	N/A	64	0	100
Reena et al. [87]	Vaginal NTR	Prospective	1.5	No subjective (nonvalidated) or objective SUI (not specified)	78	Pyridium pad test; reduction with ring pessary	Objective SUI (not specified)	N/A	7/53 (13)	N/A	N/A	N/A	87
Schierlitz et al. [88]	Vaginal NTR or SCP	RCT	6	No subjective SUI (nonvalidated)	39	UDS up to capacity; stress test with or without reduction; speculum or opened forceps	Need for SUI surgery	3/39 (8)	N/A	N/A	N/A	8	N/A
Sierra et al. [89]	Any including anterior/apical compartment	Retrospective	6	No objective SUI on clinical examination	97	UDS up to capacity; reduction with ring pessary, speculum, or scopette	Subjective SUI (nonvalidated)	N/A	2/97 (2)	N/A	N/A	N/A	98
Song et al. [90]	Vaginal NTR	Prospective	6	No subjective (nonvalidated) or objective SUI (CST)	206	Stress test with full bladder and 1-h pad test; reduction with ring pessary	Subjective SUI (UDI-6, IIQ-7)	18/45 (40)	30/161 (19)	38	83	40	81
Srikrishna et al. [91]	Not specified	Prospective	24	No objective SUI (video-urodynamics)	48	Video-urodynamics up to capacity; reduction with ring pessary	Need for SUI surgery	10/45 (22)	3/161 (2)	77	82	22	98
							Subjective SUI (KHK) confirmed with video-urodynamics	2/5 (40)	1/43 (2)	67	93	40	98

Table 8 (continued)

Reference	Type of POP surgery	Study design	Follow-up (months)	Baseline continence	n <sup>a</sup>	Test for OSUI	Definition of de novo SUI	Rate of de novo SUI		Sensitivity, %	Specificity, %	PPV, %	NPV, %
								Test positive, n (%)	Test negative, n (%)				
Svenningsen et al. [92]	Any	Prospective	Mean 5	No subjective (not specified) or objective SUI (CST)	137	Manual reduction at 100ml	Subjective SUI (validated)	(40)	(16)	9	97	40	84
						Pessary reduction at 100 ml		(22)	(17)	9	94	22	83
						Pessary reduction at 300 ml		(50)	(13)	28	94	50	87
						Pessary 1 week		(47)	(11)	50	88	47	89
Van der Ploeg et al. [93]	Any vaginal	RCT	12	Subjective SUI maximum once/week and no objective SUI (CST with full bladder)	182	Office evaluation stress test (subjectively full bladder) or urodynamics (up to 300 ml) and/or maximum capacity; reduction with swab	Bothersome SUI (UDI), objective SUI (CST at 300 ml) and/or any treatment for SUI	18/47 (38)	11/135 (8)	62	81	38	92
						Office evaluation stress test (subjectively full bladder); with or without reduction; reduction with swab on forceps	Bothersome SUI (UDI) and/or any treatment for SUI	9/32 (28)	7/140 (5)	56	85	28	95
Visco et al. [95]	SCP	RCT	3	Subjective SUI never or rarely (Medical, Epidemiological, and Social Aspects of Aging questionnaire)	77	UDS up to capacity; with or without reduction; reduction with swab on forceps		3/22 (14)	4/55 (7)	43	73	14	93
						UDS 300 ml; reduction with ring pessary with support	Subjective SUI (PFDI), objective SUI (stress test at 300 ml) and/or any treatment for SUI	1/2 (50)	19/46 (41)	5	96	50	59
						UDS 300 ml; manual reduction		4/8 (50)	18/53 (34)	18	90	50	66
Van der Ploeg et al. [94]	Any vaginal	RCT	12	Subjective UI maximum once/week and no bothersome UI (UDI)	77	UDS 300 ml; reduction with swab		11/14 (79)	22/63 (35)	33	93	79	65
						UDS 300 ml; reduction with forceps		4/8 (50)	20/41 (49)	17	84	50	51
						UDS 300 ml; reduction with speculum		11/20 (55)	17/42 (40)	39	74	55	60
					297 <sup>b</sup>	All methods		31/52 (60)	96/245 (39)	24	88	60	61

**Table 8** (continued)

Reference	Type of POP surgery	Study design	Follow-up (months)	Baseline continence	n <sup>a</sup>	Test for OSUI	Definition of de novo SUI	Rate of de novo SUI		Sensitivity, %	Specificity, %	PPV, %	NPV, %
								Test positive, n (%)	Test negative, n (%)				
Wei et al. [96]	Any vaginal	RCT	3	No subjective SUI (PFDI)	170	Stress test at 300 ml; reduction with swab	Stress, urgency, or mixed UI defined as a positive CST, bothersome symptoms, and/or treatment for UI	41/57 (72)	43/113 (38)	49	81	72	62
Yamada et al. [97]	Anterior colporrhaphy	Retrospective	Mean 58	No subjective (nonvalidated) or objective SUI	10	1-h pad test and stress test; reduction with ring pessary or vaginal pack	Subjective SUI (nonvalidated)	N/A	0/10 (0)	N/A	N/A	N/A	100

Diagnostic accuracy (sensitivity, specificity, positive predictive value, negative predictive value) of occult stress urinary incontinence for de novo stress urinary incontinence is shown. Some of the original studies reported diagnostic accuracy values; some studies provided rates of de novo SUI after positive and/or negative test, and diagnostic accuracy values were calculated based on these data. POP pelvic organ prolapse, OSUI occult stress urinary incontinence, SUI stress urinary incontinence, PPV positive predictive value, NPV negative predictive value, UDS urodynamic study, N/A not applicable, TVM transvaginal mesh, CST cough stress test, SCP sacrocolpopexy, RCT randomized controlled trial, NTR native tissue repair, UI urinary incontinence, ICIQ-UI International Consultation on Incontinence Questionnaire–Urinary Incontinence, UDI Urinary Distress Inventory, UDI-6 Urinary Distress Inventory Short Form, IQ-7 Incontinence Impact Questionnaire Short Form, KHQ King’s Health Questionnaire

<sup>a</sup>Only women without concomitant anti-incontinence surgery were included

<sup>b</sup>Total number of women 165; each subject underwent two different prolapse reduction methods

Another study compared the predictive value of demonstrable SUI during basic office evaluation versus urodynamic study for de novo SUI. Stress tests were performed in the lithotomy position with (swab on forceps) and without reduction of the prolapse. During basic office evaluation women were examined with a subjectively full bladder and during urodynamic studies with 300-ml bladder filling and at maximal bladder capacity. More women demonstrated SUI during urodynamic study, but the diagnostic accuracy for bothersome de novo SUI or treatment for de novo SUI was not improved by the addition of the urodynamic study [94].

**Other predictors of de novo SUI** Two studies were aimed at identifying other risk factors for de novo SUI. Urodynamic markers that were associated with de novo SUI were low MUCP [99], low FUL [99], and bladder outlet obstruction [100].

Two studies demonstrated that occult SUI is also seen in posterior wall prolapse [101, 102] up to the same extent as with anterior wall prolapse [101].

**Prediction model for de novo SUI** A model and risk calculator developed to predict de novo SUI among women without preoperative SUI symptoms contains seven predictors: age, number of previous vaginal births, urine leakage associated with urgency, history of diabetes, BMI, preoperative reduction stress test result, and placement of a midurethral sling during surgery. The model predicted absolute risk accurately, with slight tendencies to overestimate the risk when the probability reached 50% or greater. The concordance index (interpretation: 0.5, not better than chance to 1, perfect discrimination) was 0.73 in the original study [103], and it outperformed both expert opinion and preoperative stress testing in discriminating between women who developed de novo SUI during 12 months follow-up and not. However, when the model was applied to other samples (external validation), the results for the concordance index or area under the curve decreased to 0.62, 0.63, and 0.69 [103–105]. One study assessed the model’s performance as a diagnostic test using a probability of de novo SUI of >50% as a cut-off for a positive test. Using this cut-off, a positive test had a predictive value of 27% (i.e., 27% of women with an estimated risk of 0.5 or higher actually developed SUI). This illustrates how the model overestimates the risk when the baseline risk is lower than in the original sample [105].

**Summary: assessment of SUI in patients with POP** The evaluation of SUI in patients with POP is very complex and recommendations vary widely.

1. In women with POP and SUI, the cough stress test should be performed with at least 200-ml bladder volume and with the prolapse reduced either with a speculum or pessary in order to have the highest chance of identifying a positive result.

2. Assessment of UDS in women prior to POP surgery has been shown to change management in a small percentage of cases, for example, when SUI (clinical or occult) coexists with voiding dysfunction. The management may change by the avoidance of a concomitant continence procedure or the choice of one with a perceived lower risk of associated voiding dysfunction.
3. There are no comparative data on different diagnostic alternatives correlating with postoperative outcomes as studies such as VALUE [106] and VUSIS [107] excluded women with prolapse beyond the hymen.
4. In an unselected POP population, a negative reduction stress test during preoperative urodynamic assessment has a median negative predictive value of 78% (range 45–90%) for postoperative SUI. There is conflicting evidence regarding the predictive value of further urodynamic parameters such as MUCP and FUL.
5. More preoperatively continent women will demonstrate occult SUI during a urodynamic assessment compared with office evaluation stress test but this does not have greater accuracy for bothersome de novo SUI or treatment for de novo SUI. The demonstration of preoperative occult SUI during urodynamic assessment has a positive predictive value for de novo SUI of 40% (0–79%) and its absence has a negative predictive value of 91% (51–100%) respectively.
6. A de novo SUI prediction model that incorporates seven variables and outperforms pure chance, expert opinion, and reduction cough stress test alone. However, in follow-up studies the model performed poorly, overestimating the risk when compared with the original study.

To sum up, the most useful information from the evaluation of a patient with POP with regard to postoperative stress incontinence is the high negative predictive value of a negative stress reduction test.

#### Further research

1. Future research should look to improve the performance of current prediction testing, and develop new predictive parameters. These could probably be identified by deepening our understanding of the biological and biomechanical explanations behind de novo and persistent SUI.
2. The prognostic value of MUCP and FUL should be reassessed in further studies.
3. Persistent and de novo SUI probably have different prognostic factors, thus developing separate models may be feasible and increase accuracy.
4. Researchers should follow The Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis statement when presenting a new or validating an existing prediction model [108].

#### Evaluation of hydronephrosis and hematuria in patients with POP

There were two studies that discussed the prevalence of hydronephrosis and hematuria in women with POP. The study on hydronephrosis evaluated 180 patients and found some degree of hydronephrosis in 30%. A multivariate statistical analysis revealed only the two following factors associated with hydronephrosis. First, anterior compartment prolapse, as defined by POP-Q point Ba; noting that for every 1-cm increase, the relative risk of hydronephrosis increases by 1.68. Second, cystometric capacity; it was found that every 100-ml increase in maximum cystometric capacity increases the relative risk of hydronephrosis by 1.5. However, the model only predicted about 30% of the hydronephrosis [109].

The study evaluating microscopic hematuria (defined as  $\geq$  red blood cells per high power field) noted its presence in 20.1% in a population of 1,040 women. This population is at a very low risk of urinary tract malignancy and the authors suggested that the cut-off for significant microscopic hematuria in this population should be re-evaluated [110].

To summarize: the severity of anterior vaginal wall prolapse and cystometric capacity are associated with hydronephrosis in a limited number of studies; prediction models are not well developed.

#### Assessment of gastrointestinal tract symptoms in women with POP

A review of the existing literature on the assessment of GIT symptoms in women with POP identified 2,251 titles and abstracts, of which 17 studies were included in the final review of this section (Fig. 3). Studies were included whose primary population or a significant portion of the study population were women with POP, who then underwent evaluation of the GIT other than or in addition to symptom assessment and clinical examination (Table 9).

#### Defecography

Several studies compared various defecography imaging modalities with each other [112, 118, 124, 125]. Difficulties in evaluation of the existing literature included the use of various methods for the assessment of prolapse on physical examination, including the Baden–Walker halfway system, the POP-Q system, and several manuscript-specific nonstandardized examination techniques. In addition, various methods of performing the imaging and interpretation of results were described. In studies of fluoroscopic defecography, there was variability in which compartments were opacified with contrast; although the rectum was universally opacified, other possible compartments included the bladder, vagina, perineum, peritoneum, and small bowel.



**Fig. 3** Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram for gastrointestinal radiographic/physiological testing

Three studies of fluoroscopic defecography found that this imaging modality detected more enteroceles than physical examination [111, 113, 117]. Two studies found that MRI defecography was able to diagnose enteroceles more readily than physical examination, and one of these found that MRI defecography was also able to diagnose more enteroceles than fluoroscopic defecography [122, 125]. Two studies found that sigmoidoceles were not diagnosed on examination but were identified by fluoroscopic defecography [112, 117]. One study found that the size of the posterior vaginal wall prolapse, as assessed by physical examination, was associated with the finding of enterocele and/or rectal intussusception on fluoroscopic defecography [114].

Patient symptoms were assessed in two studies that found that defecatory symptoms were not significantly associated with findings on radiographic imaging or examination [115, 116]. One study found no relationship between

defecatory symptoms in women with posterior vaginal wall prolapse and abnormal defecography. The other found no relationship between defecatory symptoms and posterior vaginal wall prolapse on examination or rectocele or enterocele on defecography [115, 116]. One study found that two thirds of women with a rectocele and symptoms of obstructed defecation or anal incontinence had intussusception (13.5% Oxford Grade I, 41% Grade II, and 13.5% Grade III) on MR defecography and were more likely to have an enterocele [119].

### Anal physiological testing and anal ultrasound versus physical examination

Anal physiology and anorectal endosonography testing added limited information to the routine physical examination evaluation of POP patients for identifying intussusception [126, 127].

Patients with fecal incontinence may benefit from this testing. In terms of the clinical consequences of the imaging investigation, two studies found that the imaging results led to a change in surgical plan for 22–41% of patients [112, 117].

### Definitions/interpretation of radiographic imaging studies

Consensus on definitions and interpretations of fluoroscopic defecography and MRI defecography have been developed by multiple stakeholder societies including the IUGA [128, 129]. Although these documents represent consensus on the use of these imaging modalities in patients with defecatory disorders, they “do not” contain information pertinent to patients with pelvic organ prolapse regarding specific methods and measurements. There is no consensus on whether or not patients with prolapse and no GI symptoms should undergo any testing beyond a thorough physical examination. It has been agreed upon that imaging should include measurements performed during the defecation phase rather than only with strain to improve sensitivity [123, 128, 129]. Studies in which there was no defecography phase have limited applicability.

**Summary: assessment of GIT symptoms in women with POP** Summary of supplemental evaluation for GI dysfunction in women with POP is an area requiring a significant amount of research before any concrete recommendation can be made.

1. There were no studies that reported on patient outcomes in those evaluated by fluoroscopic defecography, MRI defecography, or anal physiology testing, and those who did not undergo this evaluation. Therefore, the clinical significance of this testing, particularly in asymptomatic patients, remains uncertain. It does seem that some ana-

**Table 9** Evidence table for the evaluation of prolapse in women with symptoms of obstructed defecation and anal incontinence

Reference	Study design	Population	Method(s) of clinical assessment	Results	Discussion
<b>Fluoroscopic defecography</b>					
Kelvin et al. [111]	Retrospective cohort study, USA	n=170 consecutive women with symptoms of pelvic floor dysfunction referred for dynamic cystoproctography	BW ±POP-Q	Only 74% POP-Q—POP-Q not used for analysis Findings on BW vs DCP Rectocele 91% BW, 76% DCP Enterocoele 40% BW, 28% DCP Cystocele 81% BW, 94% DCP 86% had previous pelvic surgery 41% patients had a change in surgical plan owing to imaging results POP-Q vs DCCP vs dMRI	Descriptive study showing that cystoceles and rectoceles are similarly diagnosed by both BW and DCP, but more enterocoeles diagnosed by examination  Low concordance of findings between modalities
Kaufman et al. [112]	Retrospective descriptive cohort study, USA	n=22 women with symptomatic prolapse went on to pelvic reconstructive surgery	Questionnaires Physical examination, POP-Q DCCP Had defecography phase dMRI No defecography phase	Cystocele 68% POP-Q, 45% DCCP, 41% dMRI Rectocele 86% POP-Q, 82% DCCP, 50% dMRI Enterocoele 36% POP-Q, 41% DCCP, 36% dMRI Sigmoidocele 0% POP-Q, 9% DCCP, 0% dMRI Levator ani defect 0% POP-Q, 0% DCCP, 18% dMRI Internal rectal prolapse 9% POP-Q, 45% DCCP, 0% dMRI Full-thickness rectal prolapse 9% POP-Q, 0% DCCP, 0% dMRI	Levator ani defects only diagnosed by dMRI Sigmoidocele only diagnosed by DCCP Lack of defecography phase during MRI likely contributes to findings Descriptive study suggesting CDP might contribute to characterization of prolapse, but limited by lack of use of either POP-Q or BW and small numbers
Lopez et al. [113]	Prospective cohort study, Sweden	n=25 women with POP on clinical examination planning to undergo surgery	Clinical examination (no POP-Q or BW) Questionnaires CDP	No statistical analysis Pre-operatively: cystocele on clinical examination vs CDP 28% vs 88% Pre-operatively: rectocele on clinical examination vs CDP 96% vs 84%	CDP may be helpful in diagnosing enterocoeles Descriptive study limited by lack of statistical analysis, lack of POP-Q or BW, mixed sex population, and lack of defecography phase
Takano and Hamada [114]	Prospective cohort, Japan	n=66, which included 55 female patients, 11 male patients	Clinical examination (no POP-Q or BW) DCR: opacification of the ileum, bladder, vagina, rectum, and perineum No defecography phase	No statistical analysis 75% of patients with symptoms of vaginal prolapse showed descent of the vagina on DCR 78% of patients with uterine descent had an enlarged angle between the vaginal axis and horizontal line at the superior border of the sacrum on DCR *68% of patients with symptoms of descent of the rectum or obstructed defecation had descent of the rectum on DCR	







**Table 9** (continued)

Reference	Study design	Population	Method(s) of clinical assessment	Results	Discussion
<b>MR defecography</b>					
Hausammann et al. [119]	Prospective cohort study, Switzerland	n=37 women	Dynamic, single-shot MRI sequence without defecography phase BW	Rectal descent = 5 2/3 patients had moderate to large rectocele on MRD No significant association between size of rectocele on MRD and constipation or fecal incontinence 67.5% of women with a rectocele had a concomitant intussusception Significantly more likely to have an enterocele (p=0.013) Obstructed defecation symptoms did not differ between isolated rectocele and rectocele + intussusception	Patients with a rectocele on examination may have other pelvic floor defects as well
Aziz et al. [120]	Case series	Patients with rectocele and defecatory dysfunction n=7 patients with pelvic floor disorder symptoms and a history of cystectomy and hysterectomy referred for MRD	Symptom questionnaires (Cleveland clinic constipation score and Wexner faecal incontinence score) MRD (open) Physical examination POP-Q MRD Physical examination	Higher grade intussusception was associated with FI (p=0.048) 5 POP-Q stage II or III 2 POP-Q stage 0 MRD findings: 4 patients = anterior enterocele (small bowel), moderate 3 patients = anterior sigmoidocele, moderate Symptoms 96% bothersome POP Spearman correlation coefficient between MRD grading compared with examination	MRD may be useful in post-cystectomy patients with vaginal bulge Study limited by very specific population MRD not significantly correlated with BW
Pollock et al. [121]	Retrospective cohort study,	n=54 women  170 patients with POP screened  116 excluded because of incomplete examination or MRD information	POP-Q or BW MRD	Overall rho -0.001; p=0.998 rho 0.305; p=0.025 rho 0.436; p=0.001	Overall POP-Q stage and anterior wall correlated positively and significantly with MRD MRD may provide different information than clinical examination, particularly BW staging

Table 9 (continued)

Reference	Study design	Population	Method(s) of clinical assessment	Results	Discussion
Lin et al. [122] (same group as Pollock et al. [121])	Retrospective cohort study, USA	<i>n</i> =178	Physical examination, BW	Patients with POP specifically not reported	MRD may provide additional information on the presence of an enterocele
				Physical examination compared with MRD for enterocele detection	Anterior wall had the best correlation between examination and MRD
				Sensitivity 0.300, specificity 0.926	Findings impacted by how MRD grading is defined
				Spearman correlation coefficient between MRD grading and BW grading	Agreement between BW grade 3,4 and MRD moderate to severe
		Anterior		rho=0.652, moderate positive	84.6%
		Apical		rho=0.195, poor	63%
		Posterior		rho=0.277, poor	78.7%
Arif-Tiwari et al. [123] (same group as Lin et al. [122] and Pollock et al. above [121])	Retrospective cohort study, USA	274 patients with POP or other pelvic floor disorder underwent MRD 96 excluded for male sex, incomplete examination or MRD, inability to defecate rectal gel <i>n</i> =237	MRD Dynamic MR with Valsalva only vs defecography phase	56% prior surgery for POP or UI Vaginal prolapse 22.8% 67.4% prior hysterectomy 0% prolapse detected by Valsalva only but not defecography phase Percentage POP detected by defecography phase but not Valsalva only: Cystocele 37.6% Rectocele 25.7% <i>p</i> <0.0001	Suggests that dynamic MRI for patients with POP should include defecography phase
		274 with symptoms of POP			
		37 patients excluded for male sex or inability to tolerate or defecate rectal gel	No physical examination data		

**Table 9** (continued)

Reference	Study design	Population	Method(s) of clinical assessment	Results	Discussion	
Faucheron et al. [124]	Prospective cohort study, France	n=50 patients with posterior vaginal wall prolapse who ultimately had surgical repair	Physical examination  POP-Q DCCP MRD  Findings at surgery Studies undergone by all patients but not reported on: Colonic transit time study	Peritoneocele DCCP Sensitivity 0.833; specificity 1.000 MRD Sensitivity 0.633, specificity 1.000 Detection of defects and interobserver agreement of findings at surgery and radiographic findings Posterior colpocele Rectocele	MRD and DCCP had good interobserver agreement for rectocele and posterior colpocele	
Lienemann et al. [125]	Case-control study, Germany	n=66	Anal manometry Endoanal US Colonoscopy  Physical examination	Peritoneocele Full-thickness rectal prolapse Internal rectal prolapse Diagnosis of enterocele Present Absent Diagnosis of enterocele Present Absent Diagnosis of enterocele Present Absent	DCCP MRD 91%; kappa=0.69, good 93%; kappa=0.79, good 87%; kappa=0.72, good 95%; kappa=0.80, good 93%; kappa=0.85, excellent Examination MR-CCRG	DCCP was better at detecting peritoneocele, full-thickness, and internal rectal prolapse, possibly because of more physiological positioning for DCP MR-CCRG was better than DCP at diagnosing enteroceles
		55 patients with POP 11 controls without POP	DCP MR-CCRG	29 5	14 20	MR-CCRG detected enteroceles missed on examination

Table 9 (continued)

Reference	Study design	Population	Method(s) of clinical assessment	Results	Discussion
<b>Anal physiology testing</b>					
Groenendijk et al. [126]	Prospective cohort study, The Netherlands	$n=59$ women with primary POP stage $\geq$ II	Symptom questionnaire (defecation distress inventory)	Patients with POP vs health controls reference values Lower squeezing pressure Delayed first sensation, desire, capacity Prolonged PNTLT $p<0.01$	AFT and AES add limited information to the routine evaluation of POP patients.
		68 enrolled	POP-Q	Patients with FI had significantly lower resting ( $p=0.036$ ) and squeezing pressures ( $p=0.046$ ) and increased risk of external sphincter defect OR= 12.75; 95% CI 2.40–66.67	
		4 dropped out	AFT: manometry, sensation, PNTLT		
		5 had testing done incorrectly	AES	Manometry was not different between patients with and without constipation	Patients with fecal incontinence may benefit from this testing
Zbar et al. [127]	Prospective cohort study, UK	$n=73$ women (14 isolated rectocele aka type 1, 26 rectocele and apical POP aka type 2, 33 controls)	BW	Anorectal sensation and sensitivity were not related to the stage of posterior wall prolapse All patients with rectocele had this finding on examination and defecography Reduced resting and squeeze pressure in type 2 rectoceles $p<0.001$	There are few consistent, differences in anal physiology between isolated rectoceles and those associated with other prolapse
				Elevated resting pressure in type 1 rectocele $p<0.001$	
				But squeeze pressure not significantly different	
				Reduced inhibitory slope in RAIR measurements in both rectocele types compared with controls (type 1 $p<0.001$ , type 2 $p=0.002$ )	
				Maximum inhibitory pressure lower in type 1 $n=0.006$	
			Defecography		
			Anorectal manometry, vector manometry, parametric assessment of the rectoanal inhibitory reflex		

BW Baden–Walker prolapse grading system, POP-Q Pelvic Organ Prolapse Quantification, DCP dynamic cystoproctography, DCCP dynamic cystocoloproctography, dMRI dynamic magnetic resonance imaging, CDP cystodefecoproctography, NOS not otherwise specified, DCR dynamic contrast roentgenography, DDI defecation distress inventory, HO heterotopic ossification, CCD colprocystodefecography, MRD magnetic resonance defecography, FI fetal incontinence, MR-CCRG magnetic resonance colprocystorectography, PNTLT pudendal nerve terminal latency time, AFT anorectal function testing, AES anal endosonography, RAIR rectoanal inhibitory index

tomical defects, including enterocele, sigmoidocele, and intussusception, are better visualized with either fluoroscopic defecography or MRI defecography, but how this relates to clinical decision-making or more specifically outcomes, remains unclear.

- In patients where these diagnoses are in question or in patients who present with GI symptoms, it is reasonable to obtain further imaging and testing beyond a routine clinical examination. However, these additional studies can be expensive and uncomfortable to patients, and currently there is no apparent benefit to identifying an underlying condition that would influence treatment decisions and outcomes. Until a benefit is established, their routine use in asymptomatic women with POP should be discouraged outside of research protocols.

**Further research** Future studies comparing imaging and physiological testing with clinical examination need to compare their results with standardized clinical evaluation in the form of the POP-Q. Standardized minimum criteria for imaging and physiological testing need to be established, as well as a standardized reporting system to allow for comparison between studies. Until these are drawn up it will remain almost impossible to evaluate the literature.

Studies in patients with POP and no GI complaints comparing radiographic/physiological testing with no testing need to be evaluated with meaningful outcome measures.

**Acknowledgements** Prof. Robert Freeman, University Hospitals Plymouth NHS Trust, UK; Mugdha Kulkarni, Urogynaecologist, Monash Health, Melbourne, Australia; Yizhen (Amy) Liu MBBS, BmedSci, Obstetrics and Gynaecology Registrar, Monash Health, Melbourne, Australia, Research Associate, Monash University, Melbourne Australia.

**Authors' contributions** All authors contributed equally and therefore have been mentioned in alphabetical order.

**Funding** Open Access funding enabled and organized by CAUL and its Member Institutions

## Declarations

**Conflicts of interest** None.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

- Harvey MA, Chih HJ, Geoffrion R, et al. International Urogynecology Consultation Chapter 1 Committee 5: relationship of pelvic organ prolapse to associated pelvic floor dysfunction symptoms: lower urinary tract, bowel, sexual dysfunction and abdominopelvic pain. *Int Urogynecol J.* 2021;32(10):2575–94 <https://doi.org/10.1007/s00192-021-04941-5>.
- Cichowski S, Grzybowska ME, Halder GE, et al. International Urogynecology consultation: patient reported outcome measures (PROs) use in the evaluation of patients with pelvic organ prolapse. *Int Urogynecol J.* 2022;33(10):2603–31. <https://doi.org/10.1007/s00192-022-05315-1>.
- Geomini PMAJ, Mol B-WJ, Bremer GL, Brölmann HAM. Inter-observer reproducibility of the Halfway grading system: a scoring system for assessment of pelvic organ prolapse. *J Gynecol Surg.* 2000;16(2):79–82. <https://doi.org/10.1089/gyn.2000.16.79>.
- Groenendijk A, Blok S, Birnie E, Bonsel G. Interobserver agreement and intersystem comparison of the Halfway system of Baden and Walker versus the pelvic organ prolapse-quantitation prolapse classification system in assessing the severity of pelvic organ prolapse. *Female Pelvic Med Reconstr Surg.* 2005;11:243–50. <https://doi.org/10.1097/01.spv.0000190322.85212.3e>.
- Manonai J, Mouritsen L, Palma P, Contreras-Ortiz O, Korte JE, Swift S. The inter-system association between the simplified pelvic organ prolapse quantification system (S-POP) and the standard pelvic organ prolapse quantification system (POPQ) in describing pelvic organ prolapse. *Int Urogynecol J.* 2011;22(3):347–52. <https://doi.org/10.1007/s00192-010-1286-y>.
- Parekh M, Swift S, Lemos N, et al. Multicenter inter-examiner agreement trial for the validation of simplified POPQ system. *Int Urogynecol J.* 2011;22(6):645–50. <https://doi.org/10.1007/s00192-011-1395-2>.
- Center-by-center results of a multicenter prospective trial to determine the inter-observer correlation of the simplified POP-Q in describing pelvic organ prolapse. Accessed 29 November 2022. [https://www.researchgate.net/publication/51798389\\_Center-by-center\\_results\\_of\\_a\\_multicenter\\_prospective\\_trial\\_to\\_determine\\_the\\_inter-observer\\_correlation\\_of\\_the\\_simplified\\_POP-Q\\_in\\_describing\\_pelvic\\_organ\\_prolapse](https://www.researchgate.net/publication/51798389_Center-by-center_results_of_a_multicenter_prospective_trial_to_determine_the_inter-observer_correlation_of_the_simplified_POP-Q_in_describing_pelvic_organ_prolapse)
- Bump RC, Mattiasson A, Bø K, et al. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. *Am J Obstet Gynecol.* 1996;175(1):10–7. [https://doi.org/10.1016/s0002-9378\(96\)70243-0](https://doi.org/10.1016/s0002-9378(96)70243-0).
- Swift S, Morris S, McKinnie V, et al. Validation of a simplified technique for using the POPQ pelvic organ prolapse classification system. *Int Urogynecol J Pelvic Floor Dysfunct.* 2006;17(6):615–20. <https://doi.org/10.1007/s00192-006-0076-z>.
- Karp DR, Peterson TV, Jean-Michel M, Lefevre R, Davila GW, Aguilar VC. “Eyeball” POP-Q examination: shortcut or valid assessment tool? *Int Urogynecol J.* 2010;21(8):1005–9. <https://doi.org/10.1007/s00192-010-1139-8>.
- Silva WA, Kleeman S, Segal J, Pauls R, Woods SE, Karram MM. Effects of a full bladder and patient positioning on pelvic organ prolapse assessment. *Obstet Gynecol.* 2004;104(1):37–41. <https://doi.org/10.1097/01.AOG.0000131619.97936.e2>.
- Reich A, Kohorst F, Kreienberg R, Flock F. Influence of bladder volume on pelvic organ prolapse quantification results. *Gynecol Obstet Investig.* 2010;70(2):82–6. <https://doi.org/10.1159/000292507>.
- Shek KL, Dietz HP. Assessment of pelvic organ prolapse: a review. *Ultrasound Obstet Gynecol.* 2016;48(6):681–92 <https://doi.org/10.1002/uog.15881>.

14. Barber MD, Lambers A, Visco AG, Bump RC. Effect of patient position on clinical evaluation of pelvic organ prolapse. *Obstet Gynecol.* 2000;96(1):18–22. [https://doi.org/10.1016/s0029-7844\(00\)00859-0](https://doi.org/10.1016/s0029-7844(00)00859-0).
15. Digesu GA, Khullar V, Cardozo L, Robinson D. Inter-observer reliability of digital vaginal examination using a four-grade scale in different patient positions. *Int Urogynecol J Pelvic Floor Dysfunct.* 2008;19(9):1303–7. <https://doi.org/10.1007/s00192-008-0635-6>.
16. Digesu GA, Athanasiou S, Cardozo L, Hill S, Khullar V. Validation of the pelvic organ prolapse quantification (POP-Q) system in left lateral position. *Int Urogynecol J Pelvic Floor Dysfunct.* 2009;20(8):979–83. <https://doi.org/10.1007/s00192-009-0884-z>.
17. Pearce M, Swift S, Goodnight W. Pelvic organ prolapse: is there a difference in POPQ exam results based on time of day, morning or afternoon? *Am J Obstet Gynecol.* 2008;199(2):200.e1–5. <https://doi.org/10.1016/j.ajog.2008.05.012>.
18. Ow LL, Subramaniam N, Kamisan Atan I, Friedman T, Martin A, Dietz HP. Should genital hiatus/perineal body be measured at rest or on Valsalva? *Female Pelvic Med Reconstr Surg.* 2019;25(6):415–8. <https://doi.org/10.1097/SPV.0000000000000608>.
19. Brazzell HD, Claydon CS, Li J, et al. Does neuromuscular blockade affect the assessment of pelvic organ prolapse? *Int Urogynecol J.* 2012;23(11):1599–603. <https://doi.org/10.1007/s00192-012-1771-6>.
20. Leerasiri P, Wachasiddhisilpa P, Hengrasme P, Asumpinwong C. Relationship of degree of uterine prolapse between pelvic examination in lithotomy position with cervical traction and pelvic examination in standing position. *Int Urogynecol J.* 2018;29(8):1173–7. <https://doi.org/10.1007/s00192-018-3579-5>.
21. Dunivan GC, Lyons KE, Jeppson PC, et al. Pelvic organ prolapse stage and the relationship to genital hiatus and perineal body measurements. *Female Pelvic Med Reconstr Surg.* 2016;22(6):497–500. <https://doi.org/10.1097/SPV.0000000000000323>.
22. Lowder JL, Oliphant SS, Shepherd JP, Ghetti C, Sutkin G. Genital hiatus size is associated with and predictive of apical vaginal support loss. *Am J Obstet Gynecol.* 2016;214(6):718.e1–8. <https://doi.org/10.1016/j.ajog.2015.12.027>.
23. Girgis M, Shek KL, Dietz HP. Total vaginal length: does it matter for assessing uterine prolapse? *Int Urogynecol J.* 2019;30(8):1279–82. <https://doi.org/10.1007/s00192-018-3779-z>.
24. Borello-France DF, Handa VL, Brown MB, et al. Pelvic-floor muscle function in women with pelvic organ prolapse. *Phys Ther.* 2007;87(4):399–407. <https://doi.org/10.2522/ptj.20060160>.
25. Felicíssimo MF, Carneiro MM, Saleme CS, Pinto RZ, da Fonseca AMRM, da Silva-Filho AL. Intensive supervised versus unsupervised pelvic floor muscle training for the treatment of stress urinary incontinence: a randomized comparative trial. *Int Urogynecol J.* 2010;21(7):835–40. <https://doi.org/10.1007/s00192-010-1125-1>.
26. Ghetti C, Gregory WT, Edwards SR, Otto LN, Clark AL. Severity of pelvic organ prolapse associated with measurements of pelvic floor function. *Int Urogynecol J Pelvic Floor Dysfunct.* 2005;16(6):432–6. <https://doi.org/10.1007/s00192-004-1274-1>.
27. Slieker-ten Hove M, Pool-Goudzwaard A, Eijkemans M, Steegers-Theunissen R, Burger C, Vierhout M. Pelvic floor muscle function in a general population of women with and without pelvic organ prolapse. *Int Urogynecol J.* 2010;21(3):311–9. <https://doi.org/10.1007/s00192-009-1037-0>.
28. Gruenwald I, Mustafa S, Gartman I, Lowenstein L. Genital sensation in women with pelvic organ prolapse. *Int Urogynecol J.* 2015;26(7):981–4. <https://doi.org/10.1007/s00192-015-2637-5>.
29. Mattox TF, Lucente V, McIntyre P, Miklos JR, Tomezsko J. Abnormal spinal curvature and its relationship to pelvic organ prolapse. *Am J Obstet Gynecol.* 2000;183(6):1381–4discussion 1384. <https://doi.org/10.1067/mob.2000.111489>.
30. Meyer I, McArthur TA, Tang Y, McKinney JL, Morgan SL, Richter HE. Pelvic floor symptoms and spinal curvature in women. *Female Pelvic Med Reconstr Surg.* 2016;22(4):219–23. <https://doi.org/10.1097/SPV.0000000000000271>.
31. Stein TA, Kaur G, Summers A, Larson KA, Delancey JOL. Comparison of bony dimensions at the level of the pelvic floor in women with and without pelvic organ prolapse. *Am J Obstet Gynecol.* 2009;200(3):241.e1–5. <https://doi.org/10.1016/j.ajog.2008.10.040>.
32. Segal JL, Vassallo BJ, Kleeman SD, Silva WA, Karram MM. Paravaginal defects: prevalence and accuracy of pre-operative detection. *Int Urogynecol J Pelvic Floor Dysfunct.* 2004;15(6):378–83discussion 383. <https://doi.org/10.1007/s00192-004-1196-y>.
33. Whiteside JL, Barber MD, Paraiso MF, Hugney CM, Walters MD. Clinical evaluation of anterior vaginal wall support defects: interexaminer and intraexaminer reliability. *Am J Obstet Gynecol.* 2004;191(1):100–4. <https://doi.org/10.1016/j.ajog.2004.01.053>.
34. Elliott CS, Yeh J, Comiter CV, Chen B, Sokol ER. The predictive value of a cystocele for concomitant vaginal apical prolapse. *J Urol.* 2013;189(1):200–3. <https://doi.org/10.1016/j.juro.2012.08.177>.
35. Grimes CL, Tan-Kim J, Nager CW, et al. Outcome measures to assess anatomy and function of the posterior vaginal compartment. *Int Urogynecol J.* 2014;25(7):893–9. <https://doi.org/10.1007/s00192-013-2303-8>.
36. Groenendijk AG, van der Hulst VP, Birnie E, Bonsel GJ. Correlation between posterior vaginal wall defects assessed by clinical examination and by defecography. *Int Urogynecol J Pelvic Floor Dysfunct.* 2008;19(9):1291–7. <https://doi.org/10.1007/s00192-008-0632-9>.
37. Rachaneni S, Atan IK, Shek KL, Dietz HP. Digital rectal examination in the evaluation of rectovaginal septal defects. *Int Urogynecol J.* 2017;28(9):1401–5. <https://doi.org/10.1007/s00192-017-3285-8>.
38. Patnam R, Edenfield A, Swift S. Defining normal apical vaginal support: a relook at the POSST study. *Int Urogynecol J.* 2019;30(1):47–51. <https://doi.org/10.1007/s00192-018-3681-8>.
39. Comparison of estimated cervical length from the Pelvic Organ Prolapse Quantification exam and actual cervical length at hysterectomy: can we accurately determine cervical elongation? Accessed 29 November 2022. [https://www.researchgate.net/publication/232187684\\_Comparison\\_of\\_Estimated\\_Cervical\\_Length\\_From\\_the\\_Pelvic\\_Organ\\_Prolapse\\_Quantification\\_Exam\\_and\\_Actual\\_Cervical\\_Length\\_at\\_Hysterectomy\\_Can\\_We\\_Accurately\\_Determine\\_Cervical\\_Elongation](https://www.researchgate.net/publication/232187684_Comparison_of_Estimated_Cervical_Length_From_the_Pelvic_Organ_Prolapse_Quantification_Exam_and_Actual_Cervical_Length_at_Hysterectomy_Can_We_Accurately_Determine_Cervical_Elongation)
40. Crosby EC, Sharp KM, Gasperut A, Delancey JOL, Morgan DM. Apical descent in the office and the operating room: the effect of prolapse size. *Female Pelvic Med Reconstr Surg.* 2013;19(5):278–81. <https://doi.org/10.1097/SPV.0b013e31829c6365>.
41. Berger MB, Kolenic GE, Fenner DE, Morgan DM, DeLancey JOL. Structural, functional, and symptomatic differences between women with rectocele versus cystocele and normal support. *Am J Obstet Gynecol.* 2018;218(5):510.e1–8. <https://doi.org/10.1016/j.ajog.2018.01.033>.
42. Lowder JL, Park AJ, Ellison R, et al. The role of apical vaginal support in the appearance of anterior and posterior vaginal prolapse. *Obstet Gynecol.* 2008;111(1):152–7. <https://doi.org/10.1097/01.AOG.0000297309.25091.a0>.
43. Bø K, Anglès-Acedo S, Batra A, et al. International urogynecology consultation chapter 3 committee 2; conservative treatment of patient with pelvic organ prolapse: pelvic floor muscle training. *Int Urogynecol J.* 2022;33(10):2633–67. <https://doi.org/10.1007/s00192-022-05324-0>.



44. Dain L, Auslander R, Rosen T, Segev Y, Goldschmidt E, Abramov Y. Urodynamic findings in women with pelvic organ prolapse and obstructive voiding symptoms. *Int J Gynaecol Obstet.* 2010;111(2):119–21. <https://doi.org/10.1016/j.ijgo.2010.06.007>.
45. Frigerio M, Manodoro S, Cola A, Palmieri S, Spelzini F, Milani R. Detrusor underactivity in pelvic organ prolapse. *Int Urogynecol J.* 2018;29(8):1111–6. <https://doi.org/10.1007/s00192-017-3532-z>.
46. Mueller E, Wei J, Nygaard I, et al. The correlation of voiding variables between non-instrumented uroflowmetry and pressure-flow studies in women with pelvic organ prolapse. *Neurourol Urodyn.* 2008;27(6):515–21. <https://doi.org/10.1002/nau.20568>.
47. Lazarou G, Scotti RJ, Mikhail MS, Zhou HS, Powers K. Pessary reduction and postoperative cure of retention in women with anterior vaginal wall prolapse. *Int Urogynecol J Pelvic Floor Dysfunct.* 2004;15(3):175–8. <https://doi.org/10.1007/s00192-004-1138-8>.
48. Lo TS, Shailaja N, Hsieh WC, Uy-Patrimonio MC, Yusoff FM, Ibrahim R. Predictors of voiding dysfunction following extensive vaginal pelvic reconstructive surgery. *Int Urogynecol J.* 2017;28(4):575–82. <https://doi.org/10.1007/s00192-016-3144-z>.
49. Ulrich A, Davis P, Propst K, O'Sullivan DM, Tulikangas P. Elevated postvoid residual urine volume: identifying risk factors and predicting resolution in women with pelvic organ prolapse. *Female Pelvic Med Reconstr Surg.* 2018;24(6):444–8. <https://doi.org/10.1097/SPV.0000000000000471>.
50. Araki I, Haneda Y, Mikami Y, Takeda M. Incontinence and detrusor dysfunction associated with pelvic organ prolapse: clinical value of preoperative urodynamic evaluation. *Int Urogynecol J Pelvic Floor Dysfunct.* 2009;20(11):1301–6. <https://doi.org/10.1007/s00192-009-0954-2>.
51. Asfour V, Gargasole C, Fernando R, Digesu GG, Khullar V. Urodynamics are necessary for patients with asymptomatic pelvic organ prolapse. *Neurourol Urodyn.* 2018;37(8):2841–6. <https://doi.org/10.1002/nau.23796>.
52. Yalcin OT, Yildirim A, Hassa H. The effects of severe cystocele on urogynecologic symptoms and findings. *Acta Obstet Gynecol Scand.* 2001;80(5):423–7.
53. Liang CC, Chang YL, Lin YH, Chang SD. Significance of bladder trabeculation in postmenopausal women with severe pelvic organ prolapse: clinical and urodynamic assessments. *Menopause.* 2013;20(8):813–7. <https://doi.org/10.1097/GME.0b013e31827f09a0>.
54. Cassadó J, España-Pons M, Díaz-Cuervo H, Rebollo P; GISPEM group. How can we measure bladder volumes in women with advanced pelvic organ prolapse? *Ultrasound Obstet Gynecol.* 2015;46(2):233–8. <https://doi.org/10.1002/uog.14678>.
55. Abrams P. Bladder outlet obstruction index, bladder contractility index and bladder voiding efficiency: three simple indices to define bladder voiding function. *BJU Int.* 1999;84(1):14–5. <https://doi.org/10.1046/j.1464-410x.1999.00121.x>.
56. Schäfer W. Analysis of bladder-outlet function with the linearized passive urethral resistance relation, linPURR, and a disease-specific approach for grading obstruction: from complex to simple. *World J Urol.* 1995;13(1):47–58. <https://doi.org/10.1007/BF00182666>.
57. Frigerio M, Manodoro S, Cola A, Palmieri S, Spelzini F, Milani R. Risk factors for persistent, de novo and overall overactive bladder syndrome after surgical prolapse repair. *Eur J Obstet Gynecol Reprod Biol.* 2019;233:141–5. <https://doi.org/10.1016/j.ejogrb.2018.12.024>.
58. Glass D, Lin FC, Khan AA, et al. Impact of preoperative urodynamics on women undergoing pelvic organ prolapse surgery. *Int Urogynecol J.* 2020;31(8):1663–8. <https://doi.org/10.1007/s00192-019-04084-8>.
59. Jha S, Tooze-Hobson P, Parsons M, Gull F. Does preoperative urodynamics change the management of prolapse? *J Obstet Gynaecol.* 2008;28(3):320–2. <https://doi.org/10.1080/01443610802044825>.
60. Lo TS, Nagashu S, Hsieh WC, Uy-Patrimonio MC, Yi-Hao L. Predictors for detrusor overactivity following extensive vaginal pelvic reconstructive surgery. *Neurourol Urodyn.* 2018;37(1):192–9. <https://doi.org/10.1002/nau.23273>.
61. Roovers JPWR, van Laar JOEH, Loffeld C, Bremer GL, Mol BW, Bongers MY. Does urodynamic investigation improve outcome in patients undergoing prolapse surgery? *Neurourol Urodyn.* 2007;26(2):170–5. <https://doi.org/10.1002/nau.20328>.
62. Serati M, Salvatore S, Siesto G, et al. Urinary symptoms and urodynamic findings in women with pelvic organ prolapse: is there a correlation? Results of an artificial neural network analysis. *Eur Urol.* 2011;60(2):253–60. <https://doi.org/10.1016/j.eururo.2011.03.010>.
63. España-Pons M, Diez-Itza I, Anglès-Acedo S, Covernton PJO. Cough stress tests to diagnose stress urinary incontinence in women with pelvic organ prolapse with indication for surgical treatment. *Neurourol Urodyn.* 2020;39(2):819–25. <https://doi.org/10.1002/nau.24288>.
64. Pollak JT, Jenkins P, Kopka SL, Davila GW. Effect of genital prolapse on assessment of bladder neck mobility by the Q-tip test. *Obstet Gynecol.* 2003;101(4):662–5. [https://doi.org/10.1016/s0029-7844\(03\)00067-x](https://doi.org/10.1016/s0029-7844(03)00067-x).
65. Kim SO, Chung HS, Hwang EC, Oh KJ, Kwon D. Point aa of the POP-Q system as a predictive value of urethral mobility in women. *Int Urogynecol J.* 2011;22(6):687–91. <https://doi.org/10.1007/s00192-010-1316-9>.
66. Leruth J, Fillet M, Waltregny D. Incidence and risk factors of postoperative stress urinary incontinence following laparoscopic sacrocolpopexy in patients with negative preoperative prolapse reduction stress testing. *Int Urogynecol J.* 2013;24(3):485–91. <https://doi.org/10.1007/s00192-012-1888-7>.
67. Alas AN, Chinthakanan O, Espallat L, Plowright L, Davila GW, Aguilar VC. De novo stress urinary incontinence after pelvic organ prolapse surgery in women without occult incontinence. *Int Urogynecol J.* 2017;28(4):583–90. <https://doi.org/10.1007/s00192-016-3149-7>.
68. Jeon MJ, Kim JY, Moon YJ, Bai SW, Yoo EH. Two-year urinary outcomes of sacrocolpopexy with or without transobturator tape: results of a prolapse-reduction stress test-based approach. *Int Urogynecol J.* 2014;25(11):1517–22. <https://doi.org/10.1007/s00192-014-2410-1>.
69. Kasturi S, Diaz SI, McDermott CD, et al. De novo stress urinary incontinence after negative prolapse reduction stress testing for total vaginal mesh procedures: incidence and risk factors. *Am J Obstet Gynecol.* 2011;205(5):487.e1–4. <https://doi.org/10.1016/j.ajog.2011.07.006>.
70. Park J, McDermott CD, Terry CL, Bump RC, Woodman PJ, Hale DS. Use of preoperative prolapse reduction stress testing and the risk of a second surgery for urinary symptoms following laparoscopic sacral colpoproctopexy. *Int Urogynecol J.* 2012;23(7):857–64. <https://doi.org/10.1007/s00192-011-1648-0>.
71. Lo TS, Nawawi EA, Wu PY, bt Karim N, Al-Kharabsheh A. Predictors for persistent urodynamic stress incontinence following extensive pelvic reconstructive surgery with and without midurethral sling. *Int Urogynecol J.* 2016;27(3):399–406. <https://doi.org/10.1007/s00192-015-2837-z>.
72. Frigerio M, Manodoro S, Palmieri S, Spelzini F, Milani R. Risk factors for stress urinary incontinence after native-tissue vaginal repair of pelvic organ prolapse. *Int J Gynaecol Obstet.* 2018;141(3):349–53. <https://doi.org/10.1002/ijgo.12443>.
73. Van der Ploeg JM, Steyerberg EW, Zwolsman SE, van der Vaart CH, Roovers JPWR. Stress urinary incontinence after vaginal

- prolapse repair: development and internal validation of a prediction model with and without the stress test. *Neurourol Urodyn.* 2019;38(4):1086–92. <https://doi.org/10.1002/nau.23958>.
74. Haylen BT, Maher CF, Barber MD, et al. An International Urogynecological Association (IUGA)/International Continence society (ICS) joint report on the terminology for female pelvic organ prolapse (POP). *Int Urogynecol J.* 2016;27(2):165–94. <https://doi.org/10.1007/s00192-015-2932-1>.
  75. Ballert KN, Biggs GY, Isenalumhe A, Rosenblum N, Nitti VW. Managing the urethra at transvaginal pelvic organ prolapse repair: a urodynamic approach. *J Urol.* 2009;181(2):679–84. <https://doi.org/10.1016/j.juro.2008.10.009>.
  76. Costantini E, Zucchi A, Giannantoni A, Mearini L, Bini V, Porena M. Must colposuspension be associated with sacropexy to prevent postoperative urinary incontinence? *Eur Urol.* 2007;51(3):788–94. <https://doi.org/10.1016/j.eururo.2006.08.034>.
  77. Ellström Engh AM, Ekeryd A, Magnusson Å, Olsson I, Otterlind L, Tobiasson G. Can de novo stress incontinence after anterior wall repair be predicted? *Acta Obstet Gynecol Scand.* 2011;90(5):488–93. <https://doi.org/10.1111/j.1600-0412.2011.01087.x>.
  78. Ennemoser S, Schönfeld M, von Bodungen V, Dian D, Friese K, Jundt K. Clinical relevance of occult stress urinary incontinence (OSUI) following vaginal prolapse surgery: long-term follow-up. *Int Urogynecol J.* 2012;23(7):851–5.
  79. Goessens E, Deriemaeker H, Cammu H. The use of a vaginal pessary to decide whether a mid urethral sling should be added to prolapse surgery. *J Urol.* 2020;203(3):598–603. <https://doi.org/10.1097/JU.0000000000000575>.
  80. Hafidh BA, Chou Q, Khalil MM, Al-Mandee H. De novo stress urinary incontinence after vaginal repair for pelvic organ prolapse: one-year follow-up. *Eur J Obstet Gynecol Reprod Biol.* 2013;168(2):227–30. <https://doi.org/10.1016/j.ejogrb.2012.12.029>.
  81. Karateke A, Tug N, Cam C, Selcuk S, Asoglu MR. Concomitant surgical correction of occult stress urinary incontinence by TOT in patients with pelvic organ prolapse. *Eur J Obstet Gynecol Reprod Biol.* 2011;154(1):105–7. <https://doi.org/10.1016/j.ejogrb.2010.08.003>.
  82. Kleeman S, Vassallo B, Segal J, Hungler M, Karram M. The ability of history and a negative cough stress test to detect occult stress incontinence in patients undergoing surgical repair of advanced pelvic organ prolapse. *Int Urogynecol J Pelvic Floor Dysfunct.* 2006;17(1):27–9. <https://doi.org/10.1007/s00192-005-1367-5>.
  83. Klutke JJ, Ramos S. Urodynamic outcome after surgery for severe prolapse and potential stress incontinence. *Am J Obstet Gynecol.* 2000;182(6):1378–81. <https://doi.org/10.1067/mob.2000.106176>.
  84. Liang CC, Chang YL, Chang SD, Lo TS, Soong YK. Pessary test to predict postoperative urinary incontinence in women undergoing hysterectomy for prolapse. *Obstet Gynecol.* 2004;104(4):795–800. <https://doi.org/10.1097/01.AOG.0000140689.90131.01>.
  85. Manodoro S, Spelzini F, Frigerio M, Nicoli E, Verri D, Milani R. Is occult stress urinary incontinence a reliable predictive marker? *Female Pelvic Med Reconstr Surg.* 2016;22(4):280–2. <https://doi.org/10.1097/SPV.0000000000000272>.
  86. Misraï V, Roupêt M, Cour F, Chartier-Kastler E, Richard F. De novo urinary stress incontinence after laparoscopic sacral colpopexy. *BJU Int.* 2008;101(5):594–7. <https://doi.org/10.1111/j.1464-410X.2007.07291.x>.
  87. Reena C, Kekre AN, Kekre N. Occult stress incontinence in women with pelvic organ prolapse. *Int J Gynaecol Obstet.* 2007;97(1):31–4. <https://doi.org/10.1016/j.ijgo.2006.12.011>.
  88. Schierlitz L, Dwyer PL, Rosamilia A, et al. Pelvic organ prolapse surgery with and without tension-free vaginal tape in women with occult or asymptomatic urodynamic stress incontinence: a randomised controlled trial. *Int Urogynecol J.* 2014;25(1):33–40. <https://doi.org/10.1007/s00192-013-2150-7>.
  89. Sierra T, Sullivan G, Leung K, Flynn M. The negative predictive value of preoperative urodynamics for stress urinary incontinence following prolapse surgery. *Int Urogynecol J.* 2019;30(7):1119–24. <https://doi.org/10.1007/s00192-018-03864-y>.
  90. Song X, Zhu L, Ding J. The value of the preoperative 1-h pad test with pessary insertion for predicting the need for a mid-urethral sling following pelvic prolapse surgery: a cohort study. *World J Urol.* 2016;34(3):361–7. <https://doi.org/10.1007/s00345-015-1590-8>.
  91. Srikrishna S, Robinson D, Cardozo L. Ringing the changes in evaluation of urogenital prolapse. *Int Urogynecol J.* 2011;22(2):171–5. <https://doi.org/10.1007/s00192-010-1253-7>.
  92. Svenningsen R, Borstad E, Spydslaug AE, Sandvik L, Staff AC. Occult incontinence as predictor for postoperative stress urinary incontinence following pelvic organ prolapse surgery. *Int Urogynecol J.* 2012;23(7):843–9. <https://doi.org/10.1007/s00192-012-1764-5>.
  93. van der Ploeg JM, Oude Rengerink K, van der Steen A, et al. Vaginal prolapse repair with or without a midurethral sling in women with genital prolapse and occult stress urinary incontinence: a randomized trial. *Int Urogynecol J.* 2016;27(7):1029–38. <https://doi.org/10.1007/s00192-015-2924-1>.
  94. van der Ploeg JM, Zwolsman SE, Posthuma S, Wiarda HS, van der Vaart CH, Roovers JPWR. The predictive value of demonstrable stress incontinence during basic office evaluation and urodynamics in women without symptomatic urinary incontinence undergoing vaginal prolapse surgery. *Neurourol Urodyn.* 2018;37(3):1011–8. <https://doi.org/10.1002/nau.23384>.
  95. Visco AG, Brubaker L, Nygaard I, et al. The role of preoperative urodynamic testing in stress-continent women undergoing sacrocolpopexy: the colpopexy and urinary reduction efforts (CARE) randomized surgical trial. *Int Urogynecol J Pelvic Floor Dysfunct.* 2008;19(5):607–14. <https://doi.org/10.1007/s00192-007-0498-2>.
  96. Wei JT, Nygaard I, Richter HE, et al. A midurethral sling to reduce incontinence after vaginal prolapse repair. *N Engl J Med.* 2012;366(25):2358–67. <https://doi.org/10.1056/NEJMoa1111967>.
  97. Yamada T, Ichiyanagi N, Kamata S, et al. Need for sling surgery in patients with large cystoceles and masked stress urinary incontinence. *Int J Urol.* 2001;8(11):599–603. <https://doi.org/10.1046/j.1442-2042.2001.00387.x>.
  98. Hwang SM, de Toledo LGM, da Silva CS, Frade AB, Matos AC, Auge APF. Is urodynamics necessary to identify occult stress urinary incontinence? *World J Urol.* 2019;37(1):189–93. <https://doi.org/10.1007/s00345-018-2366-8>.
  99. Lo TS, Bt Karim N, Nawawi EA, Wu PY, Nusee Z. Predictors for de novo stress urinary incontinence following extensive pelvic reconstructive surgery. *Int Urogynecol J.* 2015;26(9):1313–9. <https://doi.org/10.1007/s00192-015-2685-x>.
  100. Wang SY, Cao TT, Wang RZ, Yang X, Sun XL, Wang JL. Incidence and risk factors of de novo stress urinary incontinence after pelvic floor reconstruction: a nested case-control study. *Chin Med J.* 2017;130(6):678–83. <https://doi.org/10.4103/0366-6999.201592>.
  101. Smith TM, DeLancey JOL, Fenner DE. Post-reduction stress urinary incontinence rates in posterior versus anterior pelvic organ prolapse: a secondary analysis. *Int Urogynecol J.* 2013;24(8):1355–60. <https://doi.org/10.1007/s00192-012-2019-1>.
  102. Nguyen JN, Yazdany T, Burchette RJ. Urodynamic evaluation of urethral competency in women with posterior vaginal

- support defects. *Urology*. 2007;69(1):87–90. <https://doi.org/10.1016/j.urology.2006.09.068>.
103. Jelovsek JE, Chagin K, Brubaker L, et al. A model for predicting the risk of de novo stress urinary incontinence in women undergoing pelvic organ prolapse surgery. *Obstet Gynecol*. 2014;123(2 Pt 1):279–87. <https://doi.org/10.1097/AOG.000000000000094>.
  104. Jelovsek JE, van der Ploeg JM, Roovers JP, Barber MD. Validation of a model predicting de novo stress urinary incontinence in women undergoing pelvic organ prolapse surgery. *Obstet Gynecol*. 2019;133(4):683–90. <https://doi.org/10.1097/AOG.0000000000003158>.
  105. Sabadell J, Salicrú S, Montero-Armengol A, Rodriguez-Mias N, Gil-Moreno A, Poza JL. External validation of de novo stress urinary incontinence prediction model after vaginal prolapse surgery. *Int Urogynecol J*. 2019;30(10):1719–23. <https://doi.org/10.1007/s00192-018-3805-1>.
  106. Nager CW, Brubaker L, Litman HJ, et al. A randomized trial of urodynamic testing before stress-incontinence surgery. *N Engl J Med*. 2012;366(21):1987–97. <https://doi.org/10.1056/NEJMoa1113595>.
  107. Van Leijssen SAL, Kluivers KB, Mol BWJ, et al. Value of urodynamics before stress urinary incontinence surgery: a randomized controlled trial. *Obstet Gynecol*. 2013;121(5):999–1008. <https://doi.org/10.1097/AOG.0b013e31828c68e3>.
  108. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. *BMC Med*. 2015;13(1):1. <https://doi.org/10.1186/s12916-014-0241-z>.
  109. Dancz CE, Walker D, Thomas D, Özel B. Prevalence of hydronephrosis in women with advanced pelvic organ prolapse. *Urology*. 2015;86(2):250–4. <https://doi.org/10.1016/j.urology.2015.05.005>.
  110. Pillalamarri N, Shalom D, Sanidad S, Akerman M, Lind L, Winkler H. The prevalence of microscopic hematuria in a cohort of women with pelvic organ prolapse. *Int Urogynecol J*. 2015;26(1):85–90. <https://doi.org/10.1007/s00192-014-2450-6>.
  111. Kelvin FM, Hale DS, Maglinte DDT, Patten BJ, Benson JT. Female pelvic organ prolapse: diagnostic contribution of dynamic cystoproctography and comparison with physical examination. *Am J Roentgenol*. 1999;173:31–7.
  112. Kaufman H, Buller J, Thompson J, et al. Dynamic pelvic magnetic resonance imaging and cystocolpoproctography alter surgical management of pelvic floor disorders. *Dis Colon Rectum*. 2001;44:1575–83.
  113. Lopez A, Anzen B, Bremmer S, et al. Cysto-defecoperitoneography in patients with genital prolapse. *Int Urogynecol J*. 2002;13:22–9.
  114. Takano M, Hamada A. Evaluation of pelvic descent disorders by dynamic contrast roentgenography. *Dis Colon Rectum*. 2000;43(10):S6–S11.
  115. Roovers JP, van der Bom JG, van der Vaart CH, Heintz AP. Prediction of findings at defecography in patients with genital prolapse. *BJOG*. 2005;112(11):1547–53.
  116. Groenendijk AG, van der Hulst VP, Birnie E, Bonsel GJ. Correlation between posterior vaginal wall defects assessed by clinical examination and by defecography. *Int Urogynecol J*. 2008;19(9):1291–7. <https://doi.org/10.1007/s00192-008-0632-9>.
  117. Kim JH, Park SJ, Yi BH, Lee KW, Kim ME, Kim YH. Diagnostic effectiveness of dynamic colprocystoproctography in women planning for combined surgery with urinary incontinence and pelvic organ prolapse. *Gynecol Obstet Investig*. 2014;77(4):231–9. <https://doi.org/10.1159/000360135>.
  118. Vanbeckevoort D, Van Hoe L, Oyen R, Ponette E, De Ridder D, Deprest J. Pelvic floor descent in females: comparative study of colprocysto-defecography and dynamic fast MR imaging. *J Magn Reson Imaging*. 1999;377:373–7.
  119. Hausammann R, Steffen T, Weishaupt D, Beutner U, Hetzer F. Rectocele and intussusception: is there any coherence in symptoms or additional pelvic floor disorders? *Tech Coloproctol*. 2009;13:17–26. <https://doi.org/10.1007/s10151-009-0454-x>.
  120. Aziz M, Khatri G, Hess D, Zimmern P. Anterior enterocele as an etiology for anterior vaginal wall prolapse: a magnetic resonance defecography case series. *Abdom Radiol*. 2021;46:1390–4.
  121. Pollock GR, Twiss CO, Chartier S, Vedantham S, Funk J, Arif H. Comparison of magnetic resonance defecography grading with POP - Q staging and Baden – Walker grading in the evaluation of female pelvic organ prolapse. *Abdom Radiol*. 2021;46(4):1373–80.
  122. Lin F, Funk J, Tiwari H, Kalb B, Twiss C. Dynamic pelvic magnetic resonance imaging evaluation of pelvic organ prolapse compared to physical examination findings. *Urology*. 2018;119:49–54.
  123. Arif-Tiwari H, Twiss CO, Lin FC, et al. Improved detection of pelvic organ prolapse: comparative utility of defecography phase sequence to nondefecography Valsalva maneuvers in dynamic pelvic floor magnetic resonance imaging. *Curr Probl Diagn Radiol*. 2019;48(4):342–7. <https://doi.org/10.1067/j.cpradiol.2018.08.005>.
  124. Faucheron J, Barot S, Collomb D, Hohn N, Anglade D, Dubreuil A. Dynamic cystocolpoproctography is superior to functional pelvic MRI in the diagnosis of posterior pelvic floor disorders: results of a prospective study. *Colorectal Dis*. 2014;16:O240–7. <https://doi.org/10.1111/codi.12586>.
  125. Lienemann A, Anthuber C, Baron A, Reiser MDAM. Diagnosing enteroceles using dynamic magnetic resonance imaging. *Colon Rectum*. 2000;43(2):206–12.
  126. Groenendijk AG, Birnie E, Boeckxstaens GE, Roovers J-PW, Bonsel GJ. Anorectal function testing and anal endosonography in the diagnostic work-up of patients with primary pelvic organ prolapse. *Gynecol Obstet Investig*. 2009;67:187–94. <https://doi.org/10.1159/000187650>.
  127. Zbar AP, Beer-Gabel M, Aslam M. Rectoanal inhibition and rectocele: physiology versus categorization. *Int J Colorectal Dis*. 2001;16:307–12. <https://doi.org/10.1007/s003840100315>.
  128. Gurland BH, Khatri G, Ram R, et al. Consensus definitions and interpretation templates for magnetic resonance imaging of defecatory pelvic floor disorders: proceedings of the Consensus Meeting of the Pelvic Floor Disorders Consortium of the American Society of Colon and Rectal Surgeons, the Society of Abdominal Radiology, the International Continence Society, the American Urogynecologic Society, the International Urogynecological Association, and the Society of Gynecologic Surgeons. *AJR Am J Roentgenol*. 2021;217(4):800–12.
  129. Paquette I, Rosman D, Sayed R El, et al. Correction to: Consensus definitions and interpretation templates for fluoroscopic imaging of defecatory pelvic floor disorders: proceedings of the Consensus Meeting of the Pelvic Floor Consortium of the American Association of Colon and Rectal Surgeons, the Society of Abdominal Radiology, the International Continence Society, the American Urogynecologic Society, the International Urogynecological Association, and the Society of Gynecologic Surgeons. *Tech Coloproctol* 2021;25(3):357. <https://doi.org/10.1007/s10151-021-02412-z>

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Authors and Affiliations

Heather Barbier<sup>1</sup> · Cassandra L. Carberry<sup>2</sup> · Päivi K. Karjalainen<sup>3,4,5</sup> · Charlotte K. Mahoney<sup>6</sup> ·  
Valentín Manríquez Galán<sup>7</sup> · Anna Rosamilia<sup>8,9</sup> · Esther Ruess<sup>10</sup> · David Shaker<sup>11</sup> · Karishma Thariani<sup>12</sup>

<sup>1</sup> Uniformed Services University of the Health Sciences, Bethesda, MD, USA

<sup>2</sup> Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University/Women & Infants Hospital, Providence, RI, USA

<sup>3</sup> Department of Obstetrics and Gynecology, Hospital Nova of Central Finland, Jyväskylä, Finland

<sup>4</sup> Department of Obstetrics and Gynecology, Tampere University Hospital, Tampere, Finland

<sup>5</sup> Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland

<sup>6</sup> The Warrell Unit, St Mary's Hospital, Manchester, UK

<sup>7</sup> Female Pelvic Floor Unit, Clinical Hospital of Universidad de Chile, Santiago de Chile, Chile

<sup>8</sup> Urogynaecologist and Reconstructive Pelvic Floor Surgeon, Cabrini Hospital, Malvern, Victoria, Australia

<sup>9</sup> Monash Health, Monash University Department of O&G, Hudson Institute of Medical Research, Melbourne, Australia

<sup>10</sup> Department of Obstetrics and Gynecology, University Hospital of Basel, Basel, Switzerland

<sup>11</sup> Rural Clinical School Rockhampton Australia, Mater Private Hospital Rockhampton Australia, University of Queensland, St Lucia, Australia

<sup>12</sup> Fellowship in Urogynaecology & Pelvic Reconstructive Surgery, Consultant Urogynaecologist, Centre for Urogynaecology & Pelvic Health, New Delhi, India